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1. INTRODUCTION 
1.1. Protein-protein interaction 
Biological systems are made up of very large numbers of different components 
interacting at various scales. Most genes, proteins and other cell components carry 
out their functions within a complex network of interactions and a single component 
can affect a wide range of other components. Protein–protein interactions (PPIs) 
are essential events of virtually all cellular processes. A cellular interactome 
represents the whole set of molecular physical interactions between biological 
entities in cells and its investigation is essential for the comprehension of how gene 
functions and regulations are integrated within an organism. Protein complexes are 
involved in supramolecular assemblies (collagens, elastic ﬁbers, actin ﬁlaments), in 
the building of molecular machines (molecular motors, ribosomes, proteasome) 
participating to major biological processes such as immunity (antigen–antibody 
interaction), metabolism (enzyme–substrate interaction), signalling (interaction of 
messenger molecules, hormones, neurotransmitters with their cognate receptors), 
and gene expression (DNA–protein interactions). Furthermore, the sequencing of 
the genome and advances in proteomics lead to the identiﬁcation of proteins of 
unknown functions (1).  
Commonly PPIs are conceived as physical contacts with molecular docking 
between proteins that occur in a cell or in a living organism in vivo. The investigation 
of these functional links requires different experimental techniques designed to find 
such specific types of relationships. Therefore, the definition of PPI has to consider 
firstly that the interaction interface should be intentional and not accidental, i.e., the 
result of specific selected biomolecular events/forces; and then that the interaction 
interface should be non-generic, i.e., evolved for a specific purpose distinct from 
totally generic functions such as protein production, degradation, and others. Most 
drugs act by binding to speciﬁc proteins to modulate their biological activities, with 
affects biological processes. The search tool for interaction of chemicals (Stitch, 
http:// stitch.embl.de/) database (2) contains protein–chemical interaction data for 
over 68,000 chemicals, including 2200 drugs, and connects them to 1.5 million 
genes across 373 genomes. A promising application of these networks is to provide 
information and to formulate hypotheses on human diseases and therapies (drug 
discovery and targeting) (3). 
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The importance of PPIs in cell signalling is now better understood and has been the 
basis of intense research aiming to generate new pharmacological tools to regulate 
cellular responses. The dynamic formation of selective protein-protein interactions is 
an essential part of the cellular signal transduction cascades. A powerful rational 
approach is to map sequences that participate in protein-protein interactions and 
many studies have demonstrated that peptides corresponding to these sequences 
act as highly specific inhibitors or activators of signalling events and can serve as 
selective drugs, in basic research and in animal models of human diseases. 
Stabilization and/or disruption of protein-protein interactions and disruption of intra-
protein contacts during folding are all being pursued. However, despite some 
success stories, discovering small-molecule drugs that modulate protein-protein 
interactions remains an enormous challenge. 
Recent advances in peptide and peptidomimetic synthesis (4,5) are generating 
renewed enthusiasm in the use of peptides as therapeutics, for example, in vaccine 
development, angiogenesis-related and auto-immune diseases, diabetes and 
neuroprotection (6-9).  
In parallel, the role of short linear motifs in mediating protein-protein interactions in 
signaling complexes is being unraveled, and the importance of such motifs (and 
potentially of their peptidic mimics) in signal channeling has been demonstrated. 
 Cyclic peptides and other modified peptides can be highly potent as well as 
selective, providing a compromise between structural preorganization and sufficient 
flexibility to mold to a target surface and maximize binding interactions. 
One popular strategy used to search for peptides that inhibit a protein-protein 
interaction is to mimic the sequence of one of the interacting proteins (10) (Fig. 1 B).  
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Fig. 1: Schematic representation of several approaches in the general context of 
drug (or modulator of signaling) development. (A) Protein-protein interaction cartoon 
(B) Mimicking the interface sequence of one of the partners by a peptide. (C) Finding 
inhibitory peptides by biochemical screening of peptide libraries. (D) Predicting the most 
probable bound conformation of the peptide in complex with the target protein (peptide 
docking). This approach can be applied to guide optimization of peptide sequences derived 
by A or B; or to simultaneously optimize the conformation and the sequence of the peptide 
 
 
A complementary approach is to derive peptides based on the sequence of the 
enzyme rather than the substrate. It has been applied with success to several 
enzymes such as protein kinases and identified well-defined substrate-binding 
regions consisting of accessible and variable patches distributed between 
conserved and buried anchors. The variable nature of these regions suggests that 
they are involved in determining substrate specificity: from these substrate-binding 
regions several peptides of 7–11 amino acids in length have been derived (11).  
The key challenge for computational prediction of protein peptide interactions is the 
flexibility of the systems under consideration: peptides have many more degrees of 
freedom than typical small molecules. This flexibility is crucial for the rational design 
and optimization of peptides and peptidomimetics. In addition, some disruptors of 
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protein-protein interactions aim to stabilize the inactive form of the protein. Thus, the 
rational design of such inhibitors must take into consideration the conformational 
plasticity of the protein and the interplay between different conformations. 
Other methods predict the detailed interaction between the protein and the peptide, 
namely ‗‗peptide docking‘‘ (Fig. 1 D). 
As essentially all protein-mediated biological processes are based on specific 
interactions between proteins and their ligands, the inhibition of underlying 
molecular interactions is a promising strategy for the controlled interference with 
biological functions. This approach requires the availability of molecules capable of 
mimicking conformationally defined binding and/or functional sites of proteins (Fig. 
1). Furthermore, with respect to the fast growing fields of genomics and proteomics, 
libraries of molecules, having propensity to mimic conformationally defined protein 
binding sites, are valuable tools for the investigation and characterization of 
unknown binding specificities of protein–ligand interactions. The libraries represent 
copies of protein fragments, enabling the detailed analysis of the interaction at the 
level of individual amino acid residues. Moreover, when using chemical synthesis 
methods, diverse modifications, including the incorporation of building blocks other 
than the proteinogenic amino acids, as well as the alteration of the peptide 
backbone, can be used to extend the chemical and structural diversity, as well as 
the metabolic stability, of synthetic peptides.  
 
1.2. Drug Discovery  
1.2.1. High-Throughput Screening 
High-Throughput Screening (HTS) is a well-established process for lead 
discovery that comprises the synthesis and the screening of large chemical 
libraries for activity against biological targets via the use of automated and 
miniaturized assays and large-scale data analysis. In recent years, high-
throughput technologies for combinatorial and multiparallel chemical synthesis 
and automation technologies for isolation of natural products have 
tremendously increased the size and diversity of compound collections.  
A consequence growing demand for new, highly effective drugs is driven by the 
identification of novel targets derived from the human genome project and from the 
understanding of complex protein-protein interactions that contribute to the onset 
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and maintaining of pathological conditions. To illustrate the dynamics of quantitative 
and qualitative process approaches to accelerated drug development, an 
hypothetical pipeline is constructed in Fig. 2. 
 
 
  
 
Fig. 2. Drug Discovery pipelines. IND: Investigational New Drug, CTA: Clinical Trial 
Application, NDA: New Drug Application, MAA: Marketing Authorization. 
  
 
HTS has achieved a dominant role in drug discovery over the past two decades. Its 
aim is to identify active compounds (hits) by screening large numbers of diverse 
chemical compounds against selected targets and/or cellular phenotypes. The HTS 
process consists of multiple automated steps involving compound handling, liquid 
transfers, and assay signal capture, all of which unavoidably contribute to 
systematic variation in the screening data. It represents the process of testing a 
large number of diverse chemical structures against disease targets to identify 'hits'.  
Screening (HTS) is indeed widely employed to create simultaneously different sets 
of compounds and rapidly screening them for the identification of active 
components. This approach is nowadays regarded as a powerful tool for the 
discovery of new drug candidates, catalysts and materials. 
Stimulated by the automation of peptide synthesis on solid support, the concepts 
now embodied in combinatorial chemistry have completely changed the way in 
which compound collections are assembled and structure–activity relationships 
(SARs) are explored. Reactions are accelerated by microwave and other non-
traditional techniques; reaction workups are streamlined with solid-phase reagents, 
and parallel or mix-and-split formats enable chemists to make hundreds of 
analogues in the time they used to synthesize one or two.  
Increases in capacity have been driven by increases in the size of compound 
libraries, and modern screening technologies have greatly improved the analysis of 
the interaction of small molecules with novel pharmacological targets. Assay 
methods are increasingly moving away from the use of radioisotopic labels. Modern 
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fluorescent technologies now play an important role and are widely employed for 
the evaluation of more complex target systems. 
At the other extreme, there is also interest in identifying low-affinity ligands for 
pharmacological targets. In fragment-based screening, the goal is to identify 
pharmacologically active partial structures. If different fragments for adjacent 
binding sites on the target are found, they can be linked to form ligands with higher 
affinity. NMR-based techniques have emerged as the most powerful of the methods 
used to detect low-affinity ligands in biological systems. 
In addition to dynamic range and throughput, compound consumption remains one 
of the major issues in HTS. Miniaturization as well as high-density array formats 
have not only greatly improved the throughput of HTS campaigns, but also 
significantly reduced the amount of chemical material needed to determine ligand 
affinity. The newer screening techniques are able to analyze many different types of 
ligand–target interactions and have provided research teams with a huge number of 
hits from HTS campaigns and, in turn, leads for the optimization phase of drug 
discovery. 
Combinatorial methods have fundamentally ameliorated the ability to synthesize 
and screen large numbers of compounds thanks to improvements made in 
technology, instrumentation, and library design strategies, particularly in the field of 
oligonucleotides and peptides (12,13). In combinatorial screening approaches, it is 
relevant to consider the density, the coverage of chemical space, and the diversity 
and structural similarity of combinatorial libraries compared with other collections, 
particularly the known drugs; in detail, the three most important properties are size 
correlated with molecular weights (MWs), flexibility associated with the presence ⁄ 
absence of rigid scaffolds, and molecular polarity depending on functional groups 
(14–16). Synthetic mixture–based combinatorial libraries in positional scanning 
format (17) are collections of compounds systematically arranged to have both 
defined and randomized positions, which can be synthesized in narrow areas of 
chemical space, and their screening leads to the acquisition of information 
regarding specific functional groups at each variable position. These groups 
determine the activity of a specific chemical scaffold or pharmacophore (15–17). 
The identification of compounds capable to control protein–protein interactions 
represents a major goal for modern drug discovery (18–20). Both structure-based 
design and random screening of combinatorial collections have been successfully 
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applied, in this instance, and often small peptides and peptidomimetics have been 
selected as outstanding inhibitors of protein complexes (21–24). In many cases, the 
lack of sufficient structural information on protein-interacting regions renders the 
combinatorial approach the most suitable method, but the use of completely random 
peptide libraries often produces redundant chemical species that complicate the 
deconvolution phases of screening and puzzles the way to the identification of 
active compounds (25). Several methods for the generation of peptide mixtures 
have been reported since the introduction of the original idea of Furka and 
coworkers, in 1991. However most of them are based on two basic methodologies, 
known as the Mix and Split and the Pre-mix approaches. The Mix and Split (or 
portioning-mixing) method is largely accepted as the first synthetic approach used 
to create combinatorial mixtures of compounds. It consists of three basic steps: 
splitting, coupling and mixing. Firstly, resin beads (or other microreactors) are split 
in a number of aliquots that equals the number of building blocks to be utilized in the 
synthesis (splitting). Then, to each resin aliquot one building block is coupled and 
the reactions are driven to completion (coupling). Following this step, beads are 
randomly and thoroughly mixed (mixing) and then re-splitted in the same number of 
aliquots, achieving a set of homogeneous and equimolar collections of compounds. 
Repetitive execution of these basic steps for ―n‖ times will thus produce a rapid 
increase of newly generated molecules, while bead number remains constant. 
Importantly, since resin beads encounter one reactant at a time, no more than one 
compound per bead can be generated (OBOC), therefore the total number of final 
compounds is limited by the number of initial beads. To overcome the limitations 
posed by OBOC approach and thus to obtain larger libraries, the synthesis of 
peptide mixtures using pre-mixed solutions of peptides was introduced. By this 
approach, the amino acids chosen for the library are pre-mixed and then coupled to 
a single resin batch. Before coupling the last amino acid, the resin is split in a 
number of aliquots that equals the number of building blocks and to each aliquot, 
one single amino acid is separately coupled. This procedure leads to the generation 
of sub-libraries that are labelled by the N-terminal residue. Every single bead 
contains all the ensemble of peptides of the sub-library (26), as any single bead 
encounters the reagents under the same conditions. This method is faster than the 
Mix and Split and allows the preparation of very large libraries, thus producing a 
wide chemical diversity. 
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Deconvolution methods evaluate the contribution of each residue to the desired 
biological activity. There are two main deconvolution approaches: the iterative 
process (27) or the positional scanning method (17). In the first approach, a 
progressive elucidation of the active sequence is carried out by identifying one 
amino acid at a time for each position. The process involves subsequent cycles of 
screening and re-synthesis of active pools, thus producing a progressive activity 
enrichment and a contextual semplification of the peptide pools. The chemical 
synthesis of the next sublibraries is dictated by the results from the previous one, 
thus only a sub-population of the library components is re-synthesized, arriving at 
the last assay where single molecules, differing only for the last amino acid are in 
parallel prepared and tested. In the positional scanning (PS) approach, all 
sublibraries needed to determine the final active sequence are prepared at the 
beginning of the screening and, in this case, the library is replicated a number of 
times that equals the sequence length. Each variable position is tested 
independently, at the same time, using a set of sub-libraries with known residues for 
every individual position. The most active sequence is finally ―read‖ at the end of the 
process by selecting the most active pools on each known position. 
The synthesis of completely random combinatorial libraries of peptides generates a 
large number of ―quasi-duplicates‖ deriving from the strong similarity between 
several side chains. In large libraries, the need to manage large arrays of tubes and 
codes can puzzle the way to the identification of lead compounds and slows down 
the synthetic and deconvolution steps. In the perspective of simplifying the 
synthesis and deconvolution procedures without grossly affecting the probability to 
find out active peptides, a recent approach regards the reasoning on the general 
properties of L and D-amino acids, reaching a compromise between the need to 
maintain the highest possible diversity and that of reducing the number of building 
blocks. These new libraries have been named ―Simplified Libraries‖, intending with 
this any new ensemble of possible sequences achievable with a reduced and non 
redundant set of amino acids. The new set of ―non redundant‖ different residues (12 
instead of 20) is chosen following several simple rules. First of all ―quasi-identical‖ 
groups of amino acids are selected: Asp and Glu; Asn and Gln; Ile and Val; Met and 
Leu; Arg and Lys; Gly and Ala; Tyr and Trp; Ser and Thr. Then, from each group, 
one is selected trying to keep a good distribution of properties, including hydropathic 
properties, charges, pKa, aromaticity. The cysteine is converted to the stable 
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acetamidomethyl-derivative to prevent polymerization and to increase the number of 
polar residues within the final set. The distribution of residue molecular weights is 
also an important parameter in cases of deconvolution of the library by mass 
spectrometry approaches (28). 
 
1.2.2. Rationally Designed Peptide Inhibitors 
Protein-protein interactions are known to play a critical role in the normal function of 
cellular/organelle structure, immune response, protein enzyme inhibitors, signal 
transduction, and apoptosis. Rational approaches toward the recognition of protein 
surfaces may provide better insights into exactly how proteins interact with one 
another, and is an alternative to enzyme inhibitor design as a molecule-based 
disease therapy. Moreover, rational protein surface recognition is a challenging test 
of our knowledge of molecular design. The nature of protein-protein interfaces has 
been the focus of investigation for some time. Particular emphasis in the literature 
has been placed on structure, energetics, electrostatic complementarity, and 
kinetics of protein-protein interactions. An important breakthrough has been the 
identification of ―hot spots‖ on protein surfaces. A hot spot is a defined locale of ca. 
600 Å2 on the surface of a protein or near the geometric center of the protein-
protein interface. The residues that comprise the hot spot contribute significantly to 
the stability of the protein-protein complex. Mutating a hot spot residue to alanine 
results in a lower affinity of the protein for its partner. 
The main goals in designing synthetic molecules that disrupt protein-protein 
interactions through specific recognition take two complementary threads. One is 
the recognition of protein surfaces in ways that agonize a biological response, 
mediate some protein dimerization, or stabilize the native oligomerization state of 
the protein. The second objective in targeting a protein surface would be to 
selectively bind half of a dimeric interaction in a way that would sterically block 
association with the natural protein partner.  
The practice of molecular design relies on a full understanding of non covalent 
forces. Often, many of these forces (hydrogen bonding, electrostatics, van der 
Waals forces, π-π interactions, conformational energy, etc.) work in concert, making 
it difficult to isolate the contributions of any one component. Model systems can be 
used to illustrate the contributions of these forces in a systematic manner. The 
primary goal in this research is the design of molecules with predictable recognition 
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properties. Among the greatest tests of the knowledge gained from model systems 
is their application to a natural target. Here the requirements for specificity and tight 
binding are more rigorous than in the model systems. Protein surfaces represent a 
challenging target for the field of molecular design. Large surface areas (500-2000 
Å2) must be covered and multiple interactions utilized to achieve sufficient binding 
affinity to observe an effect. Oligopeptides represent an intermediate step toward 
the recognition of protein surfaces for the field of molecular design. Short peptide 
sequences (3-20 amino acids) are themselves worthwhile targets for recognition 
due to their potential applications in separation, diagnostic, or biological areas. The 
notion of peptide recognition as a stepping stone to protein binding arises because 
many of the early synthetic receptors involved a small number of functional group 
interactions. Binding a protein surface should require large arrays of interacting 
functionality in a conformationally defined context. Also, these arrays may not be 
confined to one domain or secondary structural element of the protein. Short 
peptides present an additional factor to binding because they are themselves 
usually conformationally flexible (29).  
 
1.2.3. Peptides as Drugs 
The advantages of peptide-based therapeutics derive from the underlying physics, 
chemistry and modularity of amino acids combined with the physical and chemical 
nature of the amide bond and the fact that nature has solved numerous 
physiological and pharmacological problems using peptides. These advantages 
include: the capacity for high target affinity, specificity and potency; predictable and 
relatively low cost and easy synthesis and storage; low and predictable toxicity, and 
reduced antigenicity. The advantage of low and predictable toxicity is crucial for 
small molecule drugs that often fail due to human toxicity. Similarly, due to their 
relatively small size peptide-based drugs are often superior to protein-based 
therapeutics. For example, immunogenicity, intracellular penetration, and synthesis 
and storage represent challenges for proteins that are not nearly as daunting as for 
peptides. 
The major challenges confronting the successful development of peptide drugs 
appear to be the development of successful delivery strategies and the 
development of optimal pharmacokinetics. But small molecules and proteins must 
solve these problems, too. Moreover, the study of natural peptides and proteins, 
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and recent interest in the area of peptide drug discovery indicate that peptides can 
be engineered for oral or other noninvasive routes of administration and to have 
favorable pharmacokinetic profiles. Indeed, recent investigations have explored the 
possibility of improving small molecule drug bioavailability through conjugation with 
small peptides that are the ligands of specific gut transporters (30).  
Protein-protein interactions, however, often involve the burial of large and relatively 
featureless contacting surfaces and are typically mediated by numerous and 
spatially distributed hydrogen bonding and ionic interactions that can involve sub-
nanomolar binding affinities. This, in part, explains why a herculean effort is  
sometimes required to develop small molecule inhibitors of protein-protein 
interactions and why, despite a few notable exceptions, small molecules might 
prove to be poor choices for targeting such interactions (31). A potentially more 
fruitful and less costly strategy is to develop peptide inhibitor leads from knowledge 
of how natural proteins and peptides interact. These peptide leads could then be 
developed into peptide-based or peptidomimetic compounds with superior drug 
profiles. Indeed viable peptide candidates, approximately five residues in length, 
can be obtained from protein-protein interfaces to serve as templates for peptide-
based, peptidomimetic and even small molecule drugs that inhibit protein-protein 
interactions (32). 
An equally ‗natural‘ strategy for peptide drug discovery but that contemplates the 
experimental screening of larger peptides has been outlined by Watt (33). Hence, 
developing peptide-based or peptide-derived drugs for the therapeutic modulation of 
protein-protein interactions appears to make good scientific and business sense. 
A second specific advantage of peptide-based is that peptide ligands can be 
designed that are more robust to mutational changes at protein binding or active 
sites. The hypothesized advantage derives from the potential to design peptides 
that are flexible, that bury relatively large surface areas on binding, that interact with 
proteins through a large number of spatially distributed contacts, and that interact 
with target proteins predominantly through main-chain interactions (34). 
Presumably, a peptide ligand that combined all of these binding properties would 
retain significant binding, despite the loss or substitution of various side-chains 
through mutation. There is thus a sound theoretical basis and some suggestive 
evidence for speculating that peptide drugs can be designed to be more refractory 
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to the effects of mutations in the target protein. This could have enormous 
implications for the design of antibacterial and anti-viral agents.. 
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1. INTRODUCTION 
1.1. Diabetes mellitus 
Obesity, as metabolic syndrome and diabetes mellitus are actually frequent 
disorders affecting the Western civilization. Diabetes is one of the most common 
disorders characterized by hyperglycemia resulting from defects in insulin secretion, 
action, or both. The chronic hyperglycemia of diabetes is associated with long-term 
damage, dysfunction, and failure of various organs, especially the eyes, kidneys, 
nerves, heart, and blood vessels. 
Several pathogenic processes are involved in the development of diabetes. These 
range from autoimmune destruction of the β-cells of the pancreas with consequent 
insulin deﬁciency to abnormalities that result in resistance to insulin action. The 
basis of the abnormalities in carbohydrate, fat, and protein metabolism in diabetes 
is a deﬁcient action of insulin on target tissues. Irregular insulin action results from 
inadequate insulin secretion and/or diminished tissue responses to insulin at one or 
more points in the complex pathways of hormone action. 
Symptoms of marked hyperglycemia include polyuria, polydipsia, weight loss, 
sometimes with polyphagia, and blurred vision. Impairment of growth and 
susceptibility to certain infections may also accompany chronic hyperglycemia. 
Acute, life-threatening consequences of uncontrolled diabetes are hyperglycemia 
with ketoacidosis or the nonketotic hyperosmolar syndrome (1)  
Long-term complications of diabetes include retinopathy with potential loss of vision; 
nephropathy leading to renal failure; peripheral neuropathy with risk of foot ulcers, 
amputations, and Charcot joints; and autonomic neuropathy causing 
gastrointestinal, genitourinary, and cardiovascular symptoms and sexual 
dysfunction. Patients with diabetes have an increased incidence of  atherosclerotic 
cardiovascular, peripheral arterial, and cerebrovascular disease. Hypertension and 
abnormalities of lipoprotein metabolism are often found in people with diabetes. 
According to the classification recommended by the American Diabetes Association 
(2010), diabetes mellitus can be classified as type 1 (T1DM), type 2 (T2DM), other 
specific types, and gestational diabetes mellitus. 
In type 1 diabetes, the cause is an absolute deﬁciency of insulin secretion due to 
autoimmune or idiopathic destruction of insulin-producing β-cells in the pancreas by 
CD4 and CD8 T cells and macrophages infiltrating the islets. Insulin injection is 
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always necessary for survival because of the complete lack of endogenous insulin 
(2). In type 2 diabetes, the most common, the cause is a combination of insulin 
deficiency, reduced insulin action, and insulin resistance of glucose transport in 
skeletal muscle and adipose tissue. The manifestation of type 2 diabetes is a 
continuum of insulin resistance culminating in the failure of insulin secretion to 
compensate for insulin resistance, and the progression to full diabetes ensues when 
pancreatic β-cell hypersecretion of insulin fails to compensate for insulin resistance 
(3) (Fig. 1.1).  
 
 
 
 
Fig. 1.1: Pathophysiology of T2DM 
 
 
1.1.1. Insulin signaling and pathway in insulin actions 
Insulin is the most potent anabolic hormone known and is essential for appropriate 
tissue development, growth, and maintenance of whole-body glucose homeostasis. 
It is secreted by the  β-cells of the pancreatic islets of Langerhans in response to 
increased circulating levels of glucose and amino acids after a meal.  Insulin 
regulates glucose homeostasis at many sites by reducing hepatic glucose output 
(gluconeogenesis and glycogenolysis) and by increasing the rate of glucose uptake 
in skeletal muscle and fat to regulate blood glucose concentration (Fig. 1.2). In liver 
and fat cells, insulin also promotes the synthesis and storage of carbohydrates, 
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lipids and proteins, inhibits their degradation and release into the 
circulationattenuating fatty acid release from triglycerides in fat and muscle (4).  
 
 
 
 
The first step by which insulin increases energy storage or utilization involves the 
regulated transport of glucose into the cell, mediated by the glucose transporter 
GLUT4. Insulin stimulates the translocation of a pool of GLUT4 to the plasma 
membrane, through a process of regulated recycling, in which endocytosis, sorting 
into specialized vesicles, exocytosis, tethering, docking, and fusion are tightly 
regulated (5). The precise intracellular events that mediate insulin action are 
initiated through the binding to and activation of its cell-surface receptor, the insulin 
receptor substrates (IRS), and the molecules that interact with these substrates 
(Fig. 1.3).  
 
Fig.1.2:  Glucose homeostasis 
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Fig. 1.3: Insulin signal transduction 
 
1.1.2. Insulin resistence 
Insulin resistance (IR) is a physiological condition where the natural hormone insulin 
becomes less effective at lowering blood sugars. The resulting increase in blood 
glucose may raise levels outside the normal range and cause adverse health 
effects, depending on dietary conditions. Certain cell types such as fat and muscle 
cells require insulin to absorb glucose. When these cells fail to respond adequately 
to circulating insulin, blood glucose levels rise. The liver helps regulate glucose 
levels by reducing its secretion of glucose in the presence of insulin. This normal 
reduction in the liver‘s glucose production may not occur in people with insulin 
resistance (6). 
Insulin resistance in muscle and fat cells reduces glucose uptake (and also local 
storage of glucose as glycogen and triglycerides, respectively), whereas insulin 
resistance in liver cells results in reduced glycogen synthesis and storage and a 
failure to suppress glucose production and release into the blood. Insulin resistance 
normally refers to reduced glucose-lowering effects of insulin. However, other 
functions of insulin can also be affected. For example, insulin resistance in fat cells 
reduces the normal effects of insulin on lipids and results in reduced uptake of 
circulating lipids and increased hydrolysis of stored triglycerides. Increased 
mobilization of stored lipids in these cells elevates free fatty acids in the blood 
plasma. Elevated blood fatty-acid concentrations (associated with insulin resistance 
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and diabetes mellitus Type 2), reduced muscle glucose uptake, and increased liver 
glucose production all contribute to elevated blood glucose levels. High plasma 
levels of insulin and glucose due to insulin resistance are a major component of the 
metabolic syndrome. If insulin resistance exists, more insulin needs to be secreted 
by the pancreas. If this compensatory increase does not occur, blood glucose 
concentrations increase and type 2 diabetes rises up. 
 
1.1.3. Mechanisms of Insulin resistence 
Insulin resistance may arise through a variety of mechanisms (Fig. 1.4) can be 
caused by structural or functional changes in any of the insulin regulatory actions on 
intracellular signalling mediator molecules, from the insulin receptor to the genes 
(7). The defect of glucose utilization may therefore be induced in any phase of the 
signalling process: from the binding of insulin to its receptor, through the activity of 
GLUT transporters and of proteins responsible for the translocation of these 
transporters to the cellular membrane, to the structural or functional abnormalities of 
other signaling molecules, and transcriptional factors on the route of the insulin 
signal to genes. Disorders at the level of insulin receptor have been thoroughly 
examined, especially the mutations disturbing its function as a tyrosine 
phosphatase. 
 
 
Fig. 1.4: Mechanisms connected to insulin resistance. 
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The utilization of glucose by the muscles and adipose tissue can be impaired by 
many other disturbances in the signalling processes. In patients with type 2 
diabetes, different abnormalities concerning the signal transduction cascade below 
the insulin receptor have already been found. For example, in patients with insulin 
resistance (not necessarily with type 2 diabetes), impaired IRS 1 phosphorylation in 
skeletal muscles is frequently encountered (8). In the adipose tissue of patients with 
type 2 diabetes mellitus and obesity, a decrease in glucose transport is connected 
with changes in the expression of the GLUT4 protein. In this way, a decrease of the 
glucose transport contributes to hyperglycaemia. The ―transport‖ hyperglycaemia in 
diabetes mellitus may arise in two ways: 1) as a result of a decrease in the GLUT 
transporters‘ expression and concentration, or 2) as an effect of functional 
disturbances in the process of the GLUT transporters‘ intercellular translocation. 
Studies of the impairment of cellular glucose transport in diabetes mellitus, 
particularly in type 2, should now be seen as a new potential sphere of clinical 
activity (9). In abdominal obesity — after normal body mass is restored the insulin 
receptor regains its lost tyrosine phosphatase activity. Disorders of the expression 
and translocation of glucose transporter GLUT4 could be normalized and insulin 
sensitivity restored.  
 
1.2. The Role of PED/PEA-15 in Glucose Tolerance and in Type 2 Diabete 
Several studies aimed at the identification of genetic variants associated with type 2 
diabetes and to understand their signiﬁcance to and their role in the disease. This 
effort led to the identiﬁcation of a number of diabetes susceptibility loci, which have 
been widely replicated in different and large populations (10). In expression proﬁle 
studies, phosphoprotein enriched in diabetes/ phosphoprotein enriched in 
astrocytes-15 (ped/pea-15) emerged as overexpressed a gene in adipose and 
skeletal muscle tissues and in skin ﬁbroblasts from type 2 diabetic individuals 
independently of obesity (11) and severalstudies investigate the mechanisms that 
may lead to dysregulating the expression of this gene in type 2 diabetic patients and 
in their ﬁrst-degree relatives.  
In a initial study by Condorelli et al. (11), it was shown that PED/PEA-15 
overexpression represents a common trait among type 2 diabetics, because 
approximately one-third of the individuals diagnosed with the disorder exhibit 
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PED/PEA-15 expression levels higher than 2 SD above the mean in the control 
subjects (12). Functional analysis in cultured skeletal muscle and adipose cells 
demonstrated that increased expression of PED/PEA-15 causes resistance to 
insulin action in glucose uptake (11). This abnormality depends largely on 
PED/PEA-15-induced dysfunction of the Protein Kinase C (PKC)signaling system. 
Indeed, several studies evidenced that PED/PEA-15 binds phospholipase D (PLD) 
isoforms, increasing their stability and intracellular diacylglycerol levels (13), thereby 
activating the dyacylglycerol-sensitive PKCα isoform. These studies also revealed 
that the active PKCα in PED/PEA-15-overexpressing cells and tissues prevents 
insulin induction of the PKCδ isoform. This is distinct from α and serves as a major 
activator of glucose transporter 4 (GLUT4) vesicle translocation toward the plasma 
membrane. Thus, studies in isolated muscle and adipose cells have shown that the 
overexpression of PED/PEA-15 may determine peripheral resistance to insulin 
action by dysregulating the signaling of PKC (Fig. 1.5) (14).  
 
 
Fig.1.5: Molecular mechanism of action of PED/PEA-15 in Insuline Resistance 
 
To assess the consequences of PED/PEA-15 overexpression on glucose tolerance, 
Vigliotta et al. (15) generated transgenic mice overexpressing ped/pea-15 
ubiquitously, because this same situation occurs in many individuals with type 2 
diabetes. Phenotyping these mice revealed that overexpression of PED/ PEA-15 
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impairs glucose tolerance and may lead to diabetes under appropriate 
environmental conditions. Indeed, upon high-fat diet feeding, transgenic mice 
become overtly diabetic. The impaired glucose tolerance observed in the PED/PEA-
15 transgenic mice was accompanied by signiﬁcant resistance to insulin action on 
glucose disposal, reduced insulin-stimulated glucose transport in fat and skeletal 
muscles, and inhibition of insulin effect on GLUT4 membrane translocation. The 
mechanistic signiﬁcance of these ﬁndings has been further corroborated by 
additional studies in ped/pea-15-null mice. In these animals, ablation of even a 
single copy of the ped/pea-15 gene causes a remarkable increase in insulin 
sensitivity, which is paralleled by enhanced PKCδ activity upon feeding. Thus, the 
additional concept has emerged that the control of insulin sensitivity is a 
physiological function of the PED/PEA-15 gene.  
 
1.2.1. PED/PEA-15 protein 
The Phosphoprotein Enriched in Diabetes/ Phosphoprotein Enriched in Astrocytes-
15 (PED/PEA-15) is a 15 kDa cytosolic protein widely expressed in different tissues 
and highly conserved among mammals, whose gene maps on human chromosome 
1q21-22 (16). The structure of PED/PEA-15 includes a canonical N-terminal Death  
Effector Domain (DED) of 80 amino acids that regulate apoptotic signaling 
pathways (Fig. 1.6 A). Within the N-terminus there is a nuclear export sequence 
(NES) that mediate its cytoplasmic localization. In particular, PED/PEA-15 regulates 
the actions of ERK-MAP kinase cascade by binding to ERK in the nucleus, 
exporting it into the cytoplasm and preventing the entrance into the cell cycle 
caused by sustained phospho-ERK nuclear accumulation (17).  In the C-terminal 
domain, PED/PEA-15 protein can be phosphorylated on two different residues: the 
Ser104, identified as a site of regulation for protein kinase C (PKC) (16), and the 
Ser116 regulated by calcium–calmodulin kinase 2 (CaMKII) (18) and PKB/Akt (19).  
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Fig.1.6: Schematic representation of modular structure of PED/PEA-15 (upper) and 3D-
Structure of PED/PEA-15 protein determined by NMR (lower) 
 
 
The PED protein structure, shown in Fig. 1.6 B, was determined by NMR 
spectroscopy (20); it shows the presence in the region N-terminal of a DED domain 
(Death Effector Domain) while the C-terminal portion appears to be quite 
unstructured. The DED domain belongs to the superfamily of so-called "death 
domain" (Death Domains), which also includes the domains DD (Death Domain), 
the CARD (Caspase Recruitment Domain) and PYRIN domains; they act as primary 
mediators in the protein-protein interactions necessary for the transmission and 
regulation of the apoptotic signal, and both regions appear to be necessary to make 
PED interaction with ERK proteins. The DED domain is composed of 6 antiparallel 
amphipathic α-helices grouped around a central hydrophobic core, such α-helices in 
the DED domain are linked together by small loops, two of which (α2-α3 and α4-α5) 
contain short β-structures and help to take the domain to a spatial arrangement as a 
"Greek cross", typical of DD domains, with the helices α1 and α2 localized at the 
center, and the helices α3 and α4 on one side and the α5 and α6 on the other one 
5
2
3
4
6
1
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(Fig. 1.6 B). This structure is very similar to those reported for other DED-containing 
proteins: the protein FADD (21) and the FLIC-like inhibitory protein (FLIP) (22), 
whose structures are known at the atomic level by X-ray diffraction. The DED 
domain present on its surface several charged residues that suggest different 
interactions of electrostatic nature are responsible for the recognition of ERK1/2. 
The protein contains two other important sites for regulation: a domain of 
phosphorylation by PKC (residues 99-107) and a phosphorylation site of type II 
calcium calmodulin-dependent (110-122). The antiapoptotic function is regulated by 
phosphorylation of residues Ser104 and Ser116. 
The amino acid sequence of the protein PED/PEA15 is shown in Fig. 1.7 while 
Table 1.1 shows the protein segments that include the six alpha helices of the DED. 
 
 
 
 
Fig.1.7: Primary sequence of h-PED/PEA15 
 
 Segment Helix Sequence 
PED 2-14  AEYGTLLQDLTNN 
PED 17-27  LEDEQLKSAC 
PED 33-37  SEKSE 
PED 42-51  GSAWFLESHN 
PED 61-69  SYIEHIFE 
PED 73-89  PDLLTMVVDYRTRVLKI 
 
 
Table 1.1: Helical regions of PED/PEA15 as assessed by NMR study 
 
  1
MAEYGTLLQDLTNNITLEDLEQLKSACKEDIPSEKSEEITTGSAWFSFLE
50 
 51
SHNKLDKDNLSYIEHIFEISRRPDLLTMVVDYRTRVLKISEEDELDTKLT
100 
101
RIPSAKKYKDIIRQPSEEEIIKLAPPPKKA
130 
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In addition, this protein is a interactor of phospholipase D1 (PLD1) isoforms, which 
increases stability and therefore their activities. This effect is accompanied by 
changes of some metabolic mechanisms (23).  
 
1.2.2. Phospholipase D protein 
As already reported, PED/PEA-15 interaction with PLD may represent a crucial 
event in dysregulating insulin action (15). Classical phospholipase D (PLD) 
enzymes hydrolyze the principal membrane lipid  phosphatidylcholine (PC) to 
generate phosphatidic acid (PA) and free choline (Cho) and performs a 
transphosphatidylation reaction using water or primary alcohols (ethanol or 1-
butanol) as the nucleophile to generate PA, phosphatidylethanol or 
phosphatidylbutanol (PBut), respectively (24). (Fig. 1.8) 
 
 
 
Fig.1.8: Schematic representation of enzymatic reaction of PLD 
 
PLD is a member of a superfamily, which includes phosphoinositidespecific 
phospholipase C, phospholipase A2 and sphingomyelinase; all are phospholipids-
degrading enzymes that generate biologically active products which are assumed to 
play important functions in cell regulation. In the context of these specific roles, PLD 
has been proposed to function in regulated secretion, cytoskeletal  reorganization, 
membrane trafficking, transcriptional regulation and cell-cycle control (25). PLD 
superfamily members are found in  organisms ranging from viruses to bacteria, 
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yeast, plants and animals, where PLD activity is present in a wide variety of cell 
types including blood platelets, hepatocytes, lymphocytes, fibroblasts, neuronal 
cells,  muscle cells and endothelial cells. Cloning of the plant and yeast PLDs led 
ultimately to the cloning of two mammalian isoforms: PLD1 and PLD2, each of 
which is expressed as two splice variants and localized  the first, on the Golgi or 
perinuclear vesicular structures, whereas the second, appears to be associated with  
the plasma membrane (26). (Fig. 1.9) 
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Fig.1.9: Schematic representation of modular structure of h-PLD1 and PLD2 
 
The common catalytic domain  of PLD enzymes designated as HKD, bears a 
consensus  HxxxxKxD sequence, where histidine (H), lysine (K) and aspartic acid 
(D)are critical for enzymatic activity both in vitro and in vivo, as evidenced by site 
mutations studies (27).  
Other highly conserved regions the PLD genes are the phox consensus sequence 
(PX), the pleckstrin homology (PH) domain and the PI4,5P2 binding site at their N-
terminal which are implicated in phospholipids and protein binding (26). Further, 
only in PLD1 is present a conserved loop region proposed to function as a possible 
negative regulatory element (28). The C-terminal four amino acids of mammalian 
PLDs are completely conserved and any change of these residues causes loss of 
catalytic activity (29). Mammalian PLD activity is regulated by many factors, 
including phosphoinositides, Protein kinase C-α (PKCα), ADP ribosylation factor 
(ARF), Rho GTPases such as RhoA, Cdc42, Rac1 and non-PKC protein  
phosphorylation. In comparison with PLD1, recombinant PLD2 exhibits high basal 
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activity in vitro, so it can be activated mildly by ARF, exhibiting 1,5-2 fold activation 
(30). 
 
1.2.3. PED/PLD1 interaction: D4α domain 
Several studies showed that PLD1 associated with GLUT4-containing membranes 
acted in a constitutive manner to promote the mechanisms of GLUT4 translocation 
by insulin (31). Given the proposed roles for PLD1 in regulation of GLUT4 
translocation, in signal transduction, apoptosis and its regulation by PKC, 
PED/PEA-15 is an interacting partner of crucial biological significance. Interestingly, 
observations suggested that PED/PEA-15/PLD1 binding resulted in increased PLD1 
levels, thus increasing PLD activity both in vitro and  in vivo.  
The minimum PLD1 region required for PED/PEA-15 interaction has been identiﬁed 
by Zhang et al. (32) and termed D4 (Fig. 1.10).  
 
 
 
 
 
 
 
 
Fig.1.10: Primary sequence of D4-PLD1 
 
 
The D4 region is located at the PLD1 C-terminus and contains one of the two 
phosphodiesterase domains responsible for PLD1 enzymatic activity. My research 
group has demonstrated through SPR and ELISA-like assays that PED/PEA-15 
binds in vitro the D4 domain with high afﬁnity (33,34) and, furthermore, that a PED/ 
PEA-15 region spanning residues 1–24 and termed is the mainly involved in D4 
recognition (33,34). When loaded into L6 cells overexpressing PED/PEA-15 and 
into myocytes derived from PED/PEA-15 overexpressing transgenic mice, PED-(1–
24) abrogates the PED/PEA-15-PLD1 interaction and reduces PKC activity to levels 
similar to controls. Importantly, the peptide restored insulin-stimulated glucose 
712
RSLSYPFLLPKSQTTAHELRYQVPGSVHANVQLLRSAADWSAGIKYHEES
761 
762
IHAAYVHVIENSRHYIYIENQFFISCADDKVVFNKIGDAIAQRILKAHRE
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961 
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1061 
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GTKEAIVPMEVWT
1074 
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uptake, and similar results were obtained by expression of the D4 domain in L6 
cells overexpressing PED/PEA-15, indicating that targeting PED/PEA-15- PLD1 
interaction may represent a novel strategy to improve sensitivity to insulin action 
(33). 
In a recent study, Doti et al (35), by using D4 deletion mutants (Fig. 1.11), have 
restricted the PLD1 region involved in PED/PEA15 interaction to the N-terminal 
fragment named D4α (residues 712–818). This region binds PED/PEA15 with the 
same eﬃcacy as D4 and, when transfected in diﬀerent PED/PEA15-overexpressing 
cells, it is able to reduce PKC-α activity and to restore the sensitivity of PKC-δ to 
insulin stimulation, independently of the PI3K/Akt signalling. This results suggest 
that a restricted binding interface (107 residues) on PLD1 can be used for the 
design and identification of effective antagonists. 
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Fig. 1.11: Schematic representation of PLD1 and D4 sub-domains: Designed 
truncated domains D4α, D4β and D4γ 
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1.3. Aim of the study  
Understanding the physiological role of PED/PEA-15 in glucose tolerance has been 
followed by further efforts aimed at generating novel molecules interfering with 
PED/PEA-15 function and featuring potential pharmacological activity. Since 
PED/PEA-15 interaction with PLD1 appears to represent the initial event leading to 
PED/PEA-15 effect on glucose disposal, efforts were devoted to the identiﬁcation of 
molecules inhibiting PED/PEA-15-PLD1 interaction. 
Here simplified peptide libraries have been prepared and screened in a positional 
scanning format for the identification of small peptides able to inhibit the 
PED/PEA15-D4α interaction.   
By using an-ELISA-based screening, performed on a fully automated platform, two 
simplified peptide libraries were analyzed in a positional scanning format. This 
screening led to the identification of small peptides able to inhibit PED/PEA15-D4 
interaction. The selection of inhibitors was carried out employing combined 
competitive and direct experiments, through ELISA and SPR techniques, providing  
peptides with IC50 values in the micromolar range. 
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2. EXPERIMENTAL SECTION 
2.1. Materials 
pETM vectors were from EMBL (Heidelberg, Germany), oligonucleotides were 
synthesized by Sigma-Genosys (Sigma-Aldrich, Milano, Italy). Phusyon DNA 
polymerase was from Finnenzyme (Milano, Italy). Restriction enzymes were from 
New England Biolabs (Milano, Italy). All molecular biology kits were from Qiagen 
(Milano, Italy). Escherichia coli bacterial strains were from Novagen (Milano, Italy). 
Reagents for bacterial medium were from Becton-Dickinson (Milano, Italy). All 
reagents for SDS-PAGE, chromatographic columns and AKTA FPLC, were from 
GE Healthcare (Milano, Italy). EZ-Link NHS-LC-Biotin Reagent and Pro-JectTM 
Protein Transfection Reagent kit were from PIERCE (Rockford, US). STRV-HRP, 
Sigma-fast o-Phenylenediamine dihydrochloride Tablet Sets were from Sigma-
Aldrich (Steinheim, Germany).  
Reagents for peptide synthesis (Fmoc-protected amino acids and resins, activation 
and deprotection reagents) were from Novabiochem (Laufelfingen, Switzerland) and 
InBios (Napoli, Italy). Solvents for peptide synthesis and HPLC analyses were from 
Romil (Dublin, Ireland); reversed phase columns for peptide analysis and the LC-
MS system were from ThermoFisher (Milano, Italy).  
 
2.2. Methods 
2.2.1. ELISA 
D4 deletion mutants, PED/PEA15 recombinant proteins were expressed and 
purified as already reported (33,35). Also direct binding ELISA were carried out as 
described in the same papers (33,35). All ELISAs were performed using an 
integrated platform for High-Throughput Screening (Hamilton Robotics, Bonaduz, 
CH) comprising a fully equipped Starlet 8 channel liquid handler, a robotic arm, a 
washer and a multi-wavelength plate reader. Competition ELISA experiments were 
carried out by coating D4α (0.10 μM) and pre-incubating mono-biotinylated 
PED/PEA15 at 1.0 μM with peptide sub-libraries or single purified peptides at fixed 
concentrations (100 and 200 μM); dose-response experiments were performed with 
the single purified peptides at concentrations ranging between 3-400 μM. 
Competition results were reported as % inhibition = (B/B0)X100, where B means 
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the average OD from the triplicate data points for a given analyte and B0 is the 
average OD determined without competitor. Experimental data were  fitted with 
GraphPad Prism, vers. 4.00, GraphPad Software (San Diego, California).  
 
2.2.2. Peptide Synthesis 
Peptide libraries and single peptides were prepared by the solid phase method on a 
50 μmol scale following the Fmoc strategy and using standard Fmoc-derivatized 
amino acids (36). Briefly, synthesis were performed on a fully automated 
multichannel peptide synthesizer Syro I (Multisynthech, Germany). RINK AMIDE 
resin (substitution 0.5 mmol/g) was used as solid support. Activation of amino acids 
was achieved using HBTU-HOBt-DIEA (1:1:2), whereas Fmoc deprotection was 
carried out using a 40% (v/v) piperidine solution in DMF. All couplings were 
performed for 15 minutes and deprotections for 10 minutes. Randomized positions 
were coupled using equimolar mixtures of 12 building blocks employing a 100-fold 
excess of each amino acid. Peptides were removed from the resin by treatment with 
a TFA:TIS:H2O (90:5:5, v/v/v) mixture, then they were precipitated in cold 
diethylether and lyophilized.  
 
2.2.3. Library design 
The libraries used in this study, named PS-SSPLs (Positional Scanning-Simplified 
Synthetic Peptide Libraries) consisted of four positions libraries, each with one 
position defined by one of 12 amino acids chosen as building blocks. It relies in 
employing 12 different amino acids (instead of 20) that are accurately selected in 
order to preserve a wide range of hydrophobicity, aromaticity, charges and pKa 
values and MWs (Table 2.1). Further, randomized positions were set to only four 
residues in order to approach the size of small molecules to which they, 
successively, could be converted to improve their pharmacological profile (37). 
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Table 2: Selection of building blocks for the 1
st
 generation PS-SSPLs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aaa Hydrophobic Polar Charged 
Aromatic 
or Aliphatic 
Ala X - - - 
Arg - X basic - 
Asn - X - - 
Asp - X acidic - 
Cys X - acidic - 
Gln - X - - 
Glu - X acidic - 
Gly - - - - 
His - X weak basic Aromatic 
Ile X - - Aliphatic 
Leu X - - Aliphatic 
Lys - X basic - 
Met X - - - 
Phe X - - Aromatic 
Pro X - - - 
Ser - X - - 
Thr - X weak acidic - 
Trp X - - Aromatic 
Tyr X X - Aromatic 
Val X - - Aliphatic 
 Selected 
amino acid 
Side chain 
1 Gln amide 
2 Ser polar 
3 Arg basic 
4 Ala hydrophobic 
5 Tyr hydrophobic, polar, aromatic 
6 Pro hydrophobic 
7 Met hydrophobic 
8 Cys(Acm) aliphatic 
9 Phe hydrophobic, aromatic 
10 Leu aliphatic 
11 His hydrophobic, polar 
12 Asp acidic 
 
Table 2.1: Selection of 12 building blocks 
 
In details, for residues with very similar properties, only one was chosen (for 
example Gln instead of Asn, and Asp instead of Glu). Arg and His were chosen 
instead of Lys because, though they all have a net positive charge at neutral pH, 
His also retains an aromatic character and Arg contains a unique guanidine group.  
Among other aromatic side chains, Phe and Tyr were preferred to Trp, due to their 
less tendency to oxidation. The aim of this approach is to simplify library synthesis 
and deconvolution, thus rapidly selecting lead peptides. Then residues excluded in 
the first screening are subsequently evaluated by preparing new libraries of single 
compounds where they replace the previous ones. 
The chemical diversity of each library consisted of 12(number of building 
blocks)4(randomized position)=20736 different sequences, each of one repeated 
four times, arranged in 12x4=48 sub-libraries each containing 1728 peptides (=123). 
PS-SSPL were prepared following pre-MIX methodologies (38). Two heptapeptide 
PS-SSPLs (Table 2.2) of general formula KGGXXXX and EGGXXXX (X indicates 
random residues), with four randomized positions, were used to identify specific 
inhibitors of the binding between D4α and PED/PEA15. The two charged residues 
at the N-terminus were chosen in order to substantiate and mutually confirm the 
data obtained with the two libraries and, at the same time, to make more 
homogeneous the solubility properties of the mixture compounds. Opposite charges 
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were introduced at the N-terminus in order to evaluate, and eventually subtract, the 
contribution of the tag charge itself. Since two distinct libraries were prepared in this 
format, a total of 96 different sub-libraries were prepared and analyzed. Libraries 
were screened in parallel on multiple plates with the automated platform and each 
single assay lasted on average 3h, therefore the screening was carried out in a Low 
Throughput mode (LT). 
 
Table 1: Schematic representation of the two heptapeptide PS-SSPLs employed in this study* 
A 
Peptide mixture number Peptide sequence 
1-12 H-K1G2G3O4X5X6X7-NH2 
12-24 H-K1G2G3X4O5X6X7-NH2 
24-36 H-K1G2G3X4X5O 6X7-NH2 
36-48 H-K1G2G3X4X5X6O7-NH2 
 
 
B 
Peptide mixture number Peptide sequence 
1-12 H-E1G2G3O4X5X6X7-NH2 
12-24 H-E1G2G3X4O5X6X7-NH2 
24-36 H-E1G2G3X4X5O 6X7-NH2 
36-48 H-E1G2G3X4X5X6O7-NH2 
  
Table 2.2: Schematic representation of the two heptapeptide PS-SSPL employed in 
this study: The 96 peptide mixtures of two PS-SSCLs were synthesized with specific 
amino acids at one of four randomized positions in the peptide (O4, O5, O6, O7) and the 
random amino acids (X) using an equimolar amino acid mixture. 
 
A rough characterization of peptide mixtures was performed by pool amino acid 
analysis of sub-libraries, as reported elsewhere (39) and by LC-ESI mass 
spectrometry. For this purpose, a narrow bore 50x2 mm ID C18 Biobasic column, 
equilibrated at 0.2 mL/min, was used. A gradient from 2% to 95% of acetonitrile 
(0.1% TFA) over H2O (0.1% TFA) in 170 minutes was applied and most peptides 
were eluted in a relatively narrow chromatographic window (from about 25% to 
about 55%). Averaging the mass spectra (collected between 400 and 2000 amu) 
over the retention time window where peptides were eluted, we obtained a gross 
estimation of the MWs distribution of mixture components. This distribution was 
then compared with the theoretical one expected for an equimolar mixture of the 
peptides generated in the library under analysis.  
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Single peptides were purified by preparative RP-HPLC using a Shimadzu LC-8A, 
equipped with a SPD-M10 AV detector and with a Phenomenex C18 Jupiter column 
(50x22 mm ID; 10 μm). LC-MS analyses were carried out on an LCQ DECA XP Ion 
Trap mass spectrometer equipped with an OPTON ESI source, operating at 4.2 kV 
needle voltage and 320 °C with a complete Surveyor HPLC system, comprised of 
MS pump, an autosampler and a photo diode array (PDA). Narrow bore 50x2 mm 
C18 BioBasic LC-MS columns were used for these analyses.  Peptide products 
were lyophilized and stored at -20 °C until use. 
 
2.2.4. SPR analyses 
The BIAcore 3000 SPR system for Real Time kinetic analysis was from GE 
Healthcare (Milano, Italy). All other reagents and chemicals were commercially 
available by Sigma-Aldrich or Fluka (Steinheim, Germany). D4deletion mutants 
were diluted in GndHCl 0.5 M phosphate buffer 50 mM pH7.2 and gradually 
dialyzed against HBS (10 mM Hepes, 150 mM NaCl, 3 mM EDTA, pH 7.4) 0.1 mM 
TCEP, prior to use. All proteins, PED/PEA15, D4α-MBP, D4β-MBP and MBP, were 
immobilized in 10 mM acetate buffer pH 4.0 (as indicated by previous pH-scouting 
procedures) (flow rate 5 μL/min, time injection 7 min) on a CM5 Biacore sensor 
chip, using EDC/NHS chemistry according to the manufacturer‘s instructions (40). 
Residual reactive groups were deactivated by treatment with 1 M ethanolamine 
hydrochloride, pH 8.5. Reference channels were prepared simply activating with 
EDC/NHS and deactivating with ethanolamine, in the case of PED/PEA15 as ligand. 
MBP was instead immobilized on the reference channels on the biosensors used to 
analyze the D4 deletion mutants. Competitive SPR experiments were carried out 
pre-incubating analytes with competitors at different molar ratios. When employed 
as analytes, D4 deletion mutants, PED/PEA15, MBP and single peptides stock 
solution were diluted in HBS buffer,  0.1 mM TCEP. Analyte injections of 90 μL were 
performed at a flow rate of 20 μL/min at the indicated concentrations. The 
BIAevaluation analysis package (version 4.1, GE Healthcare, Milano, Italy) 
implemented on the instrument software was used to subtract the signal of the 
reference channel and for KDs value estimation. 
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3. RESULTS 
3.1. ELISA-based LTS: identification of PED/PEA15-D4α inhibitors 
employing  PS-SSPLs 
The identification of PED/PEA15-D4α complex inhibitors was carried out employing 
SSPLs in a PS format. An automated Low Throughput Screening (LTS) procedure 
based on ELISA competitive experiments was employed to select the inhibitors. 
In a first screening cycle, the most active peptide mixture(s) were selected for each 
of the four positions. In figure 1 the inhibition percentages of the 96 sub-libraries are 
reported. Each position was analyzed separately bringing to the selection of Ser for 
position  P4, Pro for P5, Phe for P6, Tyr and Gln for P7 for the library bearing Lys at 
its N-terminus (Fig. 3.1 A). From the library having Glu in P1 were identified Tyr for 
P4, Pro and Asp for P5, His for  P6 and Tyr for P7 (Fig. 3.1 B). 
 
 
Fig. 3.1: ELISA-based screening of two simplified peptide libraries. Screening of (A) 
KGGXXXX and (B) EGGXXXX libraries in positional scanning format, by competitive 
ELISA. Each library was made of 48 pools each of them was composed by 1728 peptides. 
Sub-libraries were tested in an ELISA-based competition assay, reporting % inhibition for 
each PS-mixture. 
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In order to confirm the screening data competition experiments of individual 
peptides were performed. By combining  the selected amino acids for P4-P7, two 
single peptides for the first library (KGGSPFQ, KGGSPFY) and two sequences for 
the second (EGGYPHY, EGGYDHY) were designed. As negative control two 
sequences were selected, one for each library (KGGMAML and EGGMC(Acm)AL). 
The corresponding peptides were synthesized, purified and identified by LC-MS 
analysis (data not shown). Their inhibitory capacities were evaluated by competitive 
ELISAs, at two different concentrations (100 and 200 μM) as reported in Fig. 3.2 A-
B.  
 
Figure 3
0
5
10
15
20
25
30
KGGSPFQ KGGSPFY KGGMAML
%
 I
n
h
ib
it
io
n
A C
0
5
10
15
20
25
30
35
40
45
EGGYDHY EGGYPHY EGGMCAL
B D
-7 -6 -5 -4 -3
0.3
0.4
0.5
0.6
0.7
KGGSPFQ
KGGSPFY
KGGMAML
log C, [M]
A
b
s
, 4
9
0
n
m
-5 -4 -3
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
EGGYPHY
EGGMCAL
Log C, [M]
A
b
s
, 4
9
0
n
m
%
 I
n
h
ib
it
io
n
 
Fig. 3.2: Competitive ELISA experiments of lead peptides: Competitive ELISAs of 
single peptides deriving from the screening of (A) KGGXXXX and (B) EGGXXXX, carried 
out employing peptides at 100 and 200 μM. 
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After these preliminary experiments, selected sequences were assayed in a dose-
dependent competitive test, at a concentration range 3.00-400 µM, (Fig. 3.3 A-B), 
and by a non-linear regression fitting of experimental data, we obtained an 
estimation of IC50 values for three out of the four peptides (EGGYDHY gave a poor 
dose-response and the IC50 value couldn‘t be calculated).  
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Fig.3.3: Competitive ELISA experiments of selected peptides: Competitive ELISAs of 
selected peptides deriving from the screening of (A) KGGXXXX and (B) EGGXXXX in the 
concentration range (3.00-400 µM) 
 
A 
B 
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As reported in Table 3.1, all IC50 values were in the micromolar range, suggesting 
that no remarkable differences occur in the inhibition mechanism of Glu- and Lys- 
peptides. Given these similarities, for further investigations, we chose the peptide 
EGGYPHY which has the lowest KD value (79 µM), while the sequence 
EGGMC(Acm)AL was selected as negative control. 
 
Peptide sequence IC50 (M) 
EGGYPHY 79.2 ±1.4 
KGGSPFY 105.5 ±1.6 
KGGSPFQ 261.5±1.4 
 
Table 3.1: IC50 values of most active peptide inhibitors of the complex PED/PEA15-
D4α selected from competitive ELISA screening. 
 
 
On the basis of the amino acidic composition of this lead inhibitor, seven single new 
peptides were designed and synthesized: they contained amino acids  analogous to 
those of the lead peptide that were excluded for the construction of initial libraries.   
Since the consensus sequence was EGGYPHY both tyrosine and histidine were 
replaced by tryptophan leading to the corresponding sequences: EGGWPHY, 
EGGYPWY, EGGYPHW, EGGWPWY, EGGWPHW, EGGWPWW (Table 3.2). 
They were synthesized and assayed in the same competition ELISAs, but results 
showed that the inclusion of Trp residues did not improve inhibition properties of the 
selected lead compound (Fig. 3.4) 
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Table 3.2. New peptide sequences designed on the basis of consensus peptide  
EGGYPHY 
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Fig 3.4. Competitive ELISA experiments: Competitive ELISAs of single peptides deriving 
from the second generation, carried out employing peptides at 100 and 200 μM. 
 New derived peptides  
1  EGGWPHY  
2 EGGYPWY  
3 EGGYPHW  
4 EGGWPWY  
5 EGGWPHW  
6 EGGYPWW  
7 EGGWPWW  
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3.2. SPR experiments: identification of protein ligand 
In order to further characterize the activity of the selected peptide by SPR 
experiments, we primarily analyzed the interaction PED/PEA15-D4α by the same 
technique. Since this interaction has been so far only assessed using a direct 
binding ELISA experiment employing Biotin-Streptavidin as detection system, we 
confirmed it by a different technique that employs unlabelled bio-molecules. For this 
purpose, PED/PEA15, D4α-MBP and MBP proteins were immobilized on the chip 
surfaces, achieving, under the reported conditions (see Experimental Section for 
details), 350, 100 and 80 RU immobilization levels, respectively.  
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Fig. 3.5: SPR experiments of PED/PEA15 D4 deletion mutants. Overlay of sensorgrams 
relative to the binding to immobilized PED/PEA15 of (A) D4α protein, concentrations were 
between 0.050 and 4.0 µM; (B) plot of RUmax from each experiment versus D4α 
concentration (μM); (C) D4β protein, concentration range was 0.10-4.0 μM. Experiments 
were carried out in duplicate at a 25° C, at a constant flow rate of 20 μL/min using HBS 
0.1mM TCEP, as running buffer (90 μL injected for each experiment), signals deriving from 
MBP were subtracted from values obtained for D4 deletion mutants fused to MBP. 
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Direct binding between PED/PEA15 and D4 variants were performed by injecting 
D4-proteins solutions at increasing concentrations from 0 to 4.0 μM on immobilized 
PED protein.  
As shown in  Fig. 3.5 A-B, D4α bound to PED/PEA15 in a dose-response manner 
with a dissociation constant of 2.2±0.4 µM, that was obtained both by kinetic data 
and by plotting RUmax values, from each binding experiment, as a function of D4α 
concentrations (Fig. 3.5 B).  This KD is in very good agreement with that previously 
reported (35) and supports the view that the binding of PLD1 to PED/PEA15 is 
essentially mediated by the region D4α spanning residues 712-818. 
To further confirm this view, we also carried out SPR experiments employing D4β 
region (encompassing residues of PLD1 819-920) (Fig. 3.5 C) and the estimated 
value of KD was 100.2 ± 0.1 µM, about 50-fold lower than that of D4α. This 
experiment validate our approach to find out potential inhibitors of PED/PEA15-
PLD1 physiological interaction focusing mainly on PED/PEA15-D4α complex.  
In order to corroborate our findings, we carried out competitive SPR assays on 
PED/PEA15-D4α complex, employing the selected peptides as competitors.  
These experiments were carried out with increasing amounts of peptides 
(equivalents range 0-200) pre-incubated with a fixed concentration of D4α (1.0 µM), 
and injecting the mixture on a PED/PEA15 derivatized sensor-chip. The overlays of 
obtained sensorgrams are reported in Fig.3.6. 
As expected, we observed a clear and progressive decrease of the RUmax at 
increasing peptide concentration (Fig. 3.6 A), whereas no effects were observed 
with the negative control sequence (Fig. 3.6 B); a fitting of RUmax values against 
peptide concentration provided IC50 of 149 ± 2 μM  (Fig. 3.6 C) in fairly good 
agreement with that estimated through ELISAs. 
50 
 
 
-5
0
5
10
15
20
25
30
-100 0 100 200 300 400 500 600
Time   (s)
R
e
s
p
o
n
s
e
   
(R
U
)
-5
0
5
10
15
20
25
30
-100 0 100 200 300 400 500 600
Time (s)
R
e
s
p
o
n
s
e
   
 (
R
U
)
A
B
Figure 4
-7 -6 -5 -4 -3
10
20
C
log C, [M]
R
U
 m
a
x
 
Fig 3.6: Competitive SPR experiments of lead peptides: Overlay of sensorgrams 
relative to the competitive binding of (A) inhibitor peptide, EGGYPHY (B) negative control to 
the PED-PEA15/D4α complex. Peptides equivalents were between 0 and 200 respect to 
D4α concentration of 1.0 µM. Experiments were carried out in duplicates, at a 25° C, at a 
constant flow rate of 20 μL/min using HBS-0.1 mM TCEP, as running buffer (90 μL injected 
for each experiment). 
 
 
Further, we investigated the molecular basis of the inhibition mechanism, carrying 
out direct binding experiments on both PED/PEA15 and D4α proteins. As shown in 
Fig. 3.7 A, inhibitor peptide did  not bind to immobilized PED/PEA15, while it clearly 
recognized  the immobilized D4α, in a dose-response way (concentrations range 
200-2000 µM, Fig. 3.7 B). 
 
 
51 
 
-150
-100
-50
0
50
100
150
200
- 0 100 200 300 400 500 600
Time   (s)
100
R
e
sp
o
n
se
   
(R
U
)
A
200 µM
750 µM
2000 µM
 
 
 
B
Figure 5
20
50
80
110
140
170
200
-100 0 100 200 300 400 500 600
Time   (s)
R
e
sp
o
n
se
  (
R
U
)
200 µM
300-350 µM
500 µM
750 µM
1500-2000 µM
 
 
Fig. 3.7: Direct SPR experiments of lead peptides: Overlay of sensorgrams relative to 
the direct binding of inhibitor peptide to immobilized (A) PED-PEA15 and (B) D4α-MBP. 
Concentrations were between 200 and 2000 μM. Experiments were carried out in duplicate, 
at a 25° C, at a constant flow rate of 20 μL/min using HBS-0.1 mM TCEP as running buffer 
(90 μL injected for each experiment). 
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4. DISCUSSION 
Type 2 diabetes is a chronic disease characterized by high blood glucose levels 
generally associated to insulin resistance and is the most common form of diabetes 
(41).  
Disease onset and progression is caused by many concurrent alterations, among 
which the protein complex PED/PEA15-PLD1 in individuals expressing high levels 
of PED, is recognized as a major cause  of insulin-resistance (23,11), rendering the 
disruption of this complex a good target for therapeutic intervention.  
Small molecules, which are cheaply produced and have better pharmacological 
profiles compared to biotherapeutics, are ideal candidates as drugs, but, when the 
target is a protein-protein interaction, their use is a great challenge (42,43), due to 
the characteristics of protein interfaces, particularly the lack of grooves and pockets 
in which they could accommodate. An easier practicable way to inhibit protein-
protein interactions is represented by the use of peptides and peptidomimetics that, 
being more flexible, can adopt multiple conformations and are able to adapt to and 
to mime protein interfaces.  
Several studies reported the identification by random screening peptide 
agonists/antagonists that bind to proteins (44,45).  
Our simplified approach,  based on the use of short peptides selected from random 
libraries and constructed with small sets of amino acids, seeks to interpose between 
peptide and small-molecule synthetic approaches, since it preserves the chemical 
robustness and diversity of synthetic peptide-based screening  and, 
contemporaneously, aims to find out short active peptides that could work as 
starting template for the design of new compounds with improved affinity and 
stability. 
Here we present peptides with inhibitory activity that can be rapidly and easily 
identified by this approach, especially in the PS-LTS format. Indeed, it leads, after 
one single screening round, to the unambiguous assignment of  residues on each 
randomized position. The obtained results are further validated by the use of two 
distinct peptide libraries, differing only for the charge at their N-terminus, and by the 
convergence of the screenings on very similar sequences.  
Our study has led to the identification of several bioactive peptides having on each 
of the four explored positions, residues with very similar chemical-physical features.  
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As shown, a H-bonding residue on position P4 (Ser, Tyr), a residue with a sterically 
hindered side chain on P5 (Pro) and aromatic residues on positions P6 (His, Phe) 
and P7 (Tyr) are likely required for activity. 
It should be underscored that sequences selected from the Lys-tagged libraries are 
not identical to those identified from the Glu-tagged one, suggesting the hypothesis 
that the activity of these molecules could be partly influenced by unspecific 
contributions from the positive or negative charges at their N-terminus. This is as 
also demonstrated by the fact that addition of functional tags on the N-terminal end, 
leads to peptides  inactivation (see below). The observation that replacement of Tyr 
with Trp does not alter in either way the activity of the peptides, suggests that the 
recognition with the target protein is likely modulated by both aromatic and H-bond 
donating interactions; this latter presumably prevails at the C-terminus where 
replacement of Tyr with Gln does not substantially impair the activity.    
Since the inhibitor peptide binds to D4α, as assessed by direct SPR analysis, we 
looked for sequence similarity between the sequence EGGYPHY and the primary 
sequence of PED/PEA15. However, no similarity exists between the peptide 
sequences and PED/PEA15 regions involved in binding to PLD1,  that are PED[1-
24] (33) and PED[53-112] (46), nor with the whole sequence of the protein. Instead, 
comparing them with that of D4α, we surprisingly found that some peptide stretches 
on the protein, such as SYPF (spanning 714-717) or, more strikingly, SRHY 
(corresponding to segment 772-775, whereby only an arginine in place of a proline 
is present), are pretty identical to the identified peptides. This observation suggests 
that the peptides we have selected, could mimic a region of D4 involved in the 
dimerization of PLD1 (28,47) and could also likely explain the capacity of the 
peptides to block the interaction between the two proteins, indeed the segment 
SRHY is located within the region of D4 mainly involved in the binding with PED-
PEA15, that spans from 762 to 801 residues (35). 
Dose-response competitive ELISAs allowed to evaluate IC50 values of selected 
peptides in the micromolar range. Any attempt to evaluate  the binding with the 
target protein by tagging the peptides on the N-terminus (with biotin or fluorescent 
tags) were unsuccessful since we experienced a total loss of activity (data not 
shown).  
SPR competitive experiments carried out with the peptides completely confirmed 
the capacities of selected peptides to block complex formation and indeed the 
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micromolar IC50 values were consistent with those measured by ELISA. Direct 
binding assays to the immobilized proteins showed that the peptide recognized only 
D4α, although with a KD in a millimolar range. This discrepancy could be explained 
by a different conformational state of D4α between the PED/PEA15-bound form and 
the free one, presumably the former has a conformation more favorable for peptide 
binding. Several structural studies are in progress and preliminary data suggest that 
D4α and, in particular, the region 762-801 undergoes major conformational changes 
upon PED/PEA15 recognition.  
In conclusion, our results indicate that PED/PEA15-PLD1 protein complex appears 
to be susceptible to peptides with relatively high aromaticity and H-donor capacity, 
which were readily isolated from our simplified libraries. These small sequences can 
be used as promising  scaffolds into higher-affinity compounds both for in vivo 
applications and SAR studies that could aid the design of more efficient inhibitors 
through medicinal-chemistry approaches, preparing small focused libraries of single 
compounds where proline on position 5 is maintained, while residues on position 4, 
6 and 7 are substituted with H-bond donor/acceptor and aromatic non-natural amino 
acids. 
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1. INTRODUCTION 
1.1. Psoriasis 
Psoriasis is an inflammatory genetically  disease of the skin,  that is accompanied 
by an alteration of the proliferation and differentiation of keratinocytes that are the 
major cellular components of the epidermis. This disease shows several clinical 
forms, the most common of which is characterized by evidence of erythematous 
lesions, isolated or confluent. 
They are selectively affected limb extensor face, especially the elbows and knees, 
the sacrococcygeal region and scalp. Psoriasis has an incidence of 2% in the 
population and 5-7% of all dermatoses. It affects both sexes with equal frequency 
and can occur in childhood or later until the ninth decade. It occurs most frequently 
between 5 and 40 years, with the highest peak between 10 and 30 years. In 
psoriatic lesions are demonstrable in several biochemical, histopathological and 
immunological alterations but none of them is so specific that it is considered a 
marker of psoriasis. 
 
 
1.1.1. The causes of Psoriasis 
Although the primary cause of psoriasis is still controversial whether, this disease 
resulted from an intrinsic abnormality of the epidermal keratinocyte and/or altered 
regulation of the immune system. Numerous studies have shown unequivocally that 
T cells play a crucial role in the turnover and psoriatic keratinocyte growth (1). 
Studies in immunocompromised mice (SCID) (in which psoriatic skin asymptomatic 
and healthy grafts were transplanted) showed that intrinsic alterations of the 
keratinocyte are necessary to induce psoriasis (1). Indeed only the psoriatic skin is 
able to evolve pathologically, once transplanted immune-competent cells of the 
patient in the dermis of the animals. In addition psoriasis stems from defects in 
endogenous keratinocyte has been recently obtained through the use of genetically 
engineered animals (2-4). In particular, transgenic mice that express specifically 
high levels in the epidermis of the protein STAT3 (Signal Transducer and Activator 
of Transcription 3) (2) or lacking IKK2 inhibitor (Inhibitor of IK kinase 2) (3) develop 
skin lesions that resemble to those of psoriatic patients. Similarly, the elimination of 
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the protein in keratinocytes AP-1 (JunB/activator protein 1) (4) induces a phenotype 
in the skin of mice with histological features of psoriasis, including epidermal 
hyperplasia and a marked presence of an abundant inflammatory infiltrate dermis. 
In addition the psoriatic keratinocyte shows defects in the control of the expression 
of pro-inflammatory factors displaying altered proliferation and differentiation ability. 
For example, patients with psoriatic keratinocytes produce abnormal amounts of 
certain chemotactic substances, known to be involved in the recruitment of 
inflammatory cells, including IL-8, MCP-1 and IP-10 (1). The system of production of 
cytokines, proteins essential for intercellular communication, is severely defective in 
psoriatic keratinocytes, thus profound alterations in receptor-interleukin 1 (IL-1) and 
expression of cytokines IL-15, IL-18 and VEGF (Vascular Endothelial Growth 
Factor), were detected in the epidermis of psoriatic skin (1). 
The improper answer of psoriatic keratinocytes against IFN (interferon)-γ (5) is one 
of their intrinsic defects. IFN- is one of the most powerful inflammatory stimuli, 
abundantly present in psoriatic skin. The intradermal injection of IFN-γ in psoriatic 
asymptomatic skin determines the proliferation of keratinocytes and the 
development of psoriatic lesions (5). Therefore the increased and inappropriate 
expression of inflammatory molecules (chemotactic substances, cytokines) as well 
as the alteration of proliferative processes in the epidermis of psoriatic patients 
depends heavily on the local production of IFN-γ (5). 
 
1.2. Cytokines and IFN-γ 
Cytokines is a highly heterogeneous group of small and secret messenger proteins, 
involved in intercellular communication in multicellular organisms and some of them 
remain cell bound. Two crucial features characterize the cytokine network: their 
pleiotropy and redundancy. Pleiotropy indicates that one cytokine can cause a 
broad range of responses depending on the cell type or the differentiation stage; 
thus cytokines can orchestrate a coordinated response of different cellular 
processes. Redundancy implies that different cytokines can exert similar biological 
activities. In this way, important cellular mechanisms are preserved by a back-up 
mechanism, in which one cytokine can compensate for the loss of another. These 
compensatory mechanisms can be explained in part by the common use of certain 
receptor chains and signaling molecules by the different cytokines. 
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Originally, cytokines were classified on the basis of their biological responses, but, 
given the apparent functional pleiotropy and low sequence homology, current 
cytokine classification relies on structural similarities. According to the Cytokine 
Web (http://cmbi.bjmu.edu.cn/cmbidata/cgf/CGF_Database/cytweb/index.html) 
different fold families can be distinguished (Table 1.1). 
 
 
 
Table 1.1: Classification of the cytokines based on similarity in protein folding 
 
 
 
IFN-γ is a key cytokine that regulates a variety of cellular activities, including 
antiviral immunity, apoptosis, and cell cycle progression. In the skin, it plays a 
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pivotal role in the development of inflammatory and immune responses.  
Interferons allow communication between cells to trigger the protective defenses of 
the immune system that eradicate pathogens or tumors and are named after their 
ability to "interfere" with viral replication within host cells. Furthermore they activate 
immune cells, such as natural killer cells and macrophages, increase recognition of 
infection or tumor cells by up-regulating antigen presentation to T lymphocytes; and 
the ability of uninfected host cells to resist new infection by virus. Certain host 
symptoms, such as aching muscles and fever, are related to the production of IFNs 
during infection. About ten distinct IFNs have been identified in mammals; seven of 
these have been described for humans. They are typically divided among three IFN 
classes: Type I IFN, Type II IFN, and Type III IFN. IFNs belonging to all IFN 
classes are very important for fighting viral infections. 
Based on the type of receptor through which they signal, human interferons have 
been classified into three major types. 
 Interferon type I: All type I IFNs bind to a specific cell surface receptor 
complex known as the IFN-α receptor (IFNAR) that consists of IFNAR1 and 
IFNAR2 chains.(6) The type I interferons present in humans are IFN-α, IFN-
β and IFN-ω.(7) 
 Interferon type II: Binds to IFNGR that consists of IFNGR1 and 
IFNGR2 chains. In humans this is IFN-γ. 
 Interferon type III: Signal through a receptor complex consisting of 
IL10R2 (also called CRF2-4) and IFNLR1 (also called CRF2-12). 
Acceptance of this classification is less universal than that of type I and type 
II, and unlike the other two, it is not currently included in Medical Subject 
Headings.(8) 
 
Keratinocytes, which constitutively bear the IFN- γ receptor complex, are a primary 
target of IFN-γ (9). During immune-mediated skin diseases, after exposure to IFN- 
γ, keratinocytes become a source of a plethora of inflammatory mediators involved 
in the initiation and amplification of pathogenetic processes (10). In particular, IFN- 
γ induces the expression of numerous chemokines, including CCL2 and CXCL10, 
which drive immigration of T cells, monocytes, and dendritic cells into inflamed 
skin. IFN- γ-treated keratinocytes are also a source of CXCL8, a pleiotropic 
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chemokine showing a strong chemoattractant activity on neutrophils as well as 
tissue-protective and prosurvival functions (11). 
 
 
1.3. The JAK-STAT pathway 
IFN-γ intracellular signaling activates a number of molecular cascades initiated by 
Janus-activated kinases 1 (Jak1) and Jak2 phosphorylation and culminates in the 
activation of transcription factors, mainly Signal transducer and Activator of 
Transcription (STAT) 1 and interferon regulatory factor-1, which can induce the 
IFN-stimulated gene (ISG) expression (12).  
The cell membrane receptor for IFN-γ is composed of two subunits, IFN-γR1 and 
IFN-γR2. Upon binding to IFN-γ, the IFN- γ-Receptor complex induce clustering 
and/or reorganization of the receptor chains in such a way that the associated 
Janus tyrosine kinases (JAKs) will be brought in close proximity, allowing them to 
activate each other by cross-phosphorylation. JAK enzymes phosphorylate one 
another and then subsequently phosphorylate the IFN-γ receptor, which results in 
the formation of a docking site for the latent cytoplasmic transcription factor named 
STAT-1, a member of the STAT (signal transducer and activator of transcription) 
protein family (13). Upon phosphorylation, STAT-1 homodimerizes, translocates to 
the nucleus, and regulates gene transcription by binding to IFN-γ-activated 
sequences (GAS) in the IFN-γ-inducible genes. Homodimerization of STAT-1 is 
mediated by the binding of the phosphorylated tyrosine 701 of one STAT-1 
monomer the Src homology 2 domain of another. However, maximal transcriptional 
activity by active STAT-1 homodimers also requires STAT-1 phosphorylation at 
serine 727 (14). It has been found that STAT-1 phosphorylation plays a critical role 
in IFN-mediated innate immunity to microbial infection. STAT-1 signaling can also 
be negatively regulated by the protein inhibitor of activated STAT-1 (PIAS1) and 
suppressor of cytokine signaling (SOCS) (15). More interestingly, IFN-γ can also 
regulate expression of its inducible genes in a STAT-1-independent manner, 
suggesting that multiple signaling pathways in parallel play important roles in the 
biological response to IFN-γ (Fig.1.1). 
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Fig. 1.1: Schematic representation of the JAK/STAT pathway 
 
 
1.3.1. The JAK protein family  
This kinase family is named after Janus, the Roman god of gates and doors, 
beginnings and endings. Therefore Janus is represented with a double-faced head, 
each looking in an opposite direction. This is reminiscent of the distinctive feature 
of JAK structure: their kinase and pseudokinase domain. In mammals, the JAK 
family comprises four members: JAK1-3 and Tyk2. JAK1, JAK2 and Tyk2 are 
expressed ubiquitously, while the expression of JAK3 is restricted to cells of 
haematopoietic origin (16). Targeted disruption of the JAK2 gene results in 
embryonic lethality due to failure of erythropoiesis. Cells from these mice showed 
that this kinase is essential for different cytokine responses including IL-3, IL-5, 
GM-CSF and IFN-γ (17). JAKs are large proteins of approximately one thousand 
amino acids, the comparison of JAK sequences reveals seven regions of high 
similarity, called JAK homology (JH) domains 1 to 7 (Fig. 1.2). The C-terminal JH1 
and JH2 domains encode respectively a kinase and pseudokinase domain. 
Although this latter domain contains structural features of a tyrosine kinase, it is 
devoid of any catalytic activity. Reports suggest that this domain modulates the 
catalytic activity of the kinase domain (18). The JH1 kinase domain behaves like a 
classical tyrosine kinase: it contains tyrosine residues that become phosphorylated 
upon activation, thereby inducing conformational changes that allow binding of the 
substrates in the catalytic site of the JAK (19).  
66 
 
 
 
 
Fig. 1.2: Schematic representation of the JAK structure: JAKs share seven regions of 
high similarity (JH1-7). N-terminal domains mediate receptor association; JH1 and JH2 
encode respectively a kinase and pseudokinase domain. The ruler underneath indicates 
the number of AA. 
 
 
The N-terminal part of the JAKs, containing JH3-7, is involved in association with 
the receptor. Specifically, JAKs associate with the proline-rich, membrane-proximal 
box1 and box2 domains of class I cytokine receptors. The JH3-JH4 regions form a 
structural domain resembling a SH2 domain, but appear not to be implicated in 
phosphotyrosine-dependent interactions, as SH2 domains typically do. However, 
this region is structurally important for receptor association and receptor surface 
expression (20). Finally, the structure of the N-terminal (JH5-JH7) domains 
resembles that of Four-point-one, Ezrin, Radixin and Moesin (FERM) domains, 
which are known to mediate protein-protein interactions with for example 
phosphatidylinositolbisphosphate (PIP2) and inositoltrisphosphate (IP3) (21). This 
region mediates receptor binding and is involved in the maintenance of catalytical 
activity (22). 
 
1.3.2. The STAT protein family 
The family of mammalian STAT proteins consists of seven members: STAT1, 
STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6. They function as 
transcription factors which reside predominantly in the cytoplasm in unstimulated 
cells, most probably as preformed dimers (23). STAT1, STAT3 and STAT4 can 
form both homo- and heterodimers while for STAT5 and STAT6 only homodimers 
have been observed. STAT2 is only functional when complexed with STAT1 or 
67 
 
STAT4. Receptor binding and subsequent phosphorylation on tyrosine and serine 
residues will activate STATs followed by their nuclear translocation. In the nucleus, 
they initiate transcription by associating with specific response elements in the 
promoter of target genes. The mechanisms underlying the transport of the STATs 
between the cytoplasm and the nucleus are only partially understood. The 
predominantly cytosolic localisation for inactive STATs has been shown to reflect a 
steady-state, where continuous basal nuclear import is balanced by continuous 
basal nuclear export. After activation, the balance is shifted toward nuclear 
accumulation and during signal decay toward nuclear export. Translocation of 
STAT dimers to the nucleus is mediated by specific nuclear localisation signals 
(NLS) and involves an active nuclear import mechanism depending on Ran and 
importin-α5 (24). A nuclear export signal (NES) drives the nuclear export of STATs 
mediated by Ran and exportin 1. STAT dephosphorylation and dissociation from 
the DNA unmasks the NES sequence and activates the export mechanism (25 ). 
STATs are about 800 amino acid long and therein six structurally and functionally 
conserved domains have been identified (Fig. 1.3). The N-terminus contains a 
dimer-dimer interaction domain that apparently allows STAT dimers to form 
tetramers that can cooperatively associate with multiple tandem STAT response 
elements in the promoter (26). It was also reported that this domain is involved in 
nuclear translocation and STAT deactivation (27). The N-terminal region is linked 
to the DNA binding domain by a coiled-coil domain which consists of four helices. 
This domain can interact with other transcription factors and is also implicated in 
receptor binding, tyrosine phosphorylation and nuclear export (28).  
 
 
 
Fig. 1.3: Schematic representation of the STAT structure: P indicates phosphorylated 
residues. The ruler underneath indicates the number of AA. 
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The centrally located DNA binding domain harbours a typical β-barrel with an Ig 
fold, a structure found in various transcription factors, like NF-κB and p53. 
Obviously, it is implicated in DNA association but there are only little direct 
interaction sites (29). 
The SH2 domain is crucial for docking of the STAT to the phosphorylated tyrosine 
motifs in the receptor or in JAK kinases and it also mediates dimerisation of the 
STATs. The SH2 domain consists of a β-sheet flanked by two α-helices, which 
form a pocket structure. A conserved arginine residing in this pocket is essential for 
the interaction with phosphotyrosine residues (29). C-terminal to the SH2 domain, 
STATs have a conserved tyrosine residue which becomes phosphorylated by the 
JAK kinases upon receptor binding. Dimerization of the activated STATs is based 
on the reciprocal interaction of the SH2 domain with this 
phosphorylated tyrosine. The more variable C-terminus of STATs encodes a 
transcription activation domain (TAD). This divergence provides an opportunity to 
associate with distinct transcriptional regulators. This domain can be serine 
phosphorylated, which enhances the transcription of some genes (30). 
STAT1 deficient mice confirmed the pivotal role that STAT1 plays in the biological 
response to both type I and type II IFNs. These mice are highly susceptible to 
bacterial and viral infections (31). 
Indeed naturally occurring mutations in human STAT1 exhibit increased 
susceptibility to viral and bacterial infections (32). STAT1 seems to be also 
implicated in non immune-responses, like chondrocyte proliferation (33) and IFNγ-
mediated growth inhibition, and was revealed by the enhanced tumor susceptibility 
of STAT1-/- mice (34). 
 
1.4. SOCS family 
SOCSs are a family of intracellular proteins that play a major role in the regulation 
of cytokine responses, it counts eight members: CIS and SOCS1 through SOCS7 
(35). SOCS proteins are often expressed at low or undetectable levels in resting 
cells. They are rapidly up-regulated in response to a broad spectrum of cytokines 
and, in turn, control the duration and intensity of cytokine responses by blocking 
various aspects of the signalling pathways. SOCS proteins function in a typical 
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negative feedback loop, since they can down-modulate the signalling pathway that 
stimulates their production. The pattern of SOCS expression by a particular 
cytokine tends to vary according to the cell type or tissue. The induced SOCS 
proteins can attenuate responses of various cytokines and may be involved in 
inhibitory cross-talk between different cytokine systems, providing a mechanism by 
which concurrent signaling processes can modulate each other. Although SOCS 
proteins are induced by a range of cytokines and show a high structural and 
functional overlap, large evidence indicates the potential of specific SOCS proteins 
to modulate cytokine signalling with exquisite control.  
STAT proteins are the major regulators of SOCS gene expression. STAT binding 
sequences were identified in the SOCS promoter region and electrophoretic 
mobility shift assays confirmed STAT association to these motifs. In some cases, 
STAT induced SOCS expression is indirect. STAT1 is for example indirectly 
implicated in IFNγ mediated upregulation of SOCS1 since it drives expression of 
the interferon regulatory factor-1 (IRF-1) transcription factor which is responsible 
for SOCS1 induction (36). The general structure of SOCS proteins is evolutionary 
well preserved and common features include an N-terminal pre-SH2 domain, a 
central SH2 domain and a C-terminal SOCS box (Fig. 1.4). The N-terminal part 
varies in length and sequence similarity while the SH2 domain and SOCS box are 
most conserved. 
 
 
 
Fig. 1.4: Domain structure of the SOCS protein family: The major structural 
characteristic of the SOCS family is the presence of two domains with relatively well 
conserved AA sequence: an SH2 domain in the middle portion and a SOCS 
box at the C-terminus. Only SOCS1 and -3 possess a KIR immediately upstream of the 
SH2 domain. Conserved tyrosines in the SOCS box are represented by a black line. 
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1.4.1. The N-terminal domain: JAK kinase inhibition 
The N-terminus varies greatly in length among the SOCS members and contains 
no homology to known structural domains. Nevertheless, an extended SH2 
subdomain (ESS) helix was identified as a conserved structural element in CIS and 
SOCS1-3 and appeared to be critical for high affinity SH2 substrate interactions 
(37). Both SOCS1 and 3 can be distinguished from the other SOCS proteins by an 
additional small kinase inhibitory region (KIR)  located in the N-terminal portion and 
involved in inhibition of the JAK kinases. This region was found functionally 
interchangeable between the two SOCS suggesting a common inhibitory 
mechanism (38). The KIR region displays some sequence similarity with the 
activation loop of JAK2, suggesting that it acts as a pseudosubstrate by mimicking 
the activation loop that regulates access to the catalytic groove (37). Based on a 
structural model of SOCS1 in complex with JAK2 it was proposed that the KIR 
region suppresses JAK activity by obstructing the access of both ATP and 
substrate to their respective binding sites (39) (Fig. 1.5). Although the SH2 domain 
of SOCS3 does not have a high affinity for JAK kinases, the KIR domain of SOCS3 
shows a stronger potential for both binding and inhibition of JAKs than that of 
SOCS1 (40). The wide range of actions exhibited by SOCS1 and SOCS3 is most 
probably due to their additional ability to inhibit the catalytic activity of JAK kinases. 
 
 
 
Fig. 1.5: Structural model of the complex between JAK2 (red) and SOCS1 (yellow). 
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1.4.2. The SH2 domain: substrate specificity and competition for receptor 
motifs 
The central SH2 domain determines the target of the SOCS protein. It allows 
interaction with phosphorylated tyrosine residues of other proteins, like receptors, 
JAKs or adaptors. In this way, SOCS proteins can exert their inhibitory effects by 
competing with other signalling molecules including STATs for phosphorylated 
tyrosine motifs in the receptor complex.  
 
 
 
Fig. 1.6: Schematic representation of molecular mechanisms of SOCS actions 
 
 
 
SOCS1 directly interacts with all JAK members, thereby inhibiting their catalytic 
activity (38). It targets the phosphotyrosine at position Y1007, which lies within the 
activation loop of JAK2 (39,37). Activation of the kinase is dependent on 
phosphorylation of this particular tyrosine. The SOCS1 SH2 domain is sufficient for 
JAK2 interaction. However, as above mentioned, an additional region of 
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approximately 30 residues immediately N-terminal to the SH2 domain (the ESS) 
and the KIR are additionally required for high affinity binding and inhibition of JAK2 
activity (39,37). Remarkably, SOCS1 has also been shown to bind directly to the 
type I and type II IFN receptors, which might provide a very efficient inhibitory effect 
of SOCS1 on IFN signaling (41) (Fig. 1.6).   
 
1.4.3. The SOCS box: proteasomal targeting and protein stability 
The C-terminal SOCS box is conserved throughout the SOCS family, thus 
suggesting an important role for this region in the function and regulation of SOCS 
proteins. Different SOCS box containing protein families have been identified: clues 
to understand the function of the SOCS box came from the initial finding that the 
Von Hippel-Lindau (VHL) tumor suppressor protein interacts with its Elongin B/C 
complex via the SOCS box, linking VHL to the ubiquitin/proteasome degradation 
system (42). The Elongin B/C-Cullin-SOCS box (ECS) complex was characterized 
as a family of E3 ubiquitin ligases in which the SOCS box protein acts as the 
substrate recognition unit of the complex (43). The E3 ubiquitin ligase participates 
in the polyubiquitin tagging of associated proteins and is responsible for substrate 
specificity. In this way, SOCS box proteins may suppress signalling by linking 
associated signalling components for degradation (44). Consistent with this idea, 
proteasomal inhibitors block the inhibitory functions of SOCS and induce sustained 
JAK-STAT signalling (45). The functional importance of the SOCS box was 
confirmed by the generation of transgenic mice expressing a C-terminal truncated 
variant of SOCS1 or SOCS3. These mice exhibit impaired regulation of 
respectively INFγ and G-CSF signalling, suggesting that the SOCS box is essential 
for complete SOCS activity (46). 
 
1.5. SOCS proteins in disease: Inflammatory diseases 
SOCS proteins are crucially implicated in the regulation of JAK/STAT signalling in 
inflammation. Accordingly, alterations in SOCS protein levels, and more specific 
SOCS1, has been associated with the pathogenesis of various inflammatory 
diseases including  psoriasis. SOCS1 expression is induced by a wide variety of 
inflammatory and anti-inflammatory cytokines, including IFNγ, IL-3, IL-6 and IL-10 
and will function to counteract STAT1 activation associated with inflammatory 
disorders. Several data show that the over-expression of SOCS1 in keratinocyte 
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clones, abrogates the IFN-γ-induced expression of many pro-inflammatory genes 
such as ICAM-1 (Inter-Cellular Adhesion Molecule-1) and the MHC (Major 
Histocompatibility Complex) class II molecules, and the release of related 
chemokines, by inhibiting JAK2 and STAT1 protein activities. Furthermore, the 
protection against SOCS1-mediated cytokine-induced cytotoxicity is correlated with 
a significant inhibition of the transcription factor interferon regulatory factor-1 (IRF-
1) (47,48).  The inactivation of kinase activity of JAK2 by SOCS1 impedes the IFN-
γ-induced tyrosine phosphorylation of IFN-γ receptor (IFN-γ R)α subunit and 
consequently STAT1 activation (49,50) (Fig. 1.7). Hence the lack of STAT1 
function in keratinocytes over-expressing SOCS1 impedes the expression of pro-
inflammatory proteins such as ICAM-1 and MHC class II membrane molecules, as 
well as CXCL10, CXCL9, and CCL2 in response to IFN-γ, blocking the 
inflammatory process (50). 
 
 
SOCS induction
 
Fig. 1.7: Cytokine signal transduction. (a) Cytokines induce the dimerization 
of their cognate receptors, which leads to juxtaposition and activation 
of Janus kinases (JAKS). (b) JAKs phosphorylate the cytoplasmic domains 
of receptors, creating docking sites for cytoplasmic proteins such as 
signal transducers and activators of transcription (STATs). (c) Following 
phosphorylation by JAKs, STATs form dimers and (d) migrate to the 
nucleus to activate target genes, including those that encode the 
suppressors of cytokine signaling (SOCS). Once produced, members of 
the SOCS protein family (including SOCS-1, SOCS-3 and CIS) act back 
on the JAK–STAT pathway to temper signal transduction.  
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1.6. Therapeutic applications of SOCS 
Therapeutic application of SOCS proteins are valuable for the treatment of 
diseases in which overshoot cytokine signalling is involved, such as those related 
with inflammation or cancer. One approach would be the overexpression of SOCS 
molecule, indeed it has been demonstrated that the adenovirus-mediated 
administration of SOCS3 prevents the development of RA in experimental mouse 
models (51) and fusion of SOCS proteins with membrane-permeable peptides 
might be an alternative way to introduce them into cells. In this context, intracellular 
delivery of a cell-penetrating form of SOCS3 was proven to be effective for 
treatment of various types of inflammation and septic shock (52). A second 
approach is related to the identification of small-molecule mimetics of SOCS 
proteins. The tyrosine kinase inhibitor peptide (Tkip) is an example of a mimetic of 
SOCS1 and effectively inhibits JAK2-mediated phosphorylation of STATs. This 
peptide prevented the development of experimental allergic encephalomyelitis 
(EAE) in mice (53) and blocked the proliferation of prostate cancer cell lines (54). A 
third approach might be blocking SOCS degradation in vivo. Alternatively, the 
structural insights in SOCS interactions may provide a basis for the design of 
SOCS inhibitors. 
  
 
1.7. Aim of the work 
Johnson and coworkers investigated the anti-inflammatory effects of SOCS1 
employing peptides mimicking KIR domain: they did not inhibit JAK2 
autophosphorylation but they were able to block STAT1 activation (similar to the 
pattern or proﬁle of SOCS-1 inhibition of phosphorylation) in vitro and in vivo 
inhibiting IFN- activation of Raw 264.7 murine macrophages and Ag-specific 
splenocyte proliferation (55). Thus, they have shown in that studies (55) that the 
KIR region of SOCS-1 can directly bind to the autophosphorylation site of JAK2. 
The purpose of the project was the development of new peptide sequences 
mimicking KIR capable of to mime SOCS-1 function by inhibiting the JAK2/STAT1 
cascade induced by IFN-γ in human keratinocytes through binding and inhibition of 
JAK2 kinase activity. In order to select new peptides with improved binding 
properties for the target protein, a SARs studies of new peptides were carried out 
by using multiple approaches to chemical synthesis and biochemical assays. 
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These ﬁndings with SOCS-1 mimetics and antagonists have implications for novel 
therapeutic approaches to mimicking SOCS-1 for treatment of inﬂammatory 
diseases and for suppressing SOCS-1 to enhance the immune response against 
cancer and infectious diseases. 
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2. EXPERIMENTAL SECTION 
 
2.1. Materials 
N-α-protected Fmoc-amino acid derivatives and coupling reagents for peptide 
synthesis were from Inbios (Pozzuoli, Napoli). DIEA, Rink amide MBHA resin, tri-
isopropyl-silane (TIS) and reagents for ELISA assays were from Sigma-Aldrich 
(Milano, Italy). HPLC-grade solvents and trifluoroacetic acid (TFA) were from 
LabScan (Stillorgan, Dublin, Ireland) and were used as received unless otherwise 
stated. Other reagents and chemical suppliers are indicated in the section of  
methods. Solid phase peptide syntheses was performed on a fully automated 
multichannel peptide synthesizer Syro I (Multisynthech, Germany). Preparative RP-
HPLC were carried out on a Shimadzu LC-8A, equipped with a SPD-M10 AV 
detector and with a Phenomenex C18 Jupiter column (50x22 mm ID; 10 m). LC-
MS analyses were carried out on an LCQ DECA XP Ion Trap mass spectrometer 
equipped with an OPTON ESI source, operating at 4.2 kV needle voltage and 320 
°C and with a complete Surveyor HPLC system, comprising a MS pump, an 
autosampler and a photo diode array (PDA). Narrow bore 50x2 mm C18 BioBasic 
LC-MS columns were used for analyses. All ELISA assays to screen the synthetic 
peptides, were carried out using a fully automated system (Hamilton Robotics, 
Milano, Italy) comprising a liquid handler, an automatic arm, a washer and an 
automated Synergy 4 multi-wavelength reader (BIOTEK Instruments, Inc. Highland 
Park, VT, USA). 
 
2.2. Peptide Synthesis 
Peptide libraries and single sequences were prepared by the solid phase method 
on a 50 μmol scale following the Fmoc strategy and using standard Fmoc-
derivatized amino acids RINK AMIDE resin (substitution 0.5 mmol/g) was used as 
solid support. Activation of amino acids was achieved using HBTU/HOBt/DIEA 
(1:1:2), whereas Fmoc deprotection was carried out using a 40% (v/v) piperidine 
solution in DMF. All couplings were performed for 15 minutes and deprotections for 
10 minutes. Randomized positions were coupled using equimolar mixtures of 12 
building blocks employing a 100-fold excess of each amino acid. The focused 
simplified peptide library was prepared in the positional scanning format following 
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pre-MIX methodologies (47). Peptides were removed from the resin by treatment 
with a TFA:TIS:H2O (90:5:5, v/v/v) mixture, then they were precipitated in cold 
diethylether and lyophilized. Single peptides were purified by preparative RP-
HPLC, and their identity was evaluated by LC-MS analysis. Peptide products were 
stored at -20 °C until use. 
The MW distributions analysis of single sub-libraries was performed with LC-ESI 
mass spectrometry (averaging the mass spectra over the retention time window 
where peptides were eluted) and appeared consistent with the theoretical 
distribution of MWs calculated for the sequences present within single mixture and 
the homogeneous composition of each mixture was further assessed by amino 
acidic analysis. To perform cellular assays CPPs (Cell penetrating Peptides) 
conjugated peptides were synthesized and purified. Conjugated peptides were also 
fluoresceinated at their N-termini with Fluoresceine-βAla. 
 
2.3. ELISA Binding and competition experiments 
To perform ELISA assays, 96-well plates (Nunc, Milan, Italy) were coated with 
single Fmoc-peptides and Fmoc-peptide mixtures at fixed concentrations (0.0100 
mM) in carbonate buffer 100 mM pH 9 for 16 h at 4°C. Some wells were filled with 
buffer alone and were used as blank. After coating, the  plates were washed three 
times with PBS-T buffer (PBS containing 0.04% Tween-20) and blocked with 300 
µL of PBS containing 1% BSA, for 2 h at 37°C. After washing, solutions at 
increasing concentrations of biotinylated Jak2 peptides between 0.010 and 0.600 
mM  in carbonate buffer 100 mM were added to coated wells and incubated 1 h at 
37°C. After washing again with PBS-T, 100 μL of SA-HRP conjugated (Santa Cruz 
Biotechnology, California, USA) diluted 1:10000 with PBS was added. After 1 h 
incubation at 37°C, the plates were washed again with PBS-T and 100 µL of 
chromogenic substrate, o-phenylendiamine 0.4 mg/mL in 50 mM sodium-
phosphate-citrate buffer pH 5.0 containing 0.4 mg/mL H2O2, were added and the 
reaction was stopped by adding 50 µL of 2.5 M H2SO4 in each well. The 
absorbance was measured at 490 nm. Data points were in triplicates or duplicates 
and reported experiments are from three independent assays. Competitive ELISA 
experiments were carried out coating with Fmoc-KIR (0.010 mM) and pre-
incubating biotinylated JAK2 peptides at 0.100 mM with PS-peptides in dose-
response experiments in concentrations range 1*10-5 ÷ 0.100 mM. Data were 
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reported subtracting signals deriving by non-coated wells. Data were averaged by 
three independent experiments. Experimental data were  fitted with GraphPad 
Prism, vers. 4.00, GraphPad Software (San Diego, California). 
 
2.4. Stability Assay 
Tat-PS-5 and Tat-KIR were dissolved in water at a 10 mg/mL concentration. The 
samples were then serially diluted in PBS, pH 7.3, containing 10% fetal calf serum 
(FCS) to obtain 100 μg/mL solutions and incubated at 37 °C for 20 h. 10 μL 
aliquots (1.0 μg of total peptide) were removed every two hours. Samples were 
immediately centrifuged for 5 min at 14,000 rpm and analyzed by reverse phase-
HPLC after discarding the pellet. The experiment was carried out in duplicate and 
the data were reported as residual peptide in solution (in percentages) versus time.  
 
2.5. Peptide processing in cellular extracts  
Keratinocyte protein extracts for MS analysis were prepared using keratinocyte 
cultures pre-treated with PS-4, PS-5 and PS-KIR peptides and, then, treated with 
IFN-γ for 3h. Cells were lysed using a buffer containing 20 mM Tris-HCl, 150 mM 
NaCl, 1% Triton, and, then, analyzed by RP-HPLC-MS using a C18 column and 
mass spectrometer in SIM (Single Ion Monitoring)-mode.  
 
2.6. Keratinocyte cultures and treatments with peptides 
Normal human keratinocytes were obtained from skin biopsies of healthy 
volunteers (n = 3), as previously reported [28]. Brieﬂy, cells were cultured in the 
serum-free medium, keratinocyte growth medium (KGM; Clonetics, Walkersville, 
MD, USA), for at least 3–5 days (at 60 – 80% conﬂuence). Stimulation with 200 
U/ml rh IFN-γ (R&D Systems, Minneapolis, MN, USA) was performed in 
keratinocyte basal medium (KBM; Clonetics). Cultures were treated with 10 μM of 
PS-4, PS-5 and KIR for two hours before adding IFN-γ, and then processed for the 
different experiments. 
 
2.7. Fluorescence microscopy and FACS analysis 
Keratinocyte cultures treated for 24 h with peptides tagged with TAT or pVec 
sequences and conjugated with the fluorocrome FITC were analyzed by 
79 
 
fluorescence microscopy, prior fixation  with 3% paraformaldehyde/PBS. 
Coverslips were mounted and slides analyzed using a Zeiss LSM 510 meta-
confocal microscope (Zeiss, Oberkochen, Germany). Otherwise, peptide-treated 
keratinocytes were analyzed by flow cytometry with a FACScan equipped with Cell 
Quest software (Becton Dickinson, Mountain View, CA). 
 
2.8. Western blotting analysis 
Subconfluent keratinocyte cultures were pre-treated for 2 h with 10 mM PS-4, PS-
5 and KIR, then, stimulated for 15 min or 3 h with rh IFN-γ. Cells were lysed in a 
buffer containing 20 mM Tris-HCl, 150 mM NaCl, 1% Triton. Cell lysates were 
centrifuged, and supernatants directly evaluated for total protein amount with the 
BioRad Protein Assay (BioRad, Hercules, CA). Equal quantity of total proteins were 
separated by 10% SDS-gel electrophoresis and transferred onto a nitrocellulose 
filter (Hybond-ECL, GE Healthcare). Protein detection was performed using the 
following antibodies: anti-phosphotyrosine (PY) STAT1 (Tyr701) (Santa Cruz 
Biotechnology, Santa Cruz, CA), anti-STAT1 (Santa Cruz Biotechnology), anti–
IRF-1 (M-20; Santa Cruz Biotechnology), and anti-β-actin (C-11; Santa Cruz 
Biotechnology), and a chemiluminescence detection system (GE Healthcare, 
Amersham, UK). Relative intensity of signals was quantified using a GS-710 
densitometer (Bio-Rad). 
 
2.9. Circular Dichroism (CD) Spectroscopy 
CD spectra were recorded on a Jasco J-810 spectropolarimeter (JASCO Corp, 
Milan, Italy). CD spectra were registered at 25 °C in the far UV region from 190 to 
260 nm. Each spectrum was obtained averaging three scans, subtracting 
contributions from corresponding blanks and converting the signal to mean residue 
ellipticity in units of deg*cm2*dmol-1* res-1. Other experimental settings were: 20 
nm/min scan speed, 2.0 nm band width, 0.2 nm resolution, 50 mdeg sensitivity, 
and 4 sec response. The concentration of peptides was kept at 10×10−5 M and a 
0.1 cm path-length quartz cuvette was used. Spectra were acquired in 10 mM 
phosphate buffer at pH 7.0.  
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3. RESULTS 
3.1. Identification of crucial residues of KIR involved in JAK2 catalytic site 
recognition  
The ability of KIR (SOCS1 52-67) domain to bind to the JAK2 peptide (JAK2 1001-
1013) reproducing the JH1 domain  both in the phosphorylated (Tyr1007) pJAK2, 
and in the non-phosphorylated form, JAK2 (Table 3.1) was already reported in 
previous studies (55).  
 
 Table 1: Peptide sequences utilized in this study. Bold Y indicates a phosphorylated tyrosine.  
 
Peptide Sequence 
JAK2 
1001LPQDKEYYKVKEP1013 
pJAK2 
1001LPQDKEYYKVKEP1013 
MuIFN-γ 
95AKFEVNNPQVQR106 
KIR 
52DTHFRTFRSHSDYRRI67 
New KIR 
52DTHFRTFRSH61 
PS-5 DTC(Acm)RQTFRSH 
PS-11 DTFPQTFRSH 
PS-12 DTFFQTFRSH 
 
 
Table 3.1: Peptide sequences utilized in this study. Bold Y indicates a phosphorylated 
tyrosine 
 
 
 
In order to identify new sequences able to bind to JAK2, here we report the affinity 
of the binding employing an easy ELISA procedure that involves the immobilization 
of the synthetic peptides on the plate by means of the Fmoc group on their N-
termini (56). Dose-dependent experiments confirmed that KIR has the same affinity 
against both JAK2 peptides (54), providing KD values of 76 and 81 μM for JAK2 and 
pJAK2, respectively (Table 3.2 and Fig. 3.1). 
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 KIR  New KIR  PS-5  PS-12 
 
 KD (µM) KD (µM) KD (µM)      IC50 (µM) KD (µM) IC50 (µM) 
JAK2 76 ± 3 27 ± 6 5.0  ± 1.0 3.3 ± 1.0  3.6 ± 1.0 2.5 ± 1.2  
pJAK2 81 ± 8 16 ± 4 0.8 ± 0.1 2.4± 1.7 4.5± 0.4  2.8± 1.0 
 
 
Table 3.2: KD and IC50 values of KIR and PS peptides in the complex with JAK2 
catalytic region (in phosphorylated and non-phosphorylated form). 
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Fig 3.1: Direct ELISA assay: Biotinylated JAK2 and pJAK2 at the concentrations range 
of 0.01-0.6 mM were added in triplicate to a 96-well plate coated with either KIR, negative 
control peptide (CN) (MuIFNγ (95–106)) at the concentration of 0.0100 mM, or buffer 
alone. Data have been reported subtracting signals deriving by no-coated wells. 
 
 
In order to investigate crucial residues of KIR involved in JAK2 recognition, we 
synthesized and analyzed Ala-scan peptides of this region, in which the wild-type 
residues were systematically changed to alanine. Their binding capacities to both 
JAK2 peptides were analyzed through ELISAs, carried out at two different 
concentrations of coated Fmoc-peptides as reported in Fig. 3.2. The analysis of 
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these experiments revealed that peptides in which residues in positions 52 and 53 
(D and T) and in 57-61 (TFRSH) were changed to alanine had lower affinity, while 
changes in positions 54-56 (HFR) and 62-67 (SDYRRI)  did not affect the binding. 
These data suggested that the ability of KIR to recognize JAK2 catalytic site is 
confined within the region 52-61. To proof this hypothesis we synthesized and 
analyzed the binding properties of this shorter region of KIR, named new KIR 
(Table 3.1), and its direct ELISAs vs both JAK2 peptides, in comparison with KIR, 
are reported in Fig. 3.3. As KIR, also new KIR showed dose-dependent binding 
and data fitting provided values of KD similar for JAK2 and pJAK2, 27 μM and 16 
μM, respectively (Table 3.2). 
Thus the deletion of six residues in the C-terminal region of KIR led to a shorter 
sequence able to bind to JAK2 catalytic site with greater affinity. 
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Fig 3.2: Direct ELISA assay: Biotinylated JAK2 (upper) and pJAK2 (lower), at two 
different concentrations 0.100 – 0.200 mM were added in triplicate, to a 96-well plate 
coated with either KIR, Ala-scan peptides, CN (negative control: MuIFNγ) at the 
concentration of 0.010 mM, or buffer alone. 
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Fig 3.3: Direct ELISA assay: Biotinylated JAK2 (left) and pJAK2 (right) catalytic site  in 
a concentration range of 0.010 – 0.600 mM were added in triplicate to a 96-well plate 
coated with either KIR, new KIR, CN peptides at the concentration of 0.010 mM, or buffer 
alone. 
 
 
3.2. Generation of new KIR-mimetics through a focused simplified peptide library 
In order to identify new peptides able to mime KIR activity, we screened a focused 
simplified peptide library (56-57). This library was designed on the basis of Ala-
scanning results, randomizing residues in positions 54-56, that appeared not 
directly responsible of the interaction with JAK2 catalytic region.   
Our approach employs a minimum number (12 instead of 20) of non redundant 
amino acids as building blocks (Table 3.3).  
 
 Selected amino acid Side chain 
1 Arg basic 
2 Asp acidic 
3 Gln amide 
4 Leu aliphatic 
5 Ala hydrophobic 
6 Pro hydrophobic 
7 Met hydrophobic 
8 Ser polar 
9 Phe  hydrophobic, aromatic 
10 Cys(Acm) aliphatic  
11 Tyr hydrophobic, polar, 
aromatic 
12 His hydrophobic, polar 
 
Table 3.3: List of building blocks used to assemble the peptide library, Cys was 
chosen as acetamidomethyl derivative to avoid polymerization. 
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It is simplified in terms of a reduced number of screened compounds still capable 
to cover a wide chemical diversity, in a positional scanning format (PS-SSPL: 
Positional Scanning-Simplified Synthetic Peptide Library) (58).  
The diversity of the library consisted of 123=1728 different compounds and the PS 
format implied the synthesis of 12x3=36 sub-libraries, each composed of 144 
diverse sequences. Each sub-library was characterized by LC-MS and amino acid 
analysis (data not shown). Their experimental compositions were in agreement 
with theoretical ones. Peptide sub-libraries were tested to direct binding ELISAs, at 
one fixed concentration of coated mixtures (Fig. 3.4).  
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Fig 3.4: Direct ELISA assay: Biotinylated JAK2 (upper) and pJAK2 (lower) at the 
concentration of 0.200 mM were added in duplicate to a 96-well plate coated with either 
KIR, new KIR, CN and PS-SSPL peptide sublibraries at the concentration of 0.010 mM, or 
buffer alone. The numeration from 1 to 12 indicates peptide mixtures having known 
residue at position 55, from 13 to 24 indicates known residue at position 56 and from 25 to 
36 indicates known residue at position 57, (the number of each building block is reported in 
Table 3.3).  
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Results were expressed as percentage of binding considering new KIR as 100%. 
(0.01 mM of each Fmoc sub-library that is 6,9*10-5 mM  of each single sequence). 
By data analysis, none of the screened sub-libraries showed an improved affinity 
toward JAK2 peptides respect to new KIR and KIR and this can be ascribed to a 
concentration effect. Indeed each sequence in the mixtures is 144-fold lesser 
concentrated respect to wild-type KIR single peptides. Nevertheless, from one 
screening cycle, we have selected several amino acids for each position, 
combining experiments involving JAK2 and pJAK2: Phe and Cys(Acm) on position 
54 Arg, Phe and Pro on P55 and Gln and Leu on P56 were selected.  
The combination of identified amino acids in each position led to the design of 12  
single peptides whose sequences are reported in Table 3.4.  
 
 
Name Sequence 
New KIR DTHFRTFRSH 
PS-1 DTC(Acm)PLTFRSH 
PS-2 DTC(Acm)RLTFRSH 
PS-3 DTC(Acm)FLTFRSH 
PS-4 DTC(Acm)PQTFRSH 
PS-5 DTC(Acm)RQTFRSH 
PS-6 DTC(Acm)FQTFRSH 
PS-7 DTFPLTFRSH 
PS-8 DTFRLTFRSH 
PS-9 DTFFLTFRSH 
PS-10 DTFRQTFRSH 
PS-11 DTFPQTFRSH 
PS-12 DTFFQTFRSH 
  
 
Table 3.4: Composition of peptide sequences deriving from the screening of 
focused PS-SSPL. 
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They were synthesized and purified by RP-HPLC and identified by LC-MS (data 
not shown). Their binding capacities to JAK2 peptides were analyzed through 
direct ELISA at three fixed concentrations of coated peptides as reported in Fig. 
3.5. This experiment allowed to select sequences with an enhanced affinity respect 
to new KIR toward JAK2 peptides: PS-11 and PS-12 were selected from the 
experiment involving JAK2, while PS-5 from that with pJAK2; from both assays PS-
4 was chosen as control sequence for further analyses. 
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Fig 3.5: Direct ELISA assay: Biotinylated JAK2 (upper) and pJAK2 (lower) were added 
in duplicate at three concentrations (0.050, 0.100, 0.200 mM) to a 96-well plate coated with 
either KIR, new KIR, CN and single PS-peptides at the concentration of 0.010 mM or 
buffer alone. 
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3.3. Affinity of new KIR mimetic peptides toward JAK2 catalytic site 
Single peptides selected from PS-SSPL screening were analyzed in dose-
response direct binding ELISA and related experiments are reported in Fig. 3.6 A. 
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Fig. 3.6: Direct ELISA assay: (A) Biotinylated JAK2 (left)  and pJAK2 (right) in a 
concentrations range of  0.001 – 0.020 mM were added, in duplicate, to a 96-well plate 
coated with single peptides deriving from PS-screening, PS-5, -12, -4, at the concentration 
of 0.003 mM, or buffer alone. (B) Biotinylated JAK2 (left) and pJAK2 (right) at pre-
saturation concentration (0.100 mM) were incubated with PS-5, -12, -4 in a concentrations 
range of 1*10-5 – 0.100 mM, and were added in duplicate to a 96-well plate coated with 
Fmoc-KIR at a concentration of 0.01 mM, or buffer alone. 
 
 
Data fitting provided KD values in the high nanomolar range, as reported in Table 
3.2. PS-5 and PS-12 presented KD values 15-fold lower respect to wild type KIR, 
and noteworthy, PS-5 showed a 5-fold higher affinity toward pJAK2 compared to 
JAK2. PS-11 sequence, that bears a Proline residue at position 54, showed lesser 
affinity and seems to be unable to bind pJAK2 in the explored concentration range 
(data not shown). In order to further validate our findings, we inverted ELISA 
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experiments, immobilizing Fmoc-JAK2 peptides and evaluating the binding with 
biotinylated PS-sequences: dose-dependent experiments provided similar values 
for KDs (data not shown).  Also in this experiment PS-11 was not able to bind to 
coated JAK2 peptides and was neglected in further studies.  
With the aim to assess binding specificity and to determine whether PS-peptides 
and natural sequences bind to the same site of JAK2 peptides, competition 
experiments were carried out employing PS-5 and PS-12 as competitors of the KIR-
JAK2 peptide complexes. For this purpose, Fmoc-KIR was immobilized on the 
ELISA plate, then JAK2 peptides at a pre-saturation concentration of 0.100 mM 
were pre-incubated with new KIR, PS-5, -12 and -4 at different molar ratios. As 
shown in Fig. 3.6 B, both PS-5 and -12 peptides inhibited the binding of JAK2 
peptides to KIR in a dose-dependent fashion and data fitting provided IC50 values in 
the low micromolar range which are consistent with KD values estimated by direct 
binding (Table 3.2); new KIR peptide resulted less effective in competing with KIR. 
 
 Sequence 
PS-5 DTC(Acm)RQTFRSH 
PS13 DTC(Acm)KQTFRSH 
PS14 DTC(Acm)RNTFRSH 
PS15 DTC(Acm)KNTFRSH 
PS12 DTFFQTFRSH 
PS16 DTWFQTFRSH 
PS17 DTWWQTFRSH 
PS18 DTFWQTFRSH 
PS19 DTWFNTFRSH 
PS20 DTWWNTFRSH 
PS21 DTFWNTFRSH 
PS22 DTFFNTFRSH 
  
Table 3.4: Composition of new sequences analogs of lead peptides (underlined) 
deriving from the screening of PS-SSPL, in bold “new” residues are reported 
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In order to follow through the simplified approach, we designed 10 new peptides 
on the basis of first generation lead compounds: PS-5 and PS-12 (Table 3.4). 
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Fig. 3.7: Direct ELISA assay: Biotinylated JAK2 (upper) and pJAK2 (lower) at the 
concentrations of 0.003, 0.030, 0.150 and 0.300 mM, were added in triplicate to a 96-well 
plate coated with new PS sequences designed on the basis of (A) PS-5 and (B) PS-12 (to 
simplify only PS-16 signals are reported, those of PS- 17-22 are almost the same), or 
buffer alone. PS-4 and CN were used as negative control. 
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They were built substituting Arg with Lys, Gln with Asn and Phe with Trp. The 
analysis of binding data showed that new sequences had less affinities toward 
JAK2 peptides compared with PS-5 and PS-12 (Fig. 3.7 A-B), even if PS- 16-22, at 
0.150 and 0.300 mM, provided signals close to those of PS-12. From these 
experiments and those reported in Fig. 3.6 A, PS-12 seemed to be less effective 
and specific to bind to JAK2 catalytic site, respect to PS-5. 
 
 
3.4. Binding Properties of PS sequences toward full-length JAK2 
To validate the specificity of the recognition mechanism shown by PS mimetics of 
KIR, we carried out direct binding ELISAs of PS-5 in comparison with KIR, 
employing full-length JAK2 protein. Dose-response experiments are reported in 
Fig. 3.8; data fitting resulted in a KD value of 0.43 ± 0.09 μM, similar to that showed 
toward JAK2 peptides, while KIR gave no measurable responses.  
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Fig. 3.8: Direct ELISA assay: Biotinylated KIR and PS-5 in a concentration range of 
0.0100 – 300 μM were added in triplicate to a 96-well plate coated with JAK2 protein at the 
concentration 0.1 μM, or buffer alone. 
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3.5. Structural characterization of new KIR mimetic peptides by Circular 
Dichorism 
To evaluate the impact of intrinsic structural preferences of KIR mimetics on their 
ability to bind to JAK2 peptides, KIR, new KIR, PS-4 and PS-5 sequences were 
characterized by far-UV circular dichroism spectroscopy (CD). 
In a predicted model of SOCS1, KIR-ESS domain contained two α- helices (R57–
R69 and L74–A77) linked by a small coil segment (39). 
The CD spectrum of KIR presents a minimum at ~ 200 nm and a shoulder at ~ 220 
nm (Fig. 3.9); these features suggest, as expected, mixed conformational states, in 
which an unfolded state coexists with a helical conformation. The propensity of this 
domain to adopt helical conformation was also confirmed by TFE titration (Fig. 3.10 
A).  
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Fig. 3.9: CD spectra of the PS peptides in phosphate buffer 10 mM, PS-5, PS-4, KIR 
new KIR, as reported in figure legend. 
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The truncated sequence of new KIR showed a similar CD profile also upon the 
addition of TFE (Fig. 3.10 B). Punctual mutations in PS-peptides did not 
dramatically change the spectrum (Fig. 3.9); and furthermore while PS-5 showed a 
clear propensity to adopt helical conformations upon TFE addition(Fig. 3.10 C), the 
negative control sequence PS-4 does not (Fig. 3.10 D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.10: Overlay of CD spectra of the peptides in phosphate buffer 10 mM with 
increasing amounts of TFE, from 0 to 70 % (v/v): (A) KIR, (B) NewKIR, (C) PS-5, (D) 
PS-4. 
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3.6. Peptide uptake and stabilities studies in primary cultures of human 
keratinocytes  
To confirm the efficacy of the selected new peptides to bind JAK2 and to be 
valuable mimetics of SOCS1, we planned cellular experiments using PS peptides 
conjugated to two different cell penetrating peptides (CPP): the fragment 48-60 of 
the HIV Tat protein, and pVec, derived from the murine vascular endothelium 
cadherin (58). They were positioned at the N-terminus and C-terminus, 
respectively, of PS-peptides in order to speculate on a potential directional 
preference in the recognition mechanism between KIR mimetics and JAK2 
peptides.  
Firstly, we assessed whether the Tat and pVec conjugated peptides were still 
capable to bind to JAK2 peptides, testing them in ELISA dose-response 
experiments, in a concentration range of 0.0500-0.100 mM for biotinylated JAK2 
peptides on plate coated with conjugated peptides PS-5, -12, -4 at the 
concentration of 5.0 µM. CPP-conjugated peptides provided KD values similar to 
those of non conjugated peptides, as reported in Fig. 3.11 and table 3.5.  
 
 
 
 TatPS-5  TatPS-12 pVecPS-5 pVecPS-12 
 KD (μM) KD (μM) KD (μM) KD (μM) 
JAK2 3.0± 0.7 8±0.9 4.1± 0.6 4.7± 0.3 
pJAK2 1.8± 0.1 6.5± 0.2  6.0± 0.3 5.9± 0.4 
 
Table 3.5: KD values of KIR mimetic peptides conjugated whit CPPs in the complex 
with JAK2 and pJAK2. 
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Fig. 3.11: Direct ELISA assay: Biotinylated JAK2 (right) and pJAK2 (left) at the 
concentrations range of 0.005-0.1 mM were added in triplicate to 96-well plates coated 
with conjugated PS- sequences: (A) Tat fused PS-5, -12, -4 and (B) pVec fused to PS-5, -
12, -4, at the concentration of 0.005 mM, or buffer alone. Data have been reported 
subtracting signals deriving by no-coated wells. 
 
 
 
These data suggested that the interaction between PS and JAK2 peptides was not 
affected by the presence of CPPs and that any directionality in recognition 
mechanism was not detected. 
Subsequently, we evaluated the entry of PS peptides in cultured keratinocytes 
using Tat and pVEC-conjugated PS peptides. Cells were treated for 6 hours at room 
temperature with different concentrations of FITC-conjugated peptides, PS-5, PS-12 
and PS-4, then the cellular localization of peptides was analyzed by fluorescence 
microscopy and the uptake of conjugated peptides was quantified by FACS analysis 
(Fig. 3.12 A-B). By this experiment we established that N-term-Tat-conjugated 
peptides penetrated cells efficiently, with a  percentage of penetration of 95%. The 
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penetration ability of  pVec-conjugated peptides was less efficient (data not shown) 
and they were not further analyzed. 
Peptide treatment of cells over time was in agreement with proteases stability 
assays carried out on PS-5; indeed in parallel we verified the stability of Tat- PS-5 in 
serum in comparison with Tat-KIR.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.12: TAT-conjugated PS-4, PS-5 and KIR efficiently enter primary cultures of 
human keratinocytes. (A), Keratinocyte cultures treated for 24 h with PS-4, PS-5 and PS-
12 peptides at 0.001 mM final concentration, all conjugated with TAT sequences and 
tagged to N-terminus with the fluorocrome FITC, were analyzed by fluorescence 
microscopy. Pictures of a representative experiment are shown at a 20X magnitude. (B), 
Keratinocytes treated with Tat-tagged- or not-tagged-PS-4, PS-5 and KIR were analyzed 
by flow cytometry with a FACScan. 
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As shown in Fig. 3.13 A-B, after 6h treatment Tat-PS-5 has a residual 
concentration greater than 75% of the initial one, while Tat-KIR has been degraded 
by 75% respect to initial concentration.  The higher level of stability shown by Tat-
PS-5 can be due to the presence of non-natural side-chain (Cys-(Acm)). Peptide 
stability was also checked in cells; extracts prepared from keratinocyte cultures 
incubated with peptides were analyzed by LC-MS, and unmodified peptides were 
detected by HPLC and mass spectrometry (data not shown). 
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Fig. 3.13: Stability Assay: The resistance to enzyme degradation of (A) Tat-KIR and (B) 
Tat-PS-5  was assessed by incubation in 10% fetal calf serum for 20h. At time 0, and after 
two hours, three aliquots were removed, centrifuged to remove proteins, and analyzed by 
HPLC. Residual peptide quantity, expressed as the percentage of the initial amount versus 
time, was plotted. 
 
 
3.7. Evaluation of effects of KIR mimetic peptides on STAT1 signalling 
To evaluate the effect of PS peptides on the JAK2-STAT1 signalling, we compared 
the  ability of PS-5, KIR and PS-4 to regulate the activity of endogenous JAK2 in 
keratinocytes, in terms of inhibition of STAT1 activation in response to IFN-γ 
treatment. We found that treatments with PS-5, and less efficiently with PS-KIR, 
inhibited the STAT1 phosphorylation on Tyr 701 residue in keratinocyte cultures 
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stimulated with rh IFN-γ (Fig. 3.14), as compared to treatment with the negative 
control PS-4.  The percentage of STAT1 phoshorylation inhibition by PS-5 and KIR 
was about 80 and 65, respectively, as assessed by densitometric analyses of 
Western blotting experiments (Fig. 3.14). In contrast, PS-4 peptide did not show 
significant effects on IFN-γ-induced activation of STAT1 (Fig. 3.14 A). Surprisingly, 
in spite of  biochemical data previously shown, PS-12 appeared less able respect to 
PS-5 to block  the STAT1 activation and was not further investigated. Furthermore, 
as a possible consequence of STAT1 inhibition by PS-5 and KIR, we observed a 
strong inhibition of the IFN-γ-induced accumulation in keratinocytes of IRF-1, that is 
a transcription factor whose expression is strictly dependent on STAT1 activity (Fig. 
3.14 B). 
Fig. 8
 
 
Fig. 3.14: Densitometric analyses of Western blotting experiments: (A) Subconfluent 
keratinocyte cultures were pre-treated for 2 h with 10 M of PS-4, PS-5, PS-12, KIR 
peptides, and, then, stimulated for 15 min with IFN-. Cells were lysed and the whole-cell 
extracts were resolved by 10% SDS-gel electrophoresis, transferred to nitrocellulose 
membranes, and examined using specific Abs to phosphorylated STAT1 (p-Tyr 701). The 
membrane was stripped and reprobed with Abs specific to unphosphorylated STAT1. (B) 
Similarly, keratinocyte cultures were pre-treated with 10 M of PS-4, PS-5, KIR peptides, 
stimulated for 3 hours with IFN-, and finally, lysated. IRF-1 expression was detected by 
Western blotting analysis by using anti-IRF-1 antibody. Equal protein loading was 
assessed by probing with anti--actin. Data are representative of at least three separate 
experiments. Relative intensity of signals was quantified using a densitometer and 
reported as densitometric units. In all panels, *p< 0.001. 
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4. DISCUSSION 
IFN-γ is a key cytokine that regulates many cellular functions: antiviral immunity, 
apoptosis and cell cycle progression. In keratinocytes it is involved in inflammatory 
and immune responses (9). SOCS proteins play a critical role in modulating the 
activities of inflammatory cytokines that use tyrosine kinases in their signalling 
pathways (50). In particular SOCS1 and SOCS-3 regulate JAK2 enzymatic activity 
by at least two mechanisms: one involves binding to the activation loop of JAK2 
and the other facilitates proteasomal degradation (59). Given the primary role of 
SOCS1 to negatively regulate signalling pathways mediated by cytokine binding, 
the development of molecules able to mimic SOCSs  functions represents a 
challenging target in the field of drug discovery, both in allergy and other immune-
based diseases (60). 
Johnson and coworkers demonstrated that SOCS1-like effects can be obtained 
both employing the KIR domain (encompassing residues 52-67), and by a 
rationally designed mimetic peptide named TKip that inhibits JAK2 function by 
binding to its activation loop (54,55).  
In this framework, here we present new mimetic peptides of KIR identified through 
the screening of a focused peptide library (56,57). After the evaluation of the affinity 
between KIR and JAK2 peptides we carried out an Ala-scanning investigation of 
KIR in order to evaluate residues crucial for JAK2 recognition. Noteworthy our 
peptide-based approach was supported by previous mutation studies (37) carried 
out on the full length and on deletion mutants of SOCS1 (60).  
Our results demonstrate that the shorter fragment new KIR, binds to JAK2 
peptides more tightly: the deletion of the last six residues of KIR (62SDYRRI67) 
improves the affinity to JAK2 peptides, suggesting that they are mainly involved in 
stabilizing the α-helical secondary structure of this domain (39), as also suggested 
by CD studies and that, once taken out from protein architecture, they negatively 
interfere with JAK2 recognition. On the basis of the Ala-scan results, we have 
designed a focused peptide library in which residues directly involved in binding 
JAK2 remained unchanged, while positions 54-56 were randomized following a 
simplified approach. From the screening of PS-SSPL we identified new ligands with 
increased affinity for JAK2 catalytic site with KD values in the high nanomolar 
range. It can be observed that these peptides had a residue with a sterically 
hindered side-chain on position 54 (Cys(Acm) in PS-5 or Phe for PS-11-12) (His in 
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the w-t sequence); in position 55 natural Phe was conserved in all PS sequences 
except for PS-5 where there is Arg, in position 56, a Gln residue resulted for all PS 
binding peptides, confirming the need of a polar side chain in this position (Arg in 
w-t sequence). In order to speculate on potential conformational differences among 
PS and natural sequence: we carried out CD studies on these peptides, that 
confirmed a strong tendency of KIR protein region to adopt helical conformation, 
which is only slightly affected by C-term truncation and by mutations on positions 
54-56 and suggested a role of secondary structure of the SOCS1 domain in JAK2 
recognition mechanism. Competitive experiments confirmed PS sequences 
recognition specificity and that they bind to the same site of JAK2 peptides. Among 
PS peptides, PS-5 resulted the most interesting and effective and it was employed 
for preliminary cellular experiments. Indeed it showed the lowest value of 
dissociation constants and a remarkable difference between the binding to JAK2 
and pJAK2: it has a stronger affinity (5-fold greater) for the phosphorylated 1007Y 
at the JAK2 site. This evidence suggest that wild-type peptides and PS-5 recognize 
the same site on JAK2 but not in the same way: presumably the presence a 
positive charge (R55) and a H-bond-prone side chain (Q56) establish more intense 
electrostatic or polar interactions with the negative phosphate moiety on Y1007. 
Furthermore PS-5 contains a non-natural residue (Cys(Acm)) that renders this 
sequence more stable to protease degradation and the most suitable to be tested 
in experiments involving keratinocytes cells.  
In these experiments, PS-5 caused a strong decrease of the phosphorylation 
levels of STAT1 induced by IFN-γ, and in parallel, of  the STAT1-dependent gene 
IRF-1. On these data, it can be assumed that PS-5 peptide can effectively inhibit 
pro-inflammatory genes induced by IFN-γ, and, ultimately suppress the IFN-γ-
dependent immune responses in keratinocytes, similarly to the findings of Johnson 
and co-workers that demonstrated that KIR peptide negatively controls type 1 T 
cell-induced inflammatory diseases in mice, including experimental allergic 
encephalomyelitis, and, therefore, has a strong therapeutic effectiveness (53).  
In this study we demonstrated that PS-5 binds to JAK2 more efficiently than KIR  
and in keratinocyte reverts the IFN-γ-induced activation of STAT1 and downstream 
effects. Future studies using the SOCS1 mimetic peptide PS-5 in experimental 
models of skin inflammation should better define the therapeutic efficacy of this 
new peptide. 
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1.INTRODUCTION 
1.1 . Ischemia 
Ischemia is a restriction in blood supply, generally due to factors in the blood 
vessels, with resultant damage or dysfunction of tissue. Rather than hypoxia (a 
more general term denoting a shortage of oxygen, usually a result of lack of oxygen 
in the air being breathed), ischemia is an absolute or relative shortage of the blood 
supply to an organ, i.e. a shortage of oxygen, glucose and other blood-borne fuels. 
A relative shortage means the mismatch of blood supply (oxygen/fuel delivery) and 
blood request for adequate metabolism of tissue. Ischemia results in tissue damage 
because of a lack of oxygen and nutrients (1).  
In very aerobic tissues such as heart and brain, at body temperature necrosis due 
to ischemia usually takes about 3–4 minutes before becoming irreversible. Ischemia 
is a feature of heart diseases, transient ischemic attacks, cerebrovascular 
accidents, ruptured sensitive to inadequate blood supply. Ischemia in brain tissue, 
for example due to stroke or head injury, causes a process called the ischemic 
cascade to be unleashed, in which proteolytic enzymes, reactive oxygen species, 
and other harmful chemicals damage and may ultimately kill brain tissue. 
Restoration of blood flow after a period of ischemia can actually be more damaging 
than the ischemia. Reintroduction of oxygen causes a greater production of 
damaging free radicals as well as allowing, via removal of the extracellular acidotic 
conditions, influx of calcium and thus calcium overloading.  
 
1.2.Neuronal Cell Death  
Cell death involving a cell-autonomous active contribution of catabolic enzymes, 
apoptosis, plays a prominent role in the evolution of hypoxic-ischemic (HI) injury in 
the neonatal brain, and apoptosis is at least as important for the loss of neurons as 
unregulated cell death, necrosis (2,3). Caspases are a class of specific cysteine 
proteases that mediate apoptotic death in a variety of cellular systems. Caspases 
are activated after HI, in particular in the immature brain (3). The molecular pathway 
leading to caspase activation is initiated by mitochondrial outer membrane 
permeabilization (MOMP), presumably as a result of the permeability transition (4) 
and/or a process regulated by proteins from the Bcl-2 family (5). MOMP results in 
the release of cytochrome c from the mitochondrial intermembrane space to the 
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cytosol, where cytochrome c can interact with Apaf-1, triggering the formation of the 
apoptosome, the caspase-9 and caspase-3 activation complex. Prevention of 
caspase activation or inhibition of caspases affords neuroprotective effects in the 
immature brain (6). Recent data demonstrate that when caspase activation is 
inhibited at or downstream of the apoptosome, neurons can undergo a delayed, 
caspase-independent death (7). One of the key components of the caspase 
independent cell death pathway is Apoptosis-Inducing Factor (AIF) (8–10) (Fig. 1.1). 
 
 
Fig. 1.1: Schematic representation of apoptotic pathways mediated by 
mitochondrial proteins. 
 
 
 
 
 
 
1.3. Apoptosis-inducing factor (AIF) protein: structure and function 
Mature apoptosis-inducing factor (AIF) is a 57 kDa flavoprotein that is confined to 
mitochondria. The AIF protein includes three domains: an amino-terminal 
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mitochondrial localization sequence (MLS) of 110 amino acids; a spacer sequence 
of 27 amino acids; and a carboxiterminal 485 amino acids domain with strong 
homology to oxidoreductases from other species. The overall structure of AIF 
displays a glutathione reductase (GR)-like fold and includes one FAD molecule per 
monomer. Similarly to the enzymes of the GR family, AIF is composed of three 
domains: an FAD-binding domain (residues 122−262 and 400−477), an NADH-
binding domain (263−399) and a C-terminal domain (478−610), which in GR 
constitutes most of its dimer interface. Both the FAD- and NADH-binding domains 
display the classical Rossmann fold, whereas the C-terminal domain is composed 
of five antiparallel β-strands (residues 477−579) followed by two α-helices (residues 
580−610) (11) (Fig. 1.2). 
 
COOHNH2AIF
MLS Spacer NLS NLS
Redox Domain
1 613
 
 
Fig. 1.2: Primary structure of apoptosis-inducing factor (AIF). AIF has an 
oxidoreductase domain, mitochondrial localization sequence (MLS) and nuclear 
localization sequence (NLS). 
 
 
AIF has a dual function in the control of stress-induced cell death (12). This protein 
is a phylogenetically old mitochondrial NADH oxidase whose local redox function is 
essential for optimal oxidative phosphorylation and for an efficient anti-oxidant 
defense. The absence of AIF can cause degeneration of cerebellar granule neurons 
and retinal ganglion cells, as has been shown for harlequin (Hq) mice (13). 
Nonetheless, AIF has also been implicated in neuronal apoptosis as a cell death 
effector. In several models of apoptosis, AIF translocates to the nucleus, where it 
induces chromatin condensation and large-scale DNA degradation by an unknown 
molecular mechanism. The nuclear translocation of AIF can be inhibited by blocking 
upstream signals of apoptosis (such as poly(ADPribose) polymerase-1) (14), 
inhibition of non-caspase cysteine proteases that are involved in the detachment of 
AIF from the inner mitochondrial membrane (15), suppression of MOMP (16) or 
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overexpression of heat-shock protein 70 (Hsp70), which can intercept AIF in the 
cytosol (17). 
This lethal action seems to be independent from its oxidoreductase activity (18). 
Thus, as seen in cytochrome c, AIF may behave as a bifunctional protein with 
dissociable apoptogenic and redox properties. However, the nuclear events caused 
by AIF apparently depend on the apoptosis inducer and the cell type, and are 
reversible at low apoptotic insult (19). 
 
 
1.4. AIF-Mediated Cell Death 
Upon apoptosis induction, AIF translocates from mitochondria to the cytosol and to 
the nucleus. During early nuclear condensation, AIF is found to be associated with 
chromatin (20). AIF protein binds to DNA and causes purified nuclei to undergo 
chromatin condensation, DNA degradation to ~50 kbp fragments and DNA loss (8).  
Although the mitochondrial release of AIF is controlled by caspases in some models 
(21), it is caspase-independent in several important paradigms of apoptosis 
induction. Thus, DNA damage can induce the caspase-independent AIF release 
either through p53 (22), or via PARP-mediated NAD depletion (23). AIF is also 
released in several in vivo models of anoikis (24), HIV-1 infection (25), and 
ischemia/reperfusion (2), even in conditions in which caspases are suppressed. 
Additional caspase-independent enzymes that have been suggested to participate 
in apoptotic chromatinolysis include endonuclease G (26), DNAse I (27), and 
cyclophilins (28). Apparently, the apoptogenic activity of AIF does not depend on its 
NADH oxidase activity. Chemical inactivation of the flavine adenine nucleotide 
(FAD) moiety required for AIF redox activitydoes not block its apotogenic function in 
cell free systems (7), and mutations that destroy the FAD binding site do not affect 
the apoptogenic function of AIF in transfection assays. Rather, mutation of amino-
acid residues required for DNA binding (but not for redox activity) abrogate the 
apoptogenic potential of AIF in the cell-free system as well as in intact cells (20). In 
C. elegans, AIF reportedly cooperates with endonuclease G, a DNAse that also 
undergoes a mitochondrio-nuclear translocation process (26). However, no such 
evidence has been obtained in the mammalian system, where endonuclease G 
appears to cooperate with DNAse I (27).To explore the mechanism through which 
AIF induces DNA degradation, Cande´ et al (29) reported that AIF can cooperate 
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with cyclophilin A (CypA) to induce chromatinolysis both in vitro and in vivo. In that 
studies they show that, in the nucleus, AIF undergoes electrostatic interactions with 
DNA and tethers CypA to chromatin. Formation of such a trimolecular complex 
(CypA/AIF/DNA) is possible because the DNA- and CypA-binding domains of AIF 
are distinct. The AIF/CypA complex then causes DNA degradation. 
 
 
1.5. Cyclophilin A  
Cyclophilins constitute a family of phylogenetically conserved proteins found in 
prokaryotes as well as in humans. Cyclophilins have peptidyl-prolyl isomerase 
activity in vitro (30), indicating that they influence the conformation of proteins in 
cells, but their functions are largely unknown (31). The founding member of the 
cyclophilin family (15 members in humans), cyclophilin A (CypA), is an abundant, 
ubiquitously expressed protein originally discovered as an intracellular ligand of the 
immunosuppressive drug cyclosporin A (CsA) (32). CypA/- embryonic stem cells 
grow normally and differentiate into hematopoietic precursor cells in vitro, indicating 
that CypA is not essential for mammalian cell viability (33). Immunosuppression is 
mediated by the CypA – CsA complex that inhibits calcineurin, a phosphatase 
crucial for T cell activation (34). CypA expression is particularly high in the brain, in 
neurons, where it is expressed mainly in the cytoplasm but also in the nucleus (35). 
Pioneering work by Montague et al. revealed that CypA possesses a latent, 
apoptosis related  DNase activity (28). CypA has been demonstrated to participate 
in excitotoxin-induced apoptosis (36) and to interact with a limited number of 
proteins, including dynein (37), the antioxidant protein Aop1 (38), the nuclear pore 
protein Nup358 (39), and apoptosis-inducing factor (AIF) (29). 
 
 
1.6. AIF/Cyp A interaction  
Several studies have shown that CypA interacts with AIF by mass spectroscopy, 
coimmunoprecipitation, pull-down assays, and molecular modeling. During the 
initial, caspase-independent stage of chromatin condensation that accompanies 
apoptosis, AIF and CypA were found to co-immunolocalize in the nucleus. 
Recombinant AIF and CypA proteins synergized in vitro in the degradation of 
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plasmid DNA, as well as in the capacity to induce DNA loss in purified nuclei. The 
apoptogenic cooperation between AIF and CypA did not rely on the CypA peptidyl-
prolyl cis–trans isomerase activity. In Cyp-expressing cells, AIF overexpression 
augmented apoptotic chromatinolysis. The AIF-dependent large-scale DNA 
fragmentation was less pronounced in CypA knockout cells as compared to 
controls. AIF mutants lacking the CypA-binding domain were inefficient apoptosis 
sensitizers in transfection experiments. Moreover, AIF failed to sensitize CypA 
knockout cells to apoptosis induction, and this defect in the AIF response was 
reversed by reintroduction of the CypA gene into CypA-deficient cells. In summary, 
AIF and CypA collaborate in chromatinolysis. 
In particular, deletion of amino acids (aa) 367–466, 269–442, or 263–399 abolished 
the interaction between AIF and CypA. Thus, the CypA interaction domain is 
located within (or close to) a stretch of ~30 amino acids (367–399) of AIF, which is 
different from its HSP70 interacting domain (aa 150–228) (17) and from its DNA-
binding sites (aa 255/265 and aa 510/518) (20). Accordingly, a molar excess of 
Hsp70 or DNA failed to block the AIF–CypA interaction. Addition of cyclosporin A, 
which inhibits the peptidyl-prolyl cis–trans isomerase activityof CypA had no effect 
on the AIF/CypA interaction, which thus occurs independently of its chaperone 
function.  
The notion that AIF interacts with CypA through a novel interaction domain was 
confirmed by molecular modeling (29). An optimal model of docking between CypA 
and AIF indicates that CypA and AIF establish extensive molecular contacts. AIF 
contributes to the interface with one of its a-helices (P345–R358) and several β-
strands (V361–N366, T328–F334, R387–A397) and turns (E359–G360, A367–
S371, K382–G386) that form together a β-sheet bulge. CypA contributes to the 
interface with one of its two a-helices (M136–G146), the following turn and β-strand 
(S147–G150), as well as part of its central β-barrel (R55–Q63, H92–A101, Q111–
T119). (Fig. 1.3). The predicted interface is stabilized by several molecular 
interactions. 
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Fig. 1.3: Molecular model of the complex between AIF and CypA. (left) Global 
view of the interaction between AIF and CypA, obtained by homology modeling on the 
known crystal structures and energy minimization calculations. (right) Close-up of the 
interface of interaction between AIF (blue) and CypA (green).  
 
 
 
1.7. Aim of the study 
Many data indicate that the lethal translocation of AIF to the nucleus requires 
interaction with CypA, suggesting a model in which two proteins that normally reside 
in separate cytoplasmic compartments acquire novel properties when moving 
together to the nucleus. In spite of the considerable amount of works performed on 
AIF, the mechanisms underlying the nuclear action of AIF are, however, largely 
unknown. The purpose of this study is the elucidation of the mechanism underlying 
the neuronal cell death mediated by AIF and CypA proteins by the selective 
disruption of the CypA-AIF complex with peptides mimicking the protein surfaces 
involved in mutual binding. Importantly, the selective interference in the formation of 
this target complex should be an ideal strategy to suppress the pro-apoptotic action 
of AIF without interfering with its implication in bioenergetic and redox metabolism 
and in the immunosuppressive features of CypA. 
Starting from structural data, peptides that mimic the mutual binding region of AIF 
and CypA have been designed and synthesized. Peptides synthesized have been 
tested by using cell-free and cell based assays. 
In particular for the screening of peptide direct binding and competition experiments 
have been developed by Surface Plasmon Resonance (SPR) techniques. For cell 
based assays we used a model of glutamate toxicity in HT-22 cells. In these 
immortalized hippocampal neurons, glutamate induces glutathione depletion and 
increased formation of reactive oxygen species (ROS) (40). Glutamate toxicity 
resulted in mitochondrial fragmentation and release of AIF from mitochondria to 
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nuclei where it induced chromatinolisys. This model is very useful to investigate the 
effects of the peptide identified on AIF-mediated neuronal cell death. 
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2. EXPERIMENTAL SECTION 
 
2.1. Materials 
N-α-protected Fmoc-amino acid derivatives and coupling reagents for peptide 
synthesis were from Inbios (Pozzuoli, Napoli). DIEA, Rink amide MBHA resin, tri-
isopropyl-silane (TIS) and reagents for ELISA assays were from Sigma-Aldrich 
(Milano, Italy). HPLC-grade solvents and trifluoroacetic acid (TFA) were from 
LabScan (Stillorgan, Dublin, Ireland) and were used as received unless otherwise 
stated. Other reagents and chemical suppliers are indicated in the section of  
methods. Solid phase peptide syntheses was performed on a fully automated 
multichannel peptide synthesizer Syro I (Multisynthech, Germany). Preparative RP-
HPLC were carried out on a Shimadzu LC-8A, equipped with a SPD-M10 AV 
detector and with a Phenomenex C18 Jupiter column (50x22 mm ID; 10 m). LC-
MS analyses were carried out on an LCQ DECA XP Ion Trap mass spectrometer 
equipped with an OPTON ESI source, operating at 4.2 kV needle voltage and 320 
°C and with a complete Surveyor HPLC system, comprising a MS pump, an 
autosampler and a photo diode array (PDA). Narrow bore 50x2 mm C18 BioBasic 
LC-MS columns were used for analyses. All ELISA assays to screen the synthetic 
peptides, were carried out using a fully automated system (Hamilton Robotics, 
Milano, Italy) comprising a liquid handler, an automatic arm, a washer and an 
automated Synergy 4 multi-wavelength reader (BIOTEK Instruments, Inc. Highland 
Park, VT, USA).  
 
2.2. AIF expression and purification 
The expression of recombinant truncated AIF (lacking the amino acids 1-121, tAIF) 
fused to a His tag was optimised in the BL21(DE3) bacterial strain and finally 
induced in the presence of 0.1 mM IPTG for 3 h at 37 °C. 200 mL pellets were re-
suspended in 10 mL cold lysis buffer (50 mM Tris, 150 mM NaCl, Triton 0.25%, 1 
mM TCEP, pH 8) supplemented with a protease inhibitor mixture (1 mM PMSF, 1.0 
μg mL−1 aprotinin, 1.0 μg mL−1 leupeptin, 1.0 μg mL−1 pepstatin, 1.0 mg mL−1 
lysozime) and incubated at room temperature for 30 min. Cells were disrupted by 
sonication on ice with 20 s on/off cycles for a total sonication time of 12 min. After 
centrifugation at 15000 rpm for 20 min at 4°C, supernatants were loaded onto a 1 
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mL Ni-NTA-resin equilibrated with 50 mM Tris, 250 mM NaCl, 1 mM TCEP, 0.1 mM 
PMSF, pH 8.0 (buffer A) and washed extensively. The protein was then eluted with 
200 mM imidazole dissolved in the same buffer. Then the product was further 
purified by size exclusion chromatography (gel filtration s200). Protein elution was 
monitored by 10% SDS-PAGE electrophoresis (Fig. 2.1). 
 
mAIFΔ1-121
mAIFΔ1-121
A
B
 
mAIFΔ1-121
~57KDa
1      2     3    4    5 
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Fig. 2.1: Purification of tAIF. (A) First step of purification of tAIF by affinity 
chromatography on Ni-NTA resin. (B) The material corresponding to peak showed in 
figure 1A was further purified by Size Exclusion Chromatography and analyzed on 
SDS–PAGE gel (C). 
 
 
 
2.3. Peptide Synthesis 
Peptides were prepared by the solid phase method on a 50 μmol scale following 
the Fmoc strategy and using standard Fmoc-derivatized amino acids RINK AMIDE 
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resin (substitution 0.5 mmol/g) was used as solid support. Activation of amino acids 
was achieved using HBTU/HOBt/DIEA (1:1:2), whereas Fmoc deprotection was 
carried out using a 40% (v/v) piperidine solution in DMF. All couplings were 
performed for 15 minutes and deprotections for 10 minutes. Peptides were 
removed from the resin by treatment with a TFA:TIS:H2O (90:5:5, v/v/v) mixture, 
then they were precipitated in cold diethylether and lyophilized. Single peptides 
were purified by preparative RP-HPLC, and their identity was evaluated by LC-MS 
analysis. Peptide products were stored at -20 °C until use. The MW was 
determined by LC-ESI mass spectrometry. To quantify the percentuage of 
transfection in neuronal cells, peptides were also fluoresceinated at their N-termini 
with Fluoresceine-βAla. 
 
2.4. SPR analysis 
The BIAcore 3000 SPR system for Real time binding assay and related reagents 
were from GE Healthcare (Milano, Italy).  
Human CypA protein (purchased from SIGMA C-3805) was immobilized at a 
concentration of 50 µg/mL in 10 mM acetate buffer pH 4.0 (flow rate 5 μL/min, time 
injection 7 min) on a CM5 Biacore sensor chip, using EDC/NHS chemistry following 
the manufacturer‘s instructions (41). Residual reactive groups were deactivated by 
treatment with 1 M ethanolamine hydrochloride, pH 8.5. Reference channel was 
prepared by activating with EDC/NHS and deactivating with ethanolamine. Binding 
assays were carried out at 20 L/min, with 4,5 min contact-time; tAIF protein and 
peptides were diluted in the running-buffer, HBS (10 mM Hepes, 150 mM NaCl, 3 
mM EDTA, pH 7.4) 0.1 mM TCEP. Analyte injections of 90 μL were performed at 
the indicated concentrations. BIAevaluation analysis package (version 4.1, GE 
Healthcare, Milano, Italy) implemented by instrument software was used to subtract 
the signal of the reference channel and to evaluate kinetic and thermodynamic 
parameters of complexes. Competitive SPR experiments with AIF peptides were 
carried out pre-incubating each peptides with tAIF at several concentrations. 
 
2.5. Circular Dichroism (CD) Spectroscopy 
CD spectra were recorded on a Jasco J-810 spectropolarimeter (JASCO Corp, 
Milan, Italy). CD spectra were registered at 25 °C in the far UV region from 190 to 
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260 nm. Each spectrum was obtained averaging three scans, subtracting 
contributions from corresponding blanks and converting the signal to mean residue 
ellipticity in units of deg*cm2*dmol-1* res-1. Other experimental settings were: 20 
nm/min scan speed, 2.0 nm band width, 0.2 nm resolution, 50 mdeg sensitivity, and 
4 sec response. The concentration of peptides was kept at 10×10−5 M and a 0.1 cm 
path-length quartz cuvette was used. Spectra were acquired in 10 mM phosphate 
buffer at pH 7.0.  
 
2.6. HT-22 cells 
HT-22 hippocampal-derived cells were cultured in Dulbecco‘s modified Eagle 
containing-calcium medium (DMEM, Invitrogen, Karlsruhe, Germany) or in DMEM 
without calcium. Both culture media were supplemented with 10% fetal calf serum, 
100U/mL penicillin, 100µg/mL streptomycin and 2mM glutamine.  
 
2.7. Transfection  
Cellular loading of peptides was performed with cationic lipid mixture Pro-Ject™ 
Protein Transfection Reagent kit according to the manufacturer's instructions 
(Pierce Prod# 89850). Briefly, HT-22 cells were transfected with thre different 
concentrations of peptides (10, 25 and 50 μM) in 24 well plates (60000 cells/well) 
for 24 h. Afterwards, cells were seeded in 96 well plates and after another 24 h HT-
22 cells were treated with glutamate (2 mM). The quantification of the transfection 
was carried out by Leica microscope The evaluation of the impact of these peptides 
was carried out by MTT assays and by xCELLigence technique. 
 
2.8. Cell viability assessment 
Quantification of cell viability was performed by 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) reduction assay at 0.5 mg/mL for 1 h. The 
reaction was terminated by removing the media and freezing the plate at -80° C for 
at least 1 h. DMSO solvent was added to each well for 1h under shaking conditions 
at 37° C. The absorbance of each well was determined with an automated 
FLUOstar Optima reader (BMG Labtechnologies GmbH, Inc., Offenburg, Germany) 
at 570 nm with a reference filter at 630 nm. In addition, real time detection of cell 
death was performed by measurements of cellular impedance by the xCELLigence 
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system (Roche, Penzberg, Germany).  
 
2.9. xCELLigence impedance-based system 
HT-22 cells were seeded at a density of 8.000-10.000 cells/well in 96-well E-plate 
(Roche Diagnostics GmbH). The impedance, depicted as cell index (CI) was used 
to monitor the real time kinetics of cellular growth and alteration of cell morphology. 
Fourthy-eight hours after transfection, the cells were treated with glutamate 2 mM. 
 
2.10. AnnexineV-PI assay 
For detection of apoptotic cells, HT-22 were loaded with 2µM AnnexineV-FITC-PI 
(Invitrogen). Flow cytometry was performed using a FACScan (BD Bioscience, 
Heidelberg, Germany). 488nm UV line argon laser was used for excitation and 
BODIPY emission was recorded on channels FL1 at 530nm (green) and FL2 at 
585nm (red). Data were collected from at least 10,000 cells (n=3). 
 
2.11.Statistical analysis  
All data are given as means ± S.D. For statistical comparisons between two 
groups, Student‘s t-test was used; multiple comparisons were performed by 
ANOVA followed by Scheffé‘s post hoc test. Calculations were made with the 
Winstat standard statistical software package (Robert Fitch Software, Bad 
Krozingen, Germany). A statistically significant difference was assumed at *p < 
0.05, **p < 0.01, ***p < 0,001. 
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3.RESULTS 
3.1.  SPR experiment: analysis of AIF protein binding to CypA 
Since this interaction has not been assessed employing any experiment in vitro, we 
analyzed it by a technique that employs unlabelled bio-molecules. For this purpose, 
Recombinant hCypA protein was immobilized on the chip surfaces, achieving, 
under the reported conditions (see Experimental Section for details), 800 RU 
immobilization levels. Direct binding between hCypA and recombinant truncated 
AIF(Δ1-121), the nuclear apoptogenic form of AIF, were performed by injecting 
AIF(Δ1-121) (tAIF) solutions at increasing concentrations from 10 to 110 nM . In 
particular, concentrations of tAIF were injected over the CypA-derivatized CM5 
sensor chip in 50 mM sodium phosphate, 150 mM NaCl, 1 mM TCEP, pH 7.4, 
buffer at 25 °C. This signal was reproducibly proportional to the concentration of 
tAIF that was injected. A speciﬁc SPR resonance signal was detected in the ﬂow-
cell, indicating that tAIF was bound to CypA and the concentration-dependence of 
the steady-state SPR signals showed a hCypA/tAIF dissociation constant (KD) of 
3±3 10-8 M (Fig. 3.1). These results show that the hCypA/tAIF interaction is direct 
and does not require additional proteins. 
 
 
 
 
Fig. 3.1: Evaluation of interaction between tAIF and CypA. SPR analysis of the 
interaction between tAIF and CypA. Results were reported as (RU/RU0)*100. 
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3.2. Design and characterization of AIF peptides 
The notion that AIF interacts with CypA through a novel interaction domain was 
confirmed by mass spectroscopy, coimmunoprecipitation, pull-down assays, and 
molecular modeling (29). These previous results showed that, in CypA-expressing 
cells, AIF overexpression augmented apoptotic chromatinolysis. The AIF-dependent 
large-scale DNA fragmentation was less pronounced in CypA knockout cells as 
compared to controls. AIF mutants lacking the CypA-binding domain were inefficient 
apoptosis sensitizers in transfection experiments. Moreover, AIF failed to sensitize 
CypA knockout cells to apoptosis induction, and this defect in the AIF response was 
reversed by reintroduction of the CypA gene into CypA-deficient cells (29).  
An optimal model of docking between CypA and AIF indicates that CypA and AIF 
establish few molecular contacts. These data showed that the formation of 
CypA/AIF complex may involve the AIF 370-394 fragment and one of the helices 
(aa 343-360). On the base of these data two potential blocking peptides AIF(370-
394), AIF(343-360) and a set of a shorter peptides AIF(370-376), AIF (376-383) and 
AIF(383-394) were designed, synthesized and characterized by Circular dicroisme.  
 
SEQUENZA DI AIF
Domain 1
Domain 2
Domain 3
370-394343-360
 
Fig. 3.2: Schematic representation of secondary structural regions of AIF, 
where the potential regions involved in the interaction are circled in red. 
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α-helixKEGMNIVEAMERFGSRNGKTα-helix-loop CypA 133-152
noneKDGRKVETDHIβ-strand AIF 383-394
noneSGKLLIKLβ-strand AIF 376-383
noneQSVGVSSβ-strand AIF 370-376
α-helixQSVGVSSGKLLIKLKDGRKVETDHIβ-sheet-turns AIF 370-394
α-helixILPEYLSNWTMEKVRREGα-helix - AIF 343-360
Structural propensitySequenceDescription
 
Table 3.1: Peptide sequences utilized in this study and their structure secondary 
propensity deriving from CD studies 
 
All peptides were chemically synthesized in good yields by SPPS, using Fmoc 
methodologies as N-terminal acetylated and C-terminal amidated derivatives and 
purified by RP-HPLC; their identity and purity were assessed by LC-MS (data not 
shown). To evaluate the impact of intrinsic structural preferences of these fragments 
on their ability to binding, all peptides were characterized by far-UV circular 
dichroism spectroscopy (CD). As expected, the peptides corresponding to the 
shorter regions (AIF(370-376), AIF(376-383) and AIF(383-394)) were unfolded, 
although these peptides contain fragments that are structured in the complex. (Fig. 
3.3). Similarly, the CD spectra of AIF(343-360) present a structural propensity to 
assume an α-helix secondary structure, in according with the secondary structure 
present in the native protein. The CD experiment carried out on AIF(370-394) 
peptide shows a propensity to assume a β-sheet structure. 
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Fig. 3.3: Overlay of CD spectra of the AIF peptides in phosphate buffer 10 mM with 
increasing a ounts of TFE, from 0 to 70 % (v/v). 
 
 
 
3.3. Analysis of AIF peptides binding to CypA 
In order to identify the AIF amino acidic region involved in the interaction with CypA, 
we set up SPR-based binding assays in which the peptide singly were injected on 
the recombinant CypA-captured chip at different concentrations. As shown in Fig. 
3.1 B, the peptide mimicking the region 370-394 is able to bind CypA in a dose-
dependent manner showing a KD value in micromolar range (70 ± 0,5* 10
-6M). 
Instead the peptide AIF(343-360) and the shorter peptides bind CypA with less 
affinity showing a KD value in millimolar range. In particular the KD value for the 
peptide AIF(343-360) is of 3.5 ± 0,7* 10-3 M, for AIF(376-383) is of 3.8 ± 0,3* 10-3  M 
and for AIF(383-394) is of 3.2 ± 0,3* 10-3  M (Fig. 3.4, B, C and D, respectively), 
while the peptide AIF(370-376) is not able to bind CypA (data not shown). All data 
suggest that the amino acidic region of AIF (spanning residues 370-394) is much 
involved in the interaction with CypA. 
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KD = 3.5 mMKD = 70 μM
KD = 3.8 mM KD = 3.2 mM
A
D
B
C
 
Fig. 3.4: SPR-binding experiments of the interaction between CypA and AIF peptides. 
A, AIF(370-394), B, AIF(343-360); C, AIF(376-383); D, AIF(383-394)). Increasing 
concentrations of AIF peptides (1 ’ 100 μM) were injected over the CypA-derivatized CM5 
sensor chip in the same conditions previously reported. 
 
 
In the following we tested if these regions are able to block the interaction between 
AIF and CypA setting up SPR-based completion assays. In each experiments, 
before being injected into the CypA-captured chip, tAIF, at the concentration of 75 
nM, was mixed with peptides at different concentrations (in the range 1’ 100 μM) 
(Fig. 3.5), including the peptides AIF(370-394) and AIF (343-360). 
In agreement to what was observed on SPR-binding experimets, the tAIF/CypA 
binding signal was reduced only when AIF was pre-incubated with the peptide 
AIF(370-394). All together these data indicated that AIF speciﬁcally associates with 
CypA with the region 370-394. 
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Fig. 3.5: AIF(370-394) peptide is able to block tAIF/CypA complex formation. SPR-
based competition experiments using AIF peptides (AIF(370-394) and AIF(343-360)). 
Results were reported as (RU/RU0)*100, where RU is the maximum response (RUmax) for 
a given competitor and RU0 is the RUmax without competitors. 
 
 
3.4. The peptide AIF(370-394) shows protection in in vitro models of AIF-
mediated cell death  
To evaluate the effect of peptide selected in vitro models of AIF-mediated cell 
death, HT-22 cells were transfected with varying doses of peptides AIF(370-394) 
and AIF(343-360) (10 µM, 25 µM, 50 µM) and an unrelated peptide at the highest 
concentration tested (50 µM), used as negative control (40). Cell viability after 
glutamate treatment (2 mM for 12 h) was assessed by MTT assays. As depicted in 
Fig. 3.6 (upper panel) the peptide AIF(370-394) showed a significant dose 
dependent protective effect compared the control treated with glutamate. While the 
peptide AIF(343-360) and the negative control did not work.   
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Fig. 3.6: The peptide AIF(370-394) shows protection in in vitro models of AIF-
mediated cell death. HT-22 cells were transfected with varying doses of peptides AIF(370-
394) (upper panel) and AIF(343-360) (lower panel) (10 µM, 25 µM, 50 µM) and an 
unrelated peptide (as negative control) at the highest concentration tested (50 µM), used as 
negative control. The Bid-inhibitor BI-6c9 (10 µM) was used as positive control. Cell viability 
after glutamate treatment (2 mM for 12 h) was assessed by MTT assays.  
 
 
Moreover, we also evaluated the protective effect of the peptide AIF(370-394) after 
glutamate treatment by AnnexinV-FITC/PI double staining. HT-22 cells transfected 
with AIF(370-394) peptide and unrelated peptide were untreated (control) or treated 
with glutamate 2 mM for 12 h. Then labeled with AnnexinV-FITC and PI, and 
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analyzed by ﬂow cytometry. In Fig. 3.7 the results were reported as percentages of 
apoptotic cells (double positive).  
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Fig. 3.7: The peptide AIF(370-394) blocks the apoptotic process in HT-22 after 
glutamate treatment. HT-22 cells were transfected with varying doses of peptides 
AIF(370-394) (10 µM, 25 µM, 50 µM) and an unrelated peptide (NC) at the highest 
concentration tested (50 µM), used as negative control. Data are shown as percentage of 
apoptotic cells (double positive). Experiments were independently repeated three times with 
n=3 per condition. 
 
 
Finally, we tested the effect of AIF(370-394) peptide during oxidative stress in HT-
22 by monitoring the cellular impedance in real time by the Xcelligence system. HT-
22 cells after transfection with AIF(370-394) and an unrelated peptide used as 
negative control (NC) were treated with glutamate 2 mM.  
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Fig. 3.8: AIF(370-394) peptide-treatement of HT-22 cells attenuates glutamate-induced 
oxidative stress. HT-22 cells after transfection with AIF(370-394) and an unrelated peptide 
used as negative control (NC) were treated with glutamate 2 mM. The cellular vitality was 
continuously monitored for 42h by the XCELLingence system. Experiments were independently 
repeated three times with n=8 per condition. 
 
 
So in conclusion we demonstrated that the administration of the peptide mimicking the 
aminoacidic regions of AIF involved in the interaction with CypA (AIF(370-394)) 
prevents the glutamate-mediated apoptotic process in HT-22 cells.  
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4. DISCUSSION 
Several prominent neurological disorders manifest symptoms that result from 
degeneration and death of neurons. The genetic and environmental factors that initiate 
neurodegeneration differ among diseases; a shared biochemical cascade of events 
appears to carry out the cell death process. Recently, the importance of cytochrome c 
release and caspase activation in neuronal apoptosis has been supplemented by novel 
insights into a causal role of caspase-independent death signaling, such as the 
mitochondrial release of apoptosis inducing factor (AIF), in delayed neuronal death 
after cerebral ischemia or brain injury (9). Several studies in vitro and in vivo 
convincingly demonstrated that the pro-apoptotic action of AIF in neurological disorders 
occurs following its release through mitochondrial membrane and its translocation to 
the nucleus where induces chromatinolysis (14). Beside, recent data show that 
translocation of AIF to the nucleus after cerebral hypoxia-ischemia, requires interaction 
with cyclophilin A (CypA), suggesting a model in which two proteins, that normally 
reside in separate cytoplasmic compartments, acquire novel properties when moving 
together to the nucleus (29). 
In spite of the considerable amount of work performed on AIF, the mechanisms 
underlying the nuclear action of AIF are, however, largely unknown. The aim of this 
project is the further elucidation of the mechanism underlying the neuronal cell death 
mediated by AIF and CypA proteins by the selective disruption of this complex with 
peptides mimicking the protein surfaces involved in mutual binding. Using Surface 
Plasmon resonance (SPR) approach we have demonstrated that Δ1-121AIF (tAIF) and 
CypA interact directly and with high affinity (KD=30nM). Then, starting from the 
molecular model of AIF-CypA complex a set of potential blocking peptides AIF(370-
394), AIF(343-360) and the shorter variants AIF(370-376), AIF (376-383) and AIF(383-
394) have been designed and synthesized. The precise domain of tAIF involved in the 
interaction with CypA was mapped by competition and direct binding SPR experiments. 
We have found that the aminoacidic region 370-394 of mouse AIF specifically 
associates to CypA (showing IC50 and a KD values in the micromolar range). Data have 
shown also that the AIF aminoacidic region 343-360 is less involved in the recognition 
of CypA exhibiting a KD value in the millimolar range. The peptide is also not able to 
block the interaction between AIF and CypA. We have developed cell-based assays to 
evaluate the effect of the peptide AIF(370-396) in neuronal cell lines. The peptide 
AIF(343-360) and another unrelated peptide have been used as negative controls. In 
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particular, these peptides have been tested in the glutamate-mediated cell death model 
system using neuronal HT-22 cell lines (40).  
More experiments have been also done to evaluate the protective effects of peptides in 
HT-22 cells by MTT assays. Results suggest that the peptide AIF(370-394) has a 
significant dose dependent protective effect while peptides AIF(343-360) and the 
negative controls (Neg Ctrl) do not work, in good agreement with biochemical 
observations. Cell death has been evaluated also by FACS analysis using Annexin V-
FITC and PI double staining. Data obtained confirm that the peptide AIF(370-394) has 
a significant dose-dependent protective effect after injury, while the peptide AIF(343-
360) and the unrelated peptides don‘t work, in good agreement with the previous 
results. The same result has been obtained monitoring the kinetics of cellular apoptosis 
in neuronal cell lines HT-22 by the XCELLingence system. 
The selective disruption of the CypA-AIF complex with this peptide mimicking the 
protein surfaces involved in mutual binding, should be an ideal strategy to suppress the 
pro-apoptotic action of AIF without interfering with its implication in bioenergetic and 
redox metabolism and in the immunosuppressive features of CypA. 
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1. INTRODUCTION 
1.1. HIV/AIDS epidemy 
Human immunodeficiency virus (HIV) is a lentivirus (a member of the retrovirus 
family) that causes acquired immunodeficiency syndrome (AIDS) (1,2) which in 
humans causes a progressive failure of the immune system and allows life-
threatening opportunistic infections and cancers to thrive. Infection with HIV occurs 
by the transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk. Within 
these fluids HIV is present as both free particles virus and within infected immune 
cells. The four major routes of transmission are unsafe sex, contaminated needles, 
breast milk, and transmission from an infected mother to her baby at birth (perinatal 
transmission). Screening of blood products for HIV has largely eliminated 
transmission through blood transfusions or infected blood products in the developed 
world. 
HIV infection (Fig. 1.1) in humans is considered pandemic by the World Health 
Organization (WHO), complacency may play a key role in HIV risk, (3,4) from its 
discovery in 1981 to 2006, AIDS killed more than 25 million people. HIV infects 
about 0.6% of the world's population (5). In 2009, AIDS claimed an estimated 1.8 
million lives, down from a global peak of 2.1 million in 2004. Approximately 260,000 
children died of AIDS in 2009. A disproportionate number of AIDS deaths occur in 
Sub-Saharan Africa, retarding economic growth and exacerbating the burden of 
poverty. An estimated 22.5 million people (68% of the global total) live with HIV in 
sub-Saharan Africa, which is also home to 90% of the world's 16.6 million children 
orphaned by HIV (6). Treatment with antiretroviral drugs reduces both the mortality 
and the morbidity of HIV infection. Although antiretroviral medication is still not 
universally available, expansion of antiretroviral therapy programs since 2004 has 
helped to turn the tide of AIDS deaths and new infections in many parts of the 
world. Intensified awareness and preventive measures, as well as the natural 
course of the epidemic, have also played a role. Nevertheless, an estimated 2.6 
million people were newly infected in 2009 (6). 
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Fig. 1.1: Human immunodeficiency virus (HIV) 
 
 
1.2.  HIV’s structure and genome 
HIV is different in structure from other retroviruses. It is roughly spherical (7) with a 
diameter of about 120 nm, around 60 times smaller than a red blood cell It is 
composed of two copies of positive single-stranded RNA that codes for the virus's 
nine genes enclosed by a conical capsid composed of 2,000 copies of the viral 
protein p24 (8) The single-stranded RNA is tightly bound to nucleocapsid proteins, 
p7, and enzymes needed for the development of the virion such as reverse 
transcriptase, proteases, ribonuclease and integrase. A matrix composed of the 
viral protein p17 surrounds the capsid ensuring the integrity of the virion particle. 
This in turn, is surrounded by the viral envelope that is composed of two 
phospholipidic layers taken from the membrane of a human cell when a newly 
formed virus particle buds from the cell. Embedded in the viral envelope are 
proteins from the host cell and about 70 copies of a complex HIV protein that 
protrudes through the surface of the virus particle (8) This protein, known as Env, 
consists of a cap made of three molecules called glycoprotein (gp) 120, and a stem 
consisting of three gp41 molecules that anchor the structure into the viral envelope. 
This glycoprotein complex enables the virus to attach to and fuse with target cells to 
initiate the infectious cycle (9). Both these surface proteins, especially gp120, have 
been considered as targets of future treatments or vaccines against HIV (Fig.1.2). 
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Fig. 1.2: Schematic representation of a mature HIV-1 particle. Positions of the major 
viral proteins, the lipid bilayer, and the genomic RNA are indicated 
 
 
The RNA genome consists of at least seven structural landmarks (LTR, TAR, RRE, 
PE, SLIP, CRS, and INS), and nine genes (gag, pol, and env, tat, rev, nef, vif, vpr, 
vpu, and sometimes a tenth tev, which is a fusion of tat env and rev), encoding 19 
proteins (Fig.1.3). Three of these genes, gag, pol, and env, contain information 
needed to make the structural proteins for new virus particles (8). For example, env 
codes for a protein called gp160 that is broken down by a viral enzyme to form 
gp120 and gp41. The six remaining genes, tat, rev, nef, vif, vpr, and vpu (or vpx in 
the case of HIV-2), are regulatory genes for proteins that control the ability of HIV to 
infect cells, produce new copies of virus (replicate), or cause disease (8). 
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Fig. 1.3: Organization of the HIV-1 genome: The relative locations of the HIV-1 open 
reading frames gag, pol, env, vif, vpr, vpu, nef, tat, and rev are indicated. The 5' and 3' 
LTRs are shown, with U3, R, and U5 regions noted. The ψ indicates the position of the 
RNA packaging signal. The major Gag domains (MA, CA, NC, p6) and the Gag spacer 
peptides (p2 and p1) are shown under the gag gene. The site of Gag N-terminal 
myristylation is denoted as ―myr‖. Under the pol gene are indicated the PR, RT (p66 and 
p51 subdomains), and IN coding regions. The SU and TM Env glycoproteins (gp120 and 
gp41, respectively) are enlarged to show the position in gp120 of the major conserved (C1-
C5) and variable (V1-V5) regions and in gp41 the location of the fusion peptide, the N- and 
C-helices, membrane-spanning domain, and the cytoplasmic tail. 
 
 
 
.  
1.3. The virus life cycle 
 
The HIV-1 replication cycle (10) may be divided into 15 discrete steps, as depicted 
in Fig. 1.4. Starting from the integration of the viral genome into a host chromosome 
the order of events leads to expression of the viral gene products, production of 
virus particles, infection of a new cell, and reintegration of the viral genome. In step 
1, viral transcripts are expressed from the promoter located in the 50 long terminal 
repeat (LTR), with Tat greatly enhancing the rate of transcription. In step 2, a set of 
spliced and genomic-length RNAs are transported from the nucleus to the 
cytoplasm, where they can be translated or packaged in this  Rev has a regulatory 
action. In step 3, viral mRNAs are translated in the cytoplasm, and the Gag and 
Gag-Pol polyproteins become localized to the cell membrane. The Env mRNA is 
translated at the endoplasmic reticulum (ER). In step 4, the core particle is 
assembled from the Gag and Gag-Pol polyproteins (later processed to MA, CA, NC, 
p6, PR, RT, and IN), Vif, Vpr, Nef, and the genomic RNA, and an immature virion 
begins to bud from the cell surface. To provide SU and TM proteins for the outer 
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membrane coat during budding, the Env polyprotein must first be released from 
complexes with CD4 (the cell surface HIV-1 receptor), which is coexpressed with 
Env in the ER. Vpu assists this process by promoting CD4 degradation, as shown in 
step 5. Env is then transported to the cell surface (step 6), where again it must be 
prevented from binding CD4. Nef promotes endocytosis and degradation of surface 
CD4 (step 7). As the particle buds and is released from the cell surface coated with 
SU and TM (step 8), the virion undergoes a morphologic change known as 
maturation (step 9). This step involves proteolytic processing of the Gag and Gag-
Pol polyproteins by PR and a less well defined function of Vif. The mature virion is 
then ready to infect the next cell, which is targeted by interactions between SU and 
CD4 and CC or CXC chemokine coreceptors (step 10). Following binding, TM 
undergoes a conformational change that promotes virus-cell membrane fusion, 
thereby allowing entry of the core into the cell (step 11). The virion core is then 
uncoated to expose a viral nucleoprotein complex, which contains MA, RT, IN, Vpr, 
and RNA (step 12). This complex is transported to the nucleus (step 13), where the 
genomic RNA is reverse transcribed by RT into a partially duplex linear DNA (step 
14). Then IN catalyzes integration of the viral DNA into a host chromosome and the 
DNA is repaired (step 15), thereby completing the viral replication cycle.  
 
 
 
Fig. 1.4: HIV-1 replication cycle. Steps 1–15 are described in the text. 
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1.3.1. Replication cycle 
HIV enters macrophages and CD4+ T cells by the adsorption of glycoproteins on its 
surface to receptors on the target cell followed by fusion of the viral envelope with 
the cell membrane and the release of the HIV capsid into the cell (11,12). 
Entry into the cell begins through the interaction of the trimeric envelope complex 
(gp160 spike) and both CD4 and a chemokine receptor (generally either CCR5 or 
CXCR4) on the cell surface (11,12). gp120 binds to integrin α4β7 activating LFA-1 
the central integrin involved in the establishment of virological synapses, which 
facilitate efficient cell-to-cell spreading of HIV-1 (13). The gp160 spike contains 
binding domains for both CD4 and chemokine receptors (11,12). 
The first step in fusion involves the high-affinity attachment of the CD4 binding 
domains of gp120 to CD4. Once gp120 is bound with the CD4 protein, the envelope 
complex undergoes a structural change, exposing the chemokine binding domains 
of gp120 and allowing them to interact with the target chemokine receptor 
(11,12).This allows for a more stable two-pronged attachment, which allows the N-
terminal fusion peptide gp41 to penetrate the cell membrane (11,12). Repeat 
sequences in gp41, HR1, and HR2 then interact, causing the collapse of the 
extracellular portion of gp41 into a hairpin. This loop structure brings the virus and 
cell membranes close together, allowing fusion of the membranes and subsequent 
entry of the viral capsid (11,12). 
After HIV has bound to the target cell, the HIV RNA and various enzymes are 
injected into the cell (11). During the microtubule-based transport to the nucleus, the 
viral single-strand RNA genome is transcribed into double-strand DNA, which is 
then integrated into a host chromosome (Fig. 1.5). 
Upon the viral capsid entry into the cell, the enzyme reverse transcriptase liberates 
the single-stranded (+) RNA genome from the attached viral proteins and copies it 
into a complementary DNA (cDNA) molecule (14). The process of reverse 
transcription is extremely error-prone, and the resulting mutations may cause drug 
resistance or allow the virus to evade the body's immune system. The reverse 
transcriptase also has ribonuclease activity that degrades the viral RNA during the 
synthesis of cDNA, as well as DNA-dependent DNA polymerase activity that 
creates a sense DNA from the antisense cDNA. The cDNA along with its 
complement form a double-stranded viral DNA that is transported into the cell 
140 
 
nucleus. The integration of the viral DNA into the host cell's genome is carried out 
by the viral integrase enzyme (14). 
 
 
 
Fig. 1.5: The HIV replication cycle 
 
 
This integrated viral DNA may then lie dormant, in the latent stage of HIV infection 
(14) but to actively produce the virus, certain cellular transcription factors need to be 
present, the most important of which is NF-κB, which is upregulated when T-cells 
become activated (15). This means that those cells most likely to be killed by HIV 
are those currently fighting infection. 
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During viral replication, the integrated DNA provirus is transcribed into mRNA, 
which is then spliced into smaller pieces. These small pieces are exported from the 
nucleus into the cytoplasm, where they are translated into the regulatory proteins 
Tat and Rev. As the newly produced Rev protein accumulates in the nucleus, it 
binds to viral mRNAs and allows unspliced RNAs to leave the nucleus, where they 
are otherwise retained until spliced (16). At this stage, the structural proteins Gag 
and Env are produced from the full-length mRNA. The full-length RNA is actually 
the virus genome; it binds to the Gag protein and is packaged into new virus 
particles. 
The final step of the viral cycle that is the assembly of new HIV-1 virons, begins at 
the plasma membrane of the host cell. The Env polyprotein (gp160) goes through 
the endoplasmic reticulum and is transported to the Golgi complex where it is 
cleaved by protease and processed into the two HIV envelope glycoproteins gp41 
and gp120. These are transported to the plasma membrane of the host cell where 
gp41 anchors the gp120 to the membrane of the infected cell. The Gag (p55) and 
Gag-Pol (p160) polyproteins also associate with the inner surface of the plasma 
membrane along with the HIV genomic RNA as the forming virion begins to bud 
from the host cell. Maturation occurs either in the forming bud or in the immature 
virion after it buds from the host cell. During maturation, HIV proteases cleave the 
polyproteins into individual functional HIV proteins and enzymes. The various 
structural components then assemble to produce a mature HIV virion that is then 
able to infect another cell. 
 
 
1.4.  Trans-Activator of Transcription(TAT) protein 
The HIV-1 promoter is located in the 5‘ LTR and contains a number of regulatory 
elements important for RNA polymerase II transcription. The LTR is composed of 
three regions: U3 (for unique, 3' end), R (for repeated) and U5 (for unique, 5' end). 
Transcription initiates at the U3/R junction. U3 contains a variety of elements that 
direct the binding of RNA polymerase II (pol II) to the DNA template. A TATA 
element, to which transcription factor IID (TFIID) binds, is located approximately 25 
nucleotides upstream of the transcription start site. Located 5' of the TATA box are 
three Sp1 and two NF-ϰB binding sites. Although mutational analyses of the HIV-1 
LTR reveal that the Sp1 and NF-ϰB sites are variably important, depending upon 
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the cell type, removal of all Sp1 and NF-ϰB sites abolishes virus replication (17). 
Upstream of the NF-ϰB sites is a domain, sometimes referred to as the ―modulatory 
region‖, which contains binding sites for several additional transcriptional factors, 
including LEF, Ets, and USF. Despite the importance of these factors, transcription 
complexes initiated at the HIV-1 promoter are rather inefficient at elongation; RNA 
synthesis is greatly increased (by more than two logs) when the transcriptional 
transactivator protein Tat is present (18,19) (Fig. 1.6). 
In the absence of Tat, polymerases generally do not transcribe beyond a few 
hundred nucleotides, though they do not appear to terminate at specific sites. It is 
still unclear how Tat causes transcribing polymerases to become sufficiently 
processive to completely transcribe the ~9-kb viral genome, but recent experiments 
suggest that Tat may assemble into transcription complexes and recruit or activate 
factors that phosphorylate the RNA polymerase II C-terminal domain (CTD), 
including the general transcription factor TFIIH and other novel kinases (20). 
 
 
 
 
Fig. 1.6: Schematic representation of the HIV-1 LTR: The position of binding sites for 
host factors (LBP-1, NF-κB, LEF, Ets, USF-1, and NFAT-1) are shown at and 5' of the 
transcription start site. The TAR stem/loop structure, with bulge, is represented at the 5' end 
of a nascent mRNA. 
 
 
 
Tat consists of between 86 and 101 amino acids depending on the subtype 
encoded by a two-exon RNA; Tat contains several distinct functional domains: an 
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activation domain, which lies within the N-terminal 48 residues of the protein and 
which itself is comprised of an acidic domain (2-11 residues), a Cys-rich region (22-
37 residues), and a hydrophobic core element (38-48 residues); a highly basic RNA 
binding domain (Arginine-rich domain); and an overlapping nuclear localization 
signal (Fig. 1.7).  
 
 
20 39 48 60
MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRPPQ
GSQTHQVSLSKQPTSQSRGDPTGPKE 
C
HIV Tat
 
 
Fig. 1.7: HIV Tat protein: in red is reported Cys-rich domain and in blue Arg-rich 
domain 
 
 
Unlike typical transcriptional activators, Tat binds not to a DNA site but rather to an 
RNA hairpin known as TAR (trans-activating response element), located at the 50 
end of the nascent viral transcripts. TAR, which is present at the 5' end of all viral 
RNAs, consists of a base-paired stem, a small (trinucleotide) non-base-paired 
bulge, and a 6-nucleotide G-rich loop. The arginine-rich domain of Tat helps 
mediate binding to a three-nucleotide bulge region of TAR, with one arginine 
residue being primarily responsible for recognition. NMR studies of TAR complexed 
to arginine (21) show a base-specific contact between the arginine side chain and a 
guanine in the RNA major groove. The complex is stabilized by additional contacts 
to the phosphate backbone and by formation of a U-A:U base triple between a 
bulge nucleotide and a base pair above the bulge. NMR studies of the full-length 
86–amino acid Tat protein have suggested that a hydrophobic core region of about 
10 amino acids adopts a defined structure but that the rest of the molecule, 
including the arginine-rich RNA-binding domain, is relatively disordered (22). It 
seems likely that Tat requires interactions with cellular proteins in addition to TAR to 
adopt a stable structure.  
This prediction was borne out recently with the identification of a cellular protein that 
interacts, via its activation domain, with Tat (23). The protein in question is cyclin T1 
(cycT1), which forms a heterodimer with a member of the cyclin-dependent kinase 
family (CDK9). The cycT1/CDK9 heterodimer is itself part of a large protein complex 
144 
 
related to the Drosophila positive-transcriptional elongation factor b (P-TEF-b). Tat 
recruits the human P-TEFb complex to TAR, resulting in the phosphorylation of the 
C-terminal domain (CTD) of RNA Pol II and a dramatic stimulation of transcriptional 
processivity (Fig. 1.8). 
 
 
 
Fig. 1.8: Mechanisms of HIV-1 Tat function. The structure of nascent HIV-1 RNA 
containing the 5′ TAR element, with bound Tat and cellular proteins is shown.  
 
 
 
1.5.  IB-α/ NF-ϰB complex 
The NF-ϰB transacting factors enhance the HIV-1 transcription by binding to the ϰB 
sites of the HIV-1 LTR (24). The NF-ϰB proteins, namely p105/p50, p100/52, 
p65/RelA, c-Rel, and RelB, share a Rel homology domain that is required for 
subunit dimerization, nuclear localization, and DNA binding (25). The NF-ϰB 
transcriptional activity is negatively regulated through the association with the IϰB 
proteins (26). IϰB-α (nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, alpha), is the best characterized and ubiquitous member of the IϰB 
family. In unstimulated cells, IϰB-α associates with the p50/p65 NF-ϰB complex, 
preventing its nuclear accumulation, the association with DNA and transcriptional 
activity of NF-ϰB (25,26). The IϰB-α/NF-ϰB complex shuttles in and out of the 
nucleus and is prevalently retained in the cytoplasm (27). Upon NF-ϰB activating 
stimuli, IϰB-α is phosphorylated at serines 32 and 36 by the ϰB kinase complex, 
ubiquitinated at lysines 21 and 22, and proteolyzed by the 26 S proteasome (25, 
26). Following the proteolysis of IϰB-α, the free NF-ϰB complex translocates to the 
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nucleus, where it binds to the ϰB sites and activates the transcription of the NF-ϰB 
dependent genes, including the IϰB-α gene (25, 26). The newly synthesized IϰB-α 
migrates to the nucleus, where it displaces the NF-ϰB complex from DNA and 
promotes its nuclear export, thus terminating the NF-ϰB transcriptional activity (28) 
(Fig. 1.9). 
 
 
 
Fig. 1.9: Classical pathway of NF-ϰB activation 
 
 
From a molecular point of view, IB-α is a 36 kDa protein composed of: a) a N-
terminal signal response region, where phosphorylation and ubiquitination occur in 
response to NF-B activation signals; b) an ankyrin (AR)-rich region made of six 
ankyrin repeats; c) a C-terminal PEST sequence rich in proline, glutamic acid, 
serine, and threonine that is involved in basal degradation of free IB-α (29). Each 
AR repeat of IB-α has a length of approximately 35 amino acids, and is composed 
of a β-hairpin followed by two anti-parallel α-helices and a variable loop. AR repeats 
represent a protein-protein interaction domain that is shared by different proteins 
with highly varied functions (30,31). In fact, IB-α binds to the NF-B dimer via its 
AR domain (spanning residues 67-287) interfering with the NF-B interaction with 
DNA. The binding affinity of IB-α to p50/p65 hetero- and p65/p65 homo-dimers is 
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in the picomolar range, and recent studies revealed that binding interface has two 
hot spots one at either end of the interface (32,33). Notably, in contrast to its 
remarkable stability in the NF-B-bound state, free IB-α is intrinsically unstable and 
is rapidly degraded through a process that does not require phosphorylation and 
ubiquitination (34). In free state, ARs 1–4 of IB-α, are compactly folded while ARs 
5–6 are presumably weakly folded and highly flexible; however, ARs 5-6 adopt a 
fully folded conformation when IB-α binds to NF-B (35,36,37). The coupled 
folding and binding of ARs 5–6 in IB-α has been proposed to modulate the binding 
affinity of IB-α to NF-B (38) as well as the switch between the basal and 
stimulated degradation mechanisms (36). Furthermore, ARs 5-6 appear to be 
involved in the mechanism by which IB-α increases the dissociation rate of NF-B 
from the DNA (39).  
 
 
1.6.  IB-α /TAT complex 
Recent studies found that IϰB-α represses the Tat-mediated transactivation of the 
HIV-1 LTR upon cell transfection. IB-α physically interacts with Tat and determines 
its nuclear export to the cytoplasm, which results in the inhibition of Tat-dependent 
HIV-1 expression (40). Consistently, recombinant HIV-1 and SIVmac239 
retroviruses that expressed the IB-S32/36A mutant, which is resistant to the 
signaling-induced proteolysis were highly attenuated in cell culture (41). They have 
shown that IϰB-α represses the Tat activity independently of the NF-ϰB inhibitory 
activity by physical association and displacement of Tat from the nucleus to the 
cytoplasm. The association of IϰB-α with the arginine rich domain of Tat requires 
both the NLS (amino acids 110–120) and the C-NES (amino acids 265–277) 
together with the binding site for Tat (amino acids 263–269) in order to interfere with 
the nuclear distribution and the transcriptional activity of Tat.  So IϰB-α binds to Tat 
in the nucleus and exports the viral transactivator to the cytoplasm, where the 
complex IϰB-α/Tat is mostly retained. IϰB-α is subjected to persistent proteolysis in 
the course of HIV-1 infection (42), in fact the HIV-1 entry through the gp120 
envelope protein binding to CD4 receptor activates the IϰB kinase complex, which 
promotes the proteolysis of IϰB-α (43). This event leads to the transcriptional 
activation of NF-ϰB-dependent genes, including the HIV-1 genome and pro-
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inflammatory genes, which in turn sustains the proteolysis of IϰB-α and the 
activation of NF-ϰB (44). For this reason, the endogenous IϰB-α does not 
counteract the viral expression in HIV-1-infected cells. The physical and functional 
interaction of IϰB-α with Tat discloses a novel mechanism of HIV-1 transcriptional 
regulation. Indeed the ratio between IϰB-α and Tat could determine the level of 
expression of the target genes, including HIV-1 (Fig. 1.10). 
 
 
 
 
Fig. 1.10: Schematic representation of the mechanism of Tat inhibition by IϰB-α. The 
IϰB-α repressor enters in the nucleus (step 1), where it associates to Tat (step 2) and 
exports the viral transactivator to the cytoplasm (step 3). The nuclear localization signal, the 
carboxyl-terminal nuclear export signal, and the Tat-binding site of IϰB-α are required for 
the nuclear export of Tat. 
 
 
In this regard, the novel mechanism of Tat inhibition by IϰB-α described here could 
assist in the development of a novel class of HIV-1 inhibitors and thus compounds 
that increase the stability of endogenous IϰB-α, such as inhibitors of IϰB kinase and 
proteasomes, could be additional tools of conventional anti-retroviral therapies by 
inhibiting the NF-ϰB-Tat-dependent HIV-1 transcription. 
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1.7.  Aim of the work 
The purpose of the project was the quantification of the binding between IB-α and 
Tat proteins through in vitro Surface Plasmon Resonance (SPR) experiments. 
Moreover, the shorter regions of the two proteins directly involved in the IϰB-α–Tat 
complex formation should be investigated through the development of new IB-α-
based peptides. The characterization of IB-α peptides will provide novel insights 
into the intrinsic properties of IB-α fragments and structural determinants of IB-
α/Tat recognition. These studies were carried out by using multiple approaches to 
chemical synthesis, biochemical assays and mutagenesis studies. 
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2. EXPERIMENTAL SECTION 
 
2.1. Materials  
Reagents for peptide synthesis (Fmoc-protected amino acids and resins, activation 
and deprotection reagents) were from Novabiochem (Laufelfingen, Switzerland) and 
InBios (Napoli, Italy). Solvents for peptide synthesis and HPLC analyses were from 
Romil (Dublin, Ireland); reversed phase columns for peptide analysis and the LC-
MS system were from ThermoFisher (Milan, Italy). Solid phase peptide syntheses 
were performed on a fully automated multichannel peptide synthesizer Syro I 
(Multisynthech, Germany). Preparative RP-HPLC were carried out on a Shimadzu 
LC-8A, equipped with a SPD-M10 AV detector and with a Phenomenex C18 Jupiter 
column (50x22 mm ID; 10 μm). LC-MS analyses were carried out on a LCQ DECA 
XP Ion Trap mass spectrometer equipped with a OPTON ESI source, operating at 
4.2 kV needle voltage and 320 °C with a complete Surveyor HPLC system, 
comprised of MS pump, an autosampler and a photo diode array (PDA). Narrow 
bore 50x2 mm C18 BioBasic LC-MS columns were used for these analyses. 
 
 
2.2. Protein and peptide synthesis 
The entire HIV-1 Tat protein [1-86] was prepared as already reported [40]. Peptides 
were synthesized employing the solid phase method on a 50 μmol scale following 
standard Fmoc strategies (45). RINK AMIDE resin (substitution 0.5 mmol/g) was 
used as solid support. Activation of amino acids was achieved using 
HBTU/HOBt/DIEA (1:1:2), whereas Fmoc deprotection was carried out using a 20% 
(v/v) piperidine solution in DMF. All couplings were performed for 15 min and 
deprotections for 10 min and at the end of peptide chain assembly peptides were 
acetylated at their N-termini. Peptides were removed from the resin by treatment 
with a TFA:TIS:H2O (90:5:5, v/v/v) mixture for 90 min at room temperature; then 
crude peptides were precipitated in cold ether, dissolved in a water/acetonitrile (1:1, 
v/v) mixture and lyophilized.  
Products were purified by RP-HPLC applying a linear gradient of 0.1% TFA CH3CN 
in 0.1% TFA water from 5% to 65% over 12 min using a semi-preparative 2.2x5 cm 
C18 column at a flow rate of 20 mL/min. Peptides and purity and identity were 
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confirmed by LC-MS. Purified peptides were lyophilized and stored at -20 °C until 
use. 
 
 
2.3. Plasmids 
The nucleotide sequence of IB- was amplified by PCR from pcDNA-3HA- IB-
 with the forward primer GGCGCTAGCATGTTCCAGGCGGCCG and reverse 
primer CGGGAATTCTCATAACGTCAGACGCTG. The PCR product was digested 
with NheI/EcoRI and ligated to pPet28c (Novagen, Darmstadt, Germany) to 
generate pPet28c-IB-. The eukaryotic expression plasmids for IκB-α 
RPSTRIQQQL/A, IB- TRIQQQL/A, IB- QQQ/A and R264/S were generated by 
site-directed mutagenesis of pcDNA-3HA-IkB- (40). pRc/CMV-p65, p3xFLAG-
CMV-Tat and  pNF-B-deleted-LTR-Luc were previously described (46); pκBluc and 
pSV-β-Gal were purchased from Promega (Madison, WI, USA).  
 
2.4. Production and purification of recombinant  
Escherichia coli BL21 (DE3) culture was transformed with pPet28c-IB- by calcium 
chloride and transformants were grown in LB medium (1 L) containing kanamycin 
(250 g/L) up to OD600nm = 0.5. Then, the bacterial culture was induced with 1 mM 
isopropyl-β-D-thiogalactopyranoside (IPTG) for 6 h. Bacteria were harvested by 
centrifugation (5000 x g) for 15 min at 4°C. The pellet was resuspended into 10 mL 
of Native Binding Buffer (50mM NaH2PO4, 500mM NaCl, 1mM DTT  and 5 mM 
Imidazole, pH 8.0), and sonicated 10 times for 10 s by using Bandelin Sonoplus 
GM70 (Bandelin Electronic, Berlin, Germany). The lysate was clarified by 
centrifugation (15000 x g) for 20 min and incubated with 5 mL of ProBond Nickel 
chelating Resin (Invitrogen, Carlsbad, CA, USA) at 4°C overnight. The resin was 
extensively washed with Wash Buffer (50mM NaH2PO4, 500mM NaCl, 20 mM 
Imidazole, pH 8.0). and, the recombinant protein 6xHis-IB- was eluted in Elution 
Buffer (50mM NaH2PO4, 500mM NaCl, 1mM DTT, 500 mM Imidazole, pH 8.0). 
6xHis-IkB-a recombinant protein was desalted with a Sephadex G-25 column (GE 
Healthcare, UK) in a buffer containing 1x PBS, 1mM DTT and 250 mM NaCl. The 
protein was concentrated at 0.2 mg/mL (5.36 M) by using Centricon columns YM-
10 (Millipore, Bedford, MA, USA). 
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2.5. SPR analysis 
The BIAcore 3000 SPR system for Real time binding assay and related reagents 
were from GE Healthcare (Milano, Italy).  
Tat protein was immobilized at a concentration of 50 µg/mL in 10 mM acetate buffer 
pH 4.0 (flow rate 5 μL/min, time injection 7 min) on a CM5 Biacore sensor chip, 
using EDC/NHS chemistry following the manufacturer‘s instructions (47). Residual 
reactive groups were deactivated by treatment with 1 M ethanolamine 
hydrochloride, pH 8.5. Reference channel was prepared by activating with 
EDC/NHS and deactivating with ethanolamine. Binding assays were carried out at 
20 L/min, with 4,5 min contact-time, IB- protein and peptides were diluted in the 
running-buffer, HBS (10 mM Hepes, 150 mM NaCl, 3 mM EDTA, pH 7.4) 0.1 mM 
TCEP. Analyte injections of 90 μL were performed at the indicated concentrations. 
BIAevaluation analysis package (version 4.1, GE Healthcare, Milano, Italy) 
implemented by instrument software was used to subtract the signal of the 
reference channel and to evaluate kinetic and thermodynamic parameters of 
complexes. 
Competitive SPR experiments with Tat peptides were carried out pre-incubating Tat 
peptides with IB-α full-length in a 2:1 ratio (Tat peptides: IB-α 160: 80 nM). 
Pep 260-272 and Pep 262-280 were analyzed in the concentration ranges 1-10 µM and 1-
20 µM, respectively, while Pep 262-287 in 1-40 µM and Pep 243-263 in 10-700 M, 
respectively. 
 
2.6. Circular Dichroism (CD) Spectroscopy 
CD spectra were recorded on a Jasco J-810 spectropolarimeter (JASCO Corp, 
Milan, Italy). CD spectra were registered at 25 °C in the far UV region from 190 to 
260 nm. Each spectrum was obtained averaging three scans, subtracting 
contributions from corresponding blanks and converting the signal to mean residue 
ellipticity in units of deg * cm2 * dmol -1* res-1. Other experimental settings were: 20 
nm/min scan speed, 2.0 nm band width, 0.2 nm resolution, 50 mdeg sensitivity, and 
4 sec response. The concentration of peptides was kept at 10×10−5 M and a 0.1 cm 
path-length quartz cuvette was used. Spectra were acquired in 10 mM phosphate 
buffer at pH 7.0.  
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Thermal denaturation profiles were obtained by measuring the temperature 
dependence of the ellipticity at 220 nm in the 20-90 °C range with a resolution of 0.5 
°C and 1.0 nm bandwidth. The heating rate was 1°C/min and the response at 16 s 
with a Peltier temperature controller. 
 
2.7. Cell culture and transfection  
HeLa cells were grown in DMEM supplemented with 10% fetal calf serum (FCS) 
and 100 µg/mL penicillin/streptomycin, and maintained at 37°C with 5% CO2. For 
plasmid transfection, cells were transfected by FUGENE HD reagent Roche 
Diagnostic GmbH, Mannheim, Germany) according to the manufacturer‘s 
instructions. Total DNA amounts were equalized by transfection of pRc/CMV empty 
vector (Invitrogen, Carlsbad, CA, USA). 
 
2.8. In vitro translation 
Wild type and mutant 3HA-IB- proteins were in vitro translated by using as 
templates pCDNA plasmids expressing the IB- sequence under T7 promoter in 
the TnT Quick Coupled Transcription/Translation Systems (Promega, Madison, WI, 
USA) according to the manufacturer‘s protocol.  For in vitro translation the FLAG-
Tat, the FLAG Tat sequence was PCR-amplified from p3xFLAG-CMV-Tat using the 
5‘T7-FLAG forward primer CGCCGGTAATACGACTCACTATAGGGACGCCA 
CCATGGACTACAAAGACCATGAC and the 3‘TAT reverse primer 
GCTCTAGACTATTCCTTCGGGCCTGTCG; the PCR product was in vitro 
translated under the T7 promoter by using the TnT Quick Coupled 
Transcription/Translation Systems (Promega). 
 
2.9. Immunoprecipitation and Western blotting 
Wild type and mutant HA-IB- (20 μL) were incubated with or without FLAG-Tat 
(20 μL) in 500 L of modified RIPA buffer [20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 
mM EDTA, 1% NP40, 1 mM PMSF, 1x Complete Protease Inhibitor (Roche 
Diagnostic GmbH)] in presence of protein G-Sepharose-coupled anti-FLAG 
antibody overnight at 4°C. Immuno-complexes were recovered by centrifugation at 
200x g for 10 min at 4° C, extensively washed in modified RIPA buffer, resuspended 
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in SDS gel loading buffer, separated by 12% SDS-PAGE, and analyzed by Western 
blotting with anti-HA and anti-FLAG antibodies.  
 
2.10. Luciferase assay 
For testing Tat transcriptional activity, HeLa cells (5x105) were transfected with 
pNF-B-deleted-LTR-Luc (0.5 g), pSV-β-Gal (0.2 g) with or without p3xFLAG-Tat 
(0.5 g), pcDNA-3HA-IB- wild type (2 g) or indicated mutants (2 g).  
For testing p65 transcriptional activity, HeLa cells (5x105) were transfected with 
pB-Luc (0.5 g), pSV-β-Gal (0.2 g) with or without pRc/CMVp65 (0.5 g), pcDNA-
3HA-IB- wild type or mutants (2 g). Forty eight h post-transfection, cells were 
lysed in lysis buffer (Dual Light Luciferase System, Tropix, Bedford, MA, USA), and 
the luciferase and β-galactosidase activities were evaluated by using Dual Light 
Luciferase System (Tropix) in a bioluminometer (Turner Biosystem, Sunnyvale, CA, 
USA). The ratio of firefly luciferase activity to β-galactosidase activity was 
expressed as relative light units. 
 
2.11. Statistical analysis 
The data were reported as the mean ± S.E. using the two-tail unpaired Student‘s t 
test to assess the statistical significance of differences between means. Differences 
between the means were accepted as statistically significant at the 99% level (p 
<0.01). 
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3. RESULTS 
 
3.1. SPR analysis of the Tat- IBα protein complex 
In order to quantify the entity of Tat-IB-α binding, SPR experiments were carried 
out.  Both proteins were preliminary obtained with a high degree of purity as 
suggested by LC-MS analysis (Fig. 3.1).  
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Fig. 3.1: MS spectra of IB-α and HIV-Tat protein. LC-MS analysis of purified (A) 6xHis-
tagged IB-α 1-317 and (C) HIV-Tat 1-86. Upper panels are UV chromatograms lower 
panels are ESI-mass profiles. Deconvoluted mass spectra of purified (B)  IB-α 1-317 
(MWth/exp 37917/37920 Da) and (D) HIV-Tat 1-86 (MWth/exp 9777/9778 Da) proteins. 
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To this end, the full length His-IB-α (1-317) was expressed in the BL21(DE3) 
bacterial strain and purified by affinity chromatography using nickel-agarose 
columns. HIV-1 Tat 1-86 was chemically synthesized following standard Fmoc 
protocols (48) and purified by RP-HPLC.  
Tat protein was efficiently immobilized on CM5 (averaged immobilization level 4000 
RU) and IB-α was employed as analyte (concentration range 0-1000 nM). Dose-
response sensorgrams revealed that IB-α (1-317) avidly bound Tat; the 
association rate appeared to be rapid (ka= 7.39*104 M-1 s-1) whereas the 
dissociation was slow (kd=7.86 10 -4 s-1) thus providing a KD value of 44.1±1.2 nM 
(Fig. 3.2 A).  
The analysis of Tat sequence unveils the presence of two characteristic domains: 
the cysteine-rich motif (residues 20-39) comprising seven Cys residues present in 
the protein and a basic region (residues 48-60) containing several arginine and 
lysine residues (Fig. 3.3) (49).  
 
       
20 39 48 60
MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRPPQ
GSQTHQVSLSKQPTSQSRGDPTGPKE 
C
HIV Tat
 
 
Fig. 3.3: HIV Tat BH10 protein, in red is reported Cys-rich domain and in blue Arg-rich 
domain 
 
In order to identify Tat regions involved in IB-α recognition, we carried out 
competition experiments by using the peptides Tat20-39 and Tat48-60 corresponding to 
the cysteine-rich and arginine-rich region of Tat, respectively. The presence of pre-
incubated Tat Cys domain with IB-α (2:1 molar ratio, 160: 80 nM) did not affect the 
entity of IB-α/Tat binding (Fig. 3.2 B). On the other hand, the presence of the 
peptide corresponding to the basic region (used in the same 2:1 ratio) significantly 
lowered the entity of IBα binding to Tat (Fig. 3.2 C).  
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Fig. 3.2: SPR experiments of Tat-IB-α. Overlay of sensorgrams relative to the binding to 
immobilized Tat of (A) IB-α protein, (concentration range 5-1000 nM); (B) IB-α (black 
line) at 80 M and a mix of IB-α at 80 M pre-incubated with Tat 20-39 at 160 M (red 
line) (C)  IB-α (plain line) at 0.80 M and a mix of IB-α at 0.80 M pre-incubated with Tat 
40-68 at 1.60 M (dotted line). Experiments were carried out in duplicate at a 25° C, at a 
constant flow rate of 20 μL/min using HBS 0.1mM TCEP, as running buffer. 
 
 
 
3.2. Identification of IB-α regions involved in Tat recognition through the 
characterization of IB-α -based peptides 
The identification of the IB-α regions involved in Tat binding was achieved through 
the characterization of ad-hoc designed IB-α peptides. Previous biochemical data 
suggested that a region close to the IB-α C-terminus was involved in the binding to 
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Tat (40). To further characterize IB-α fragments involved in the IB-α /Tat complex, 
the C-terminal region of IB-α (residues 243-317) was dissected in smaller 
fragments to unveil the role of specific determinants in the recognition process such 
as local structure and sequence and electrostatic charge. Although structural 
information on the free IB-α protein is missing, clues on the conformation adopted 
by specific regions of this protein may be inferred from the structures of its 
complexes with NF-B (29). In the structure of the IB-α/p50/p65 complex, residues 
243-280 of IB-α constitute the sixth ankyrin repeat of the protein. The C-terminus 
of the AR6 region is followed by a flexible negatively charged motif denoted as 
PEST (residues 281-287). The very C-terminal end of the protein is composed by 
an additional negatively charged fragment (residues 288-302), and by the region 
303-317. We designed peptides by dissecting and combining fragments of the AR6, 
the PEST region, and the C-terminus of the protein (Fig. 3.4 A-B). 
  
A NES AR1 AR2 AR3 AR5 AR6 PEST
IκBα
AR4
B
VNRVTYQGYSPYQLTWGRPSTRIQQQLGQLTLENLQML 
PESEDEE  SYDTESEFTEFTE DELPYDDCVFGGQRLTL 
ANK6
helix310 α-helix helix310
C-terminus
PEST
243 263 280
287 303 317
 
 
Fig. 3.4. HIV Tat and IB-α proteins. (A) Schematic representation of modular structure of 
IB-α protein; Primary structures of (B) Ankyrin 6 and C-terminus of IB-α protein (herein 
some C- and N-termini of IB-α-based designed peptides are evidenced. 
 
 
 
Indeed, AR6 was divided in two large peptides corresponding to the regions 243-
263 (Pep243-263) and 262-280 (Pep262-280). In the structure of the IB-α/NF-B 
complex Pep243-263 comprises a -hairpin motif and a 310 helix, whereas Pep262-280 
contains an α- and a 310- helix (Fig. 3.4 B and Table 3.1).  
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IkB-a peptide  Peptide sequence SPR Binding to Tat, 
KD 
243-263 harpin helix 310 VNRVTYQGYSPYQLTWGRPST + 
400 µM 
 
262-287 alpha, 310 helices and 
PEST domain 
STRIQQQLGQLTLENLQMLPESEDEE + 
200 nM 
262-280 alpha, 310 helices STRIQQQLGQLTLENLQML -  
260-272alpha helix RPSTRIQQQLGQL - 
269-287 310 helix and PEST 
domain 
LGQLTLENLQMLPESEDEE -  
281-302 negatively charged 
domain 
PESEDEESYDTESEFTEFTEDE - 
303-317 LPYDDCVFGGQRLTL - 
  
Table 3.1: IB-α-based peptides analyzed in this study 
 
 
This latter region was further reduced by considering the peptide corresponding 
only to the α-helix of AR6 (Pep260-272). The 262-280 region was also combined to 
the PEST motif in the peptide Pep262-287. Moreover, the PEST region was linked to 
the 310 helix located at the C-terminus of AR6 (Pep269-287). Finally, the highly 
negatively charged peptide Pep281-302  (total charge -12) and the C-terminal fragment 
Pep303-317 were also considered.  
All peptides were chemically synthesized in good yields by SPPS, using Fmoc 
methodologies as N-terminal acetylated and C-terminal amidated derivatives and 
purified by RP-HPLC; their identity and purity were assessed by LC-MS (data not 
shown). To evaluate the impact of intrinsic structural preferences of these fragments 
on their ability to bind Tat, all peptides were characterized by far-UV circular 
dichroism spectroscopy (CD). As expected, the peptides corresponding to the C-
terminal end of the protein (Pep281-302 and Pep303-317) were unfolded ( data not 
shown). Similarly, the CD spectra of Pep243-263 and Pep269-287 present a minimum at 
a wavelength lower than 200 nm (Fig. 3.5 A-B).  
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Fig. 3.5: CD analysis of IB-α peptides. CD spectra of the IB-α synthetic peptides in 
phosphate buffer 10 mM, (A) Pep243-263, (B) Pep269-287 (C) Pep 260-272, (D) Pep262-280  
Inset:Thermal denaturation at 220 nm (E) Pep 262-287. 
 
Although these peptides contain fragments that are structured in the IB-α/NFB 
complex (29), these findings indicate that both Pep269-287 and Pep243-260 are 
intrinsically unfolded. The spectrum of Pep260-272, which is helical in the complex, 
presents a minimum at ~ 200 nm and a shoulder at ~ 220 nm (Fig. 3.5 C); these 
features are suggestive of mixture of conformational states, in which a predominant 
unfolded state coexists with a helical conformation. The addition of eight residues at 
the C-terminus of Pep260-272 to generate the peptide Pep262-280 produces a strong 
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negative CD signal at 220 nm (Fig. 3.5 D). The analysis of the thermal dependence 
of the CD signal at 220 nm of the peptide Pep262-280 shows a clear cooperative 
transition at 52° C (inset of Fig. 3.5 D). Although the Pep262-280 spectrum does not 
match canonical spectra corresponding to individual secondary structure elements, 
these findings indicate that Pep262-280 is more structured than Pep260-272. 
Interestingly, the addition of the PEST domain to Pep262-280 to generate the peptide 
Pep262-287 drastically affects the CD spectrum (Fig. 3.5 E). Indeed, the spectrum of 
Pep262-287 becomes similar to that displayed by Pep260-272. Altogether these findings 
provide clear evidence of the mutual structural influence of the different fragments 
of this IB-α region. 
 
3.3. Analysis of Tat binding to IB-α-based peptides  
The ability of IB-α-based peptides to bind Tat was checked by using SPR direct 
binding assays. These experiments were carried out in the same way of those 
involving the full-length IB-α protein by using Tat as ligand and the IB-α-based 
peptides as analytes. Among the IB-α-based peptides, only Pep262-287 and Pep243-
263 showed detectable binding to Tat (Table 3.1). The overlay of the sensorgrams 
corresponding to the peptide Pep262-287 (Fig. 3.6), showed a clear a dose-response 
binding in the concentration range 1-40 M and the estimation of value KD is 207 ±5 
nM on the basis of the related kinetic data.  
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Fig. 3.6: SPR experiments of IB-α peptides. Overlay of sensorgrams relative to the 
direct binding of IB-α262-287 to immobilized Tat. Concentrations were between 1.0 and 40 
μM. Experiments were carried out in duplicate, at a 25° C, at a constant flow rate of 20 
μL/min using HBS-0.1 mM TCEP as running buffer. 
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The affinity of Pep243-263 for Tat was much lower as dose-response experiments 
performed in a larger concentration range (10-700 M) provided KD value of 409 ±7 
M (Fig. 3.7). 
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Fig. 3.7: SPR experiments of IB-α243-263  peptide. Overlay of sensorgrams relative to the 
direct binding of IB-α243-263 to immobilized Tat. Concentrations were between 10 and 700  
μM. Experiments were carried out in duplicate, at a 25° C, at a constant flow rate of 20 
μL/min using HBS-0.1 mM TCEP as running buffer. Estimated KD value = 409 ±7 M. 
 
 
The remarkable difference of magnitude of the KD values displayed by the two 
peptides indicated that a region embedded in the fragment 262-287 was likely 
responsible for the binding of IB-α to Tat. Notably, the reduction of the length of 
this region by cutting either its N-terminal or C-terminal ends abolished the binding 
to Tat, as shown by the inability of Pep262-280, Pep260-272, and Pep269-287 to bind to 
protein (Table 3.1).  
 
 
3.4. Characterization of IB-α mutants in the region 260-269  
We previously suggested that the IB-α region encompassing the amino acids 262-
269 could be important for the binding of this protein to Tat (40).  
This observation has been partially corroborated by the SPR analysis on the IB-α -
based peptides. Although the isolated peptide Pep260-272 is unable to bind Tat, the 
removal of the region 260-269 from the peptide Pep262-287 abolishes the binding to 
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Tat as shown by the data obtained for Pep269-287. In this framework, the role of 
specific fragments within the region 260-269 has been evaluated by using an Ala 
scanning approach. To further address the role of distinct amino acids within the 
region 260-269 in the binding to Tat, we generated the full-length mutants IB-α 
260(RPSTRIQQQL)269/A, IB-α 263(TRIQQQL)269/A, IB-α 266(QQQ)268/A, where the 
indicated amino acids were substituted with alanines. These mutants were tested 
for their ability to bind to Tat by immunoprecipitation of in vitro translated proteins. 
Consistently with previous observation (40), the substitution of amino acids 260-269 
or amino acids 263-269 abolished the binding of IB-α to Tat (Fig. 3.8, lanes 4, 6). A 
significant reduction of the binding was observed for IB-α 266(QQQ)268/A, (Fig. 3.8, 
lane  8). These results indicated that the minimal sequence of IB-α essentially 
required for Tat binding mapped within amino acids 263-269 with a partial 
contribution of the glutamine triplet at 266-268.  
As further characterization, wild type and IB- mutants were analysed for their 
inhibition of Tat transcriptional activity. To this end, Jurkat cells were transfected 
with the expression vectors of the IB-α genes together with Tat and the NF-B-
deleted Long Terminal Repeats (LTR) of HIV-1 fused to the luciferase gene. The 
use of the NF-B-deleted LTR allowed determining the effect of IB-α on the Tat 
trans-activating ability independently from its inhibition of NF-B activity. As 
compared to wild type, IB-α 260(RPSTRIQQQL)269/A and IB-α 263(TRIQQQL)269/A 
completely loss the ability to repress the Tat trans-activation of the LTR, which 
corresponded to their inability to associate to Tat; a sligth but significant inhibition 
was exhibited by IB-α 266(QQQ)268/A, which retained a partial ability to bind Tat 
(Fig. 3.9 A). 
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Figure 5
 
Fig. 3.8: Characterization of amino acid residues of IkB-a involved in the in vivo 
binding to Tat. Wild type and mutant HA-IB-proteins were in vitro translated and 
equivalent aliquots were incubated with or without FLAG-Tat; protein complexes were 
immunoprecipitated with protein G-Sepharose-coupled anti-FLAG antibody. The immuno-
complexes were separated on 12% SDS-PAGE and analyzed by Western blotting with anti-
HA and anti-FLAG antibodies. 
 
 
It is worthwhile to note that the base-pair mutations of IB-α did not affect the 
inhibition of the p65/NF-B transcriptional activity. In fact, all IB-α mutants inhibited 
the p65-mediated transactivation of the NF-B-dependent luciferase expression at 
the same extent as the wild type protein, suggesting that these mutations did not 
affect the global folding of IB-α (Fig. 3.9 B). These results also demonstrate that 
the IB-α region 263-269, which is required for the binding and inhibition of Tat, is 
not involved in the inhibition of p65 transcriptional activity.  
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Fig. 3.9: Characterization of the amino acid residues of IB- involved in the 
inhibition of Tat or NF-B transcriptional activities. HeLa cells were transfected with (A) 
the reporter plasmid pNF-B-deleted LTR-Luc with or without p3xFLAG-Tat, pcDNA-3HA-
IB- wild type or indicated mutants; (B) the reporter plasmid pB-Luc with or without 
pRc/CMV-p65, pcDNA-3HA-IB- wild type or indicated mutants. Forty-eight h post-
transfection, the luciferase activity was measured in cell extracts. The asterisks indicate a 
statistically significant inhibition according to Student's t test (*, p < 0.01). 
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4. DISCUSSION 
Protein-protein interactions play a fundamental role in the vast majority of 
physiological or pathological processes. An emerging paradigm of recent 
investigations is the involvement of the same protein in multiple and diversified 
biological partnerships. The identification and characterization of alternative 
partnerships has enormous implications for understanding the molecular 
mechanisms underlying pathological events, and for the development of new 
molecular entities able to regulate these processes (50).  
In this framework, we have recently discovered that IκB-α, in addition to the known 
partners including p50/p65 NF-kB complex (29), p53 (51) and HDAC (52), also 
binds the HIV-1 Tat transcriptional activator (49). This interaction has a remarkable 
impact on the mechanism of HIV infection as shown by the high attenuation of viral 
growth upon expression of proteolysis-resistant IκB-α mutant (41,46). As this finding 
may be exploited for the design of new strategies for combating the widespread 
HIV-1 infection, here we have characterized in detail the Tat/IB-α interaction. 
Binding experiments carried out by using SPR techniques indicates that the Tat and 
IκB-α tightly bind each other with a KD constant in the nanomolar range. The entity 
of the binding affinity between the two proteins corroborates the proposal that the 
IB-α–Tat binding plays a significant role in HIV-1 transcriptional regulation. 
Moreover, we characterized the regions of the two proteins directly involved in the 
IB-α–Tat complex formation. To this aim two alternative approaches were adopted: 
(a) the dissection of the two proteins into smaller fragments, and (b) the design and 
the characterization of IB-α mutants. The fragmentation of Tat clearly 
demonstrated that the arginine-rich region of the protein (residues 48 – 60) was 
directly involved in the protein-protein recognition; consistently with our previous 
observations (40). Although this result could suggest that electrostatic interactions 
could play a fundamental role in the binding process, the identification of the ―hot 
spot‖ regions of IB-α proved to be quite intricate. 
Indeed, the peptide Pep281-302 designed by considering essentially the negatively 
charged region 281-302 of IB-α was unable to bind to Tat. This suggests that mere 
electrostatic interactions cannot account for the tight association of the two proteins. 
Along this line, no binding was also observed for the peptide Pep269-287, which also 
contains the negatively charged PEST region. However, a remarkable binding was 
observed when the N-terminus of the peptide Pep269-287  was extended up to residue 
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262 (Pep262-287). This indicates that residues of the fragment 262-268, which 
assumes a helical conformation in the complex between IB-α -NFB (29), are 
important for the binding.  
 Noticeably, the context in which this fragment is embedded plays a role in Tat 
recognition. Indeed, the peptide Pep260-272, which contains the minimal extension of 
this fragment, is unable to bind Tat. Collectively these data suggest that the PEST 
domain, although not directly involved in the binding, plays a role in selecting the 
conformation of the region 262-268 that is prone to bind Tat. This is not surprising 
since the CD characterization of the residual structure of isolated IB-α fragments 
here reported indicates a mutual influence of the different regions.  
In order to validate, these findings in vivo and to gain further insights into IB-α-Tat 
recognition domain, three IB-α mutants were designed and characterized. The 
attention was focused on the region 260-269, with a particular emphasis to the three 
consecutive Gln residues of the region 266-268, that could bind the positively 
charged arginine-rich Tat domain. The trans-activation data confirmed a critical role 
of this region in Tat recognition, which involves the three glutamine and few nearby 
residues. Interestingly, the three IB-α mutants displayed an unaltered ability to 
inhibit p65. This is in line with the crystallographic data available for the IB-α–
p50/p65 complex and with the biochemical characterization of IB-α–p50/p65 
complex that identified two distinct ―hot spot‖ regions of IB-α for p65 binding helix 4 
and residues 276-287 (29). Therefore, distinct IB-α regions might mediate the 
interaction with the p50/p65 dimer or Tat.  
In conclusion, the findings here reported provide a detailed characterization of IB-
α-Tat recognition. The identification of a peptide that present a good affinity for Tat 
represents a promising starting point for the development of molecules able to 
sequestrate Tat to inhibit its transcriptional activity, which could be tested as 
potential therapeutics. 
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1. INTRODUCTION 
1.1. Protein splitting-Protein reassembly 
Reassembly of proteins also known as ‗‗Protein fragment complementation‘‘ 
represent a structure based dissection of a protein  through the expression or 
chemical synthesis of  two or more fragments and the their re-assembling by means 
of non-covalent interactions. This approach have had several analytical and 
biochemical applications  including study of protein–protein interactions, antibody 
screening, immunoassays and high-throughput screening.  
After protein dissection, protein regions can reassemble spontaneously  and/or 
assisted  by the interaction with a host partner. Several proteins including 
ribonuclease, chymotrypsin inhibitor-2, t-RNA synthase and inteins undergo 
spontaneous reassembly from their peptide fragments to yield active protein (1–4). 
However, formation of unordered aggregates of peptides is a major drawback of 
spontaneous reassembly of proteins (Fig. 1.1).  
 
 
 
 
 
Fig. 1.1: Schematic representation of spontaneous and assisted reassembly where X 
and Y are peptide fragments of the reporter protein and A and B are the interacting 
domains 
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To overcome this drawback, soluble oligomerization domains are attached to the 
peptide fragments, aiding the reassembly of proteins. This strategy has been 
successfully used in the reconstitution of several reporter proteins such as, 
dihydrofolate reductase, β-lactamase, aminoglycoside kinase, and green 
ﬂuorescent protein (GFP) (5–10).  
In this strategy, an enzyme or ﬂuorescent protein (the reporter) is rationally 
dissected into two fragments and the fragments fused to two proteins that are 
thought to bind to each other. Folding of the reporter enzyme from its fragments is 
catalyzed by the binding of the test proteins to each other, and is detected as 
reconstitution of enzyme activity. The strategies described above refocus chemical 
genetics and therapeutic discovery from protein targeting to ‗network-based 
targeting‘. There are some considerable advantages of network targeting that are 
summarized in this points: 
 Optimal target(s) for a network of interest can be identified in a simple cell-based 
assay. 
 The development of this approach is simple and necessitate neither the 
production of recombinant proteins nor protein purification, as is required for the 
development of large-scale in vitro based assays of drug targets; often an 
intractable problem. 
 This method enables the analysis of combinations of drugs that may impact 
multiple targets simultaneously. The ‗drug cocktail‘ procedure is becoming 
particularly relevant in the oncology arena, where recent data demonstrated 
highly synergistic effects of kinase inhibitors (e.g. in combination with traditional 
cytotoxic chemotherapeutic agents) (11). 
The most critical issue in the success of the reassembly is the site of the cleavage 
in the protein and the availability of the 3-D structure and circular permutation 
studies can aid in the design of the protein fragments. In planning successful protein 
reassembly strategies it is important to focus on small size proteins with monomeric 
structure and addressable in a biochemical assay. For overcoming a part of these 
problems, Host-guest chemistry could represent a valid strategy for the reassembly 
of two protein fragments.  
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1.2. Host-Guest Chemistry 
 Supramolecular chemistry approaches have generated a vast variety of 
multicomponent architectures by virtue of noncovalent interactions. Host-guest 
chemistry encompasses the idea of molecular recognition and interactions through 
non covalent bonding that is critical in maintaining the three-dimensional structure of 
large molecules such as proteins and is involved in many biological processes in 
which large molecules bind specifically but transiently to one another.  
 Insights gained from studies of noncovalent interactions have been of practical 
value in a wide range of applications including drug delivery, self-assembly and 
molecular recognition, chromatographic stationary phases, nanotechnology, 
sequestration of contaminants from solution, and the development of catalysts and 
chemical sensors. These applications require the availability of low-molecular-
weight receptors (12,13) natural or non-natural oligomers and polymers,(14) or 
solid-state materials (15) that interact with their analytes in high affinity, highly 
selective binding processes. 
Commons host molecules are macrocycles, as they provide cavities that can 
surround guest molecules and may be chemically modified to fine-tune their 
properties. Usually used macrocycles are (Fig.1.2): 
 Cyclodextrins, calixarenes, cucurbiturils and crown ethers, that are readily 
synthesized in large quantities. 
 Complex cyclophanes, and cryptands that can be synthesized to provide more 
tailored recognition properties. 
 Metallacycles, that are macrocyclic aggregates with metal ions in the ring, often 
formed from angular and linear modules. Common metallacycle shapes as 
triangles, squares, and pentagons, as ligand field and bearing functional groups 
as coordinating moieties that "self-assembly around metal ion. 
 Metallacrowns are metallamacrocycles, that are generated via a similar self-
assembly approach from fused chelate-rings. 
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Fig. 1.2: Structural formulas of α-, β-, and γ-cyclodextrin, [18]crown-6, a 
calix[4]arene and cucurbit[n]uril 
 
 
 
1.2.1. The Cucurbit[n]uril Family 
Although cyclodextrins (CDs) remain the macrocyle of choice for industrial 
applications on account of their commercial availability and low cost, several 
limitations arising from their low affinity and low selectivity exists. To this end, a 
new class of supramolecular host molecules, cucurbit[n]uril (CB[n]), has emerged 
as a versatile platform for fundamental and applied molecular recognition and self-
assembly studies. All the members of the CB[n] family possesses a confluence of 
properties that suggest their high potential in nanotechnology as components of 
molecular machines.  
These properties now include:  
 commercial availability in four different sizes 
 binding interactions of high affinity 
 high selectivity of binding 
 synthetic control over size, shape, and functional-group placement 
 high structural integrity 
 solubility in both organic and aqueous solution 
 association and dissociation with controlled kinetics 
 control of the molecular recognition processes by suitable electrochemical, 
photochemical, and chemical stimuli. 
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In 1981, during the reinvestigation of the condensation reaction of glycoluril and 
formaldehyde in concentrated HCl first reported by Behrend in 1905 (16), (Fig. 1.3) 
Mock et al. confirmed the remarkable macrocyclic structure consisting of six 
glycoluril units and twelve methylene bridges (CB[6]) and named it ―cucurbituril‖ 
owing to its resemblance of a pumpkin, a prominent member of the cucurbitaceae 
family (17).  
 
 
 
Fig. 1.3:  Synthesis of cucurbit[n]uril: from glycoluril under reported conditions: CH2O, 
HCl, 100°C, 18 h. 
 
 
Recently Scherman‘s group reported a new ―greener‖ method for the isolation of 
CB[5] and CB[7] based on ionic liquid binding and a solid state metathesis reaction 
(18). In this new strategy (Scheme 1.1), 1-ethyl-3-methylimidazolium bromide 
[C2mim]Br (Ka > 105 M-1 for CB[7]·[C2mim]Br,; it does not bind to CB[5] at all) (19) 
was added to an aqueous mixture of CB[5] and CB[7] followed by addition of 
NH4PF6 leading to the precipitation of the CB[7]·[C2mim]PF6 complex. The 
CB[7]·[C2mim]PF6 complex was isolated leaving an aqueous solution of CB[5] 
which was readily recrystalized to give pure CB[5]. The solid CB[7]·[C2mim]PF6 
complex was converted back to its bromide form and a solid state metathesis 
reaction using solid CB[7]·[C2mim]Br complex and solid NH4PF6 in 
dichloromethane yielded CB[7] in its pure form. The new technique not only 
provided a greener method for CB isolation, and high yield (71%), but also reduced 
the separation time from several weeks to a few days. A similar approach has also 
been applied to separate CB[6] and CB[8] (20). 
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Scheme 1.1: Isolation of CB[5] and CB[7] using ionic liquid and a solid 
state metathesis reaction 
 
 
CB[n] are cyclic methylene-bridged glycoluril oligomers whose shape resembles a 
pumpkin. Fig. 1.4 shows the X-ray crystal structures for CB[5]–CB[8] and CB[5]-
CB[10]. The cavity of CB[6] in the solid state contains three H-bonded H2O 
molecules which can be released upon guest binding. The distinctive features of 
CB[5]–CB[10] are their two portals lined by ureido carbonyl groups that provide 
entry to their hydrophobic cavity (21). Similar to the cyclodextrins, the various CB[n] 
have a common depth (9.1 Å), but their equatorial widths, annular widths a, and 
volumes vary systematically with ring size (Table 1.1). 
The portals guarding the entry to CB[n] are approximately 2 Å narrower than the 
cavity itself which results in constrictive binding that produces significant steric 
barriers to guest association and dissociation (22). 
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Fig. 1.4: Top and side views of the X-raycry stal structures of CB[5], CB[6], 
CB[7], CB[8], and CB[5]/CB[10]. The various compounds are drawn to scale. 
 
 
One of the potential limitations of the CB[n] family is their relatively poor solubility in 
water: CB[6] and CB[8] are essentially insoluble, whereas CB[5] and CB[7] possess 
modest solubility in water (Table 1.1). The solubility of the CB[n] family is generally 
lower than the cyclodextrins. Like urea itself, however, the carbonyl groups lining 
the portals of CB[n] are weak bases: the pKa value of the conjugate acid of CB[6] is 
3.02. Although the pKa values for CB[5], CB[7], and CB[8] have not been 
measured, they are likely to be similar to that of CB[6]. Accordingly, the solubility of 
CB[5]–CB[8] increase dramatically in concentrated aqueous acid. 
 
 
 
Table 1.1: Dimensions and physical properties of CB[n] 
 
 
Electrostatic effects play a crucial role in molecular recognition events in both 
aqueous and organic solution (23). Fig. 1.5 shows the electrostatic potentials of β-
CD and CB[7]. Clearly, the electrostatic potential at the portals and within the cavity 
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of CB[7] is significantly more negative than for β-CD. This difference in electrostatic 
potential has significant consequences for their recognition behavior: CB[n] exhibit 
a pronounced preference to interact with cationic guests whereas β-CD prefers to 
bind to neutral or anionic guests. 
 
 
 
Fig. 1.5: Electrostatic potential maps for a) β-CD and b) CB[7]. The red to blue 
color range spans -80 to 40 kcal mol-1 
 
 
Owing to their rigid hydrophobic cavity and two hydrophilic portals, the CB[n] family 
emerged as an interesting and promising supramolecular host (24). A plethora of 
molecules have been studied as potential guests for these supramolecular hosts 
(25). The supramolecular chemistry of CB[5] is controlled by the narrow portals 
lined with carbonyl groups which provide entry to a cavity of low volume. 
Consequently, much of the supramolecular chemistry of CB[5] has been limited to 
the binding of protons as well as metal and ammonium ions at their portals. The 
pioneering work of Buschmann et al. (26) has established equilibrium constants and 
in many cases the enthalpic (ΔH) and entropic (ΔS) contributions to ΔG for the 
binding of CB[6] to ω-amino acids and ω-amino alcohols, aliphatic alcohols, acids, 
and nitriles, bipyridine derivatives, aromatic compounds, non-ionic surfactants and 
poly(ethylene glycols), cyclodextrins, diamides, and a-amino acids and dipeptides 
(26). 
CB[7] is slightly more voluminous than β-CD and thus can bind a wider range of 
guests than CB[6] or CB[5]. CB[7] binds a variety of positively charged aromatic 
compounds. CB[7] also binds the metal complexes which suggests the use of CB[7] 
to reduce toxicity in cancer treatment. The cavity of CB[8] is similar in terms of 
volume to γ-CD, but is less conformationally flexible. CB[8] behaves like a larger 
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version of CB[5]–CB[7] in many ways, but also exhibits more complex recognition 
behavior. Just like CB[5]–CB[7], CB[8] prefers to bind to positively charged guests 
by ion–dipole interactions (27). CB[8] readily binds single guest molecules that 
partially or completely fill its cavity. Although the smaller homologues of the CB 
family can bind only one guest truly inside the cavity, CB[8] is unique in its ability to 
bind two guests as has been shown by Kim and others (28) CB[8] can serve to 
stabilize a charge transfer (CT) complex in its cavity. This result demonstrates there 
is cooperativity between the binding of the first and second aromatic rings. This 
recognition motif has been used to control intramolecular folding processes and the 
formation of vesicles (29). Kim and coworkers have also reported that 
CB[8]·Methylviologen (MV) can bind to a variety of other aromatic guests such as 
tryptophan, tyrosine, and dopamine (28). Urbach et al. demonstrated a systematic 
study on the thermodynamic parameters of amino acid binding to CB[8] (30). (Fig. 
1.6) 
 Equilibrium Association Constants for Q8-MV with Aromatic Amino Acids
 
 
Fig. 1.6: Equilibrium association constants for CB[8]-MV with aromatic 
amino acids 
 
 
 
 
1.3. Aim of the work 
The goal of this project is a proof of concept study of protein reassembly upon 
designed dissection through non covalent interaction in CB[8] cavity. 
In this direction the attention was focused toward Ubiquitin. It is a small regulatory 
protein that has been found in almost all tissues (ubiquitously) of eukaryotic 
organisms, it functions attaching to proteins and labelling them for their 
degradation. The ubiquitin-tag brings proteins to the proteasome, that is a large 
protein complex in the cell that has the prominent role of destroy and recycle 
unneeded proteins. 
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Ubiquitin has a small size with a globular three-dimensional structure in which 
secondary structures are well-localized in several regions. It was divided in two 
fragments, N-terminal and C-terminal region that were suitably labeled for their 
incapsulation in CB[8] cavity. 
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2. EXPERIMENTAL SECTION 
 
2.1. Materials 
O-(benzotriazol-1-yl)-N,N,N,N-tetramethyluronium-hexaﬂuoro-phosphate (HBTU) 
was purchased from CEM. Amino acids, DMF and NMP were purchased from 
AGTC Bioproducts. NovaPEG Rink Amide LL resin was purchased from 
NovaBiochem. All other materials were purchased from Alfa Aesar and Sigma 
Aldrich and used as received unless stated otherwise. 
 
2.2. Instrumentation 
1H NMR (400 MHz) spectra were recorded on a Bruker Avance QNP 400. HPLC 
was performed on a Varian 940LC. ESI-MS was performed on a Fischer Thermo 
Scientiﬁc LTQ Velos Ion Trap Mass Spectrometer with ESI source.  
 
2.3. Synthesis of Fmoc-Asp(Boc-Nmec-Hmb)Gly-OH 
2.3.1. Synthesis of Hmb-Gly-OBzl:  
H-Gly-OBzl, free base, 3,1 gram (18,8 mmol) was dissolved in 15 ml ethanol and a 
solution of 2,57 gram (17 mmol) 2-hydroxy-4-methoxybenzaldehyde dissolved in 40 
ml ethanol was added portion-wise. A strong yellow color was developed  and  after  
5  minutes  a  thick  precipitation  was  formed that  no  longer  could  be  stirred  
with  a  magnetic stirring bar and the solution was therefore stirred manually for 25 
minutes with a teflon rod. The solution was put on ice and 0,64 gram (17 mmol) 
solid NaBH4 was added portion wise during 10 minutes and precipitated material 
started to disappear and a turbid white solution was formed. After 30 minutes the 
reaction was terminated  by addition  of  200 ml water and the  pH adjusted to a  
stable  pH  of  3,0   with  1 M HCl  solution. After acidification all solid material 
dissolved and a clear solution was obtained. The bulk of the ethanol was removed 
by reduced  pressure, the  solution  diluted  by  100 ml  water  and  extracted  once  
with  diethyleter. The  pH  of the  water phase was raised by addition of sodium 
hydroxide solution and gradually a precipitation was formed which dissolved upon 
addition of 100 ml DCM. The pH of the aqueous layer was adjusted to pH 8, the 
DCM phase isolated and the water phase extracted with 3x5 ml DCM. The pooled 
DCM phases were washed with 150 ml water and the water phase  back-washed  
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with  3x5  ml  DCM.  The  pooled  DCM phases  were  washed  with  2x  with  
saturated  sodium chloride solution, dried with Na2SO4 and evaporated to an oil that 
was that was dissolved in 75 ml ethylacetate and filtered  through  2  cm  packed  
uncoated  TLC  silica  to  remove  unreacted  H-Gly-OBzl  and  colored  material.  
The solvent was evaporated and resulting oil was crystallized from 
EtOAc/petroleum ether. Yield 3,22 gram (62,9%). 
2.3.2. Synthesis of Fmoc-Asp-HmbGly-OBzl: 
1,87 gram (5,5 mmol) Fmoc-Asp-OH was added to 10 ml DCM and cooled to 0°C 
on ice and 0,694 gram. (5,5 mmol) diisopropylcarbodimide in 5 ml DCM was added 
portion-wise during 5 minutes. This solution was added to an ice cold solution of 
0,755 gram (free base, 5 mmol) H-Hmb-Gly-OBzl in 5 ml DCM and the solution was 
stirred for 30 minutes on ice followed by 12 hours at room temperature. To  the  
reaction  mixture  was  added  0,2  gram  ethylendiamine  and  the  solution  stirred  
for  5  minutes  followed  by addition  of  a mixture  of  50ml DCM  and  100 ml water  
containing  1% HCl. The  solution was  shaken  and  filtered through Celite to 
remove the remove precipitated diisopropylurea. The DCM phase was washed with 
2x200 ml 0,1M HCl, and once with a saturated NaCl solution, dried with Na2SO4  
and the solvent removed by reduced pressure. The  resulting  oil was  dissolved in  
20 ml EtOAc  and  petroleum  ether was  added  until the  solution  became turbid 
(≈22ml). The  solution  was  purified  added to  a  dry  flash  chromatography  
column  on to  with  a  step-wise  gradient  of  ethyl acetate in petroleum ether ( 20-
40%). Rf (TLC; EtOAc/n-hexane 35/65, v/v) 0,34. Yield 2,95 gram (solid foam). 
2.3.3. Synthesis of Fmoc-Asp-Hmb(BocNmec)Gly-OBzl:  
2,85 gram Fmoc-Asp-HmbGly-OBzl  (2) was added to 20 ml dry DCM. The  solution 
was cooled to 0°C  and  1,14 gram p-nitrophenylchloroformate was added. 
Diisopropylethylamine 0,65 gram in 5 ml DCM  was added drop wise during 5 
minutes. The  solution was  stirred  for an additional 25 minutes on ice  followed by 
addition of 1.72 gram mono-Boc-N,N‘-dimetylethylendiamine  and  1,18  gram  
diisopropylethylamine  in  5  ml  DCM.  The  solution  was stirred for 1 hour on ice, 
transferred to a separation funnel and washed with 2x200 ml 0,1 % aqueous HCl, 
2x200 ml 50 mM Na2CO3 and once with 200 ml water. All aqueous solution were 
back-washed three times with 5 ml DCM. The solution was dried with anhydrous 
Na2SO4 and the solvent removed by reduced pressure. The resulting oil was 
dissolved  20 ml EtOAc and  25 ml  petroleum ether, applied to a  dry  flash 
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chromatography and the  product eluted with a step-wise gradient of ethyl acetate in 
petroleum ether ( 30-50%). Rf (TLC;  EtOAc/n-hexane  60/40,  v/v),  0,37  and  0,48.   
No attempts were made to  resolve these products with additional chromatography 
as the desired product was obtained with high purity after the next step. Yield 3,2 
gram. 
2.3.4. Synthesis of Fmoc-Asp-(Boc-Nmec-Hmb)Gly-OH:  
3 grams Fmoc-Asp-Hmb(BocNmec)Gly-OBzl was dissolved in 50 ml EtOH, the 
solution flushed with nitrogen and 450  mg  10  % Pd(C)  was  added.  The  solution  
was  bubbled  with  a  gentle  stream  of  hydrogen  and  the  reaction monitored  by 
TLC  by withdrawing  samples at  regular intervals. After  40 minutes almost all  
starting material  had reacted and fast moving spot that probably represented 9-
methyl fluorene started to appear. The reaction mixture was flushed with nitrogen, 
filtered through Celite and the solvents removed by reduced pressure. The resulting 
solid was dissolved ethylacetate-peter 1:1 and purified with dry  flash 
chromatography. The column was initially eluted with EtOAc:petroleumether;  1:1 to  
remove traces  of  starting material  followed EtOAc-petroleum ether containing  2% 
acetic  acid. The  fractions  containing the  product  were  pooled  and  washed  
eight times  with  water  and the  pooled water  solutions  extracted  with  EtOAc  
and  washed  eight  times  with  water.  The  EtOAc  solution  was  dried  and 
evaporated to an oil that still contained traces of acetic acid. The product was 
dissolved in diethyleter and washed six times with water and this procedure was 
repeated for the pooled water solutions. The diethyleter phases were pooled, dried  
with  Na2SO4 and  evaporated  to  a  solid  foam  that  was  further  dried  at  high  
vacuum  overnight.  Rf (TLC; EtOAc/n-hexane/HOAc 78/20/2, v/v/v) Yield 2,43 gram 
(3,25 mmol). 
2.3.5. Synthesis of mono-Boc-N,N‘-dimethylethylendiamine:  
90 mmol (7,93 gram) N,N‘-dimetylethylendiamine was dissolved in 300 ml 
ethylacetate and a solution of 30 mmol (6,5 gram) di-tert-butyl dicarbonate 
dissolved in 50 ml ethylacetate was added portion-wise. When about half of the 
solution  had  been  added  the  solution  became  turbid.  The  solution  was  stirred  
for  1  hour  and  transferred  to  a separation  funnel  and  shaken with  2x20 ml 
water  and  1x50  saturated  sodium  chloride  solution. The  solution was dried with 
anhydrous Na2SO4 and the  solvent  removed  by  reduced  pressure. The  resulting  
oil was  dissolved  50 ml chloroform,  evaporated,   redissolved  in  50  ml  
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dietylether  and  evaporated  to  remove  residual  traces  of  N,N‘-
dimetylethylendiamine (bp 119°C). Residual solvents were removed under high 
vacuum for 1 hour. Yield 4, 9 gram (oil) 
 
2.4. Synthesis of C-terminal UBIQUITIN (residues 47-76)  
Solid phase peptide synthesis was performed on a Liberty Microwave Peptide 
Synthesizer (CEM Corporation) using Fmoc-strategy. The Fmoc group was 
removed in each step with 20 % (v/v) piperidine in DMF with 0.1M HOBt for 3 min 
using a microwave power of 45 W. The maximum temperature was set to 75°C. The 
coupling step was performed with 5 equiv. of Fmoc protected amino acid in DMF 
(0.2 M), 4.5 equiv. of DIC in DMF (0.45 M) and 10 equiv. of DIPEA in NMP (2 M). All 
couplings were performed for 10 min at 25 W at a maximum temperature of 75° C. 
Following completion of the sequence the peptide was released from the resin with 
concomitant removal of side chain protecting groups by treatment with 
TFA//H2O/TIS (95/2.5/2.5, v/v/v) at room temperature for 2 h. The crude peptide 
was precipitated in cold Et2O. The crude product was puriﬁed on a Varian 940-LC 
using a preparative Varian Polaris C8 column applying a linear gradient of 10 % to 
60 % B in 30 min. The mobile phases were 0.1 % TFA in H2O (eluent A) and 0.1 % 
TFA in Acetonitrile (eluent B).  
 
2.5. Synthesis of N-terminal UBIQUITIN (residues 1-46) 
 Solid phase peptide synthesis was performed on a Liberty Microwave Peptide 
Synthesizer (CEM Corporation) using Fmoc-strategy. The Fmoc group was 
removed in each step with 5 % (v/v) piperazine in DMF with 0.1M HOBt for 3 min 
using a microwave power of 45 W. The maximum temperature was set to 75°C. The 
coupling step was performed with 5 equiv. of Fmoc protected amino acid in DMF 
(0.2 M), 4.5 equiv. of DIC in DMF (0.45 M) and 10 equiv. of DIPEA in NMP (2 M). All 
couplings were performed for 10 min at 25 W at a maximum temperature of 75° C. 
Following completion of the sequence the peptide was released from the resin with 
concomitant removal of side chain protecting groups by treatment with 
TFA//H2O/TIS (95/2.5/2.5, v/v/v) at room temperature for 2 h. The crude peptide 
was precipitated in cold Et2O.  
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2.6. Synthesis of MV-C2-Benz-Mal 
 A solution of p-Maleimidobenzoyl azide (0.10 g, 0.41 mmol) in 10 mL anhydrous 
DMF was heated to 145°C for 2 h under nitrogen atmosphere in a 50 mL two-neck 
RBF, equipped with a reflux condenser. After cooling to room temperature MV-
C2H4OH 2PF6 (0.16 g, 0.32 mmol) was added and the solution was stirred over 
night. The solution was concentrated to a few millilitres in vacuo and diethylether 
was added. The precipitate was collected by suction filtration, redissolved in 10 mL 
of acetone and filtered. A solution of tetrabutylammonium chloride (0.33 g, 1.2 
mmol) in 5 mL of acetone was added and the solution was allowed to stand 
overnight in the fridge. The resulting precipitate was collected by suction filtration, 
washed with cold acetone, to yield the title compound (0.10 g, 60%) as a yellowish 
solid.  
 
2.7. Synthesis of MV- C2-Benz-Mal-N UBQ 
 To a suspension of MV-C2-Benz-Mal (10 mg, 0.012 mmol) in 100 mL of 100 mM 
phosphate buffer (pH = 7) was added N-terminal fragment Ubiquitin (30 mg, 0.0026 
mmol) and the mixture was stirred at room temperature for 24 hours. The solution 
was concentrated  by lyophilisation and ready for purification. 
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3. RESULTS 
3.1. Design of Dissection of UBIQUITIN. 
Ubiquitin, a small protein (8.5 kDa) present in all eukaryotic cells. It contains a 
highly conserved sequence of 76 amino acids that is identical in a wide variety of 
sources including humans, fish, and insects. It participates in diverse cellular 
functions, such as protein degradation, chromatin structure, and heat shock, by 
conjugation to other proteins through the carboxy terminus. This protein is highly 
conserved in evolution: yeast and human ubiquitin differ at only 3 of 76 residues. 
The carboxyl-terminal glycine of ubiquitin becomes covalently attached to the amino 
group of lysine residues of proteins destined to be degraded. The human ubiquitin 
primary sequence is as follows: 
 
1MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTL
SDYNIQKESTLHLVLRLRGG76 
 
Its crystal structure has been refined at 1.8 Å resolution (31) and the overall 
structure of ubiquitin is extremely compact and tightly hydrogen-bonded; 
approximately 87% of the polypeptide chain is involved in hydrogen-bonded 
secondary structure. Prominent secondary structural features include three and 
one-half turns of α-helix, a short piece of 310-helix, a mixed β-sheet that contains 
five strands, and seven reverse turns. There is a marked hydrophobic core formed 
between the β-sheet and α-helix. The protein features a number of unusual 
secondary structural features, including a parallel Gl β-bulge, two reverse Asx turns 
and a symmetrical hydrogen-bonding region that involves the two helices and two of 
the reverse turns (Fig. 3.1). 
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Fig. 3.1: Structural representation of Ubiquitin protein (upper) and schematic 
representation of secondary structural regions (lower) 
 
 
In protein dissection strategy the most critical issue is represented by the choice of 
the site of the cleavage in the protein, and by the visual inspection of the protein 
structure, a region of surface loop between residues 46 (alanine) and 47 (glycine) 
was chosen as splitting site (Fig. 3.2). 
 
     
1MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTL
SDYNIQKESTLHLVLRLRGG76 
 
Fig. 3.2: Primary sequence of Ubiquitin. The site of the cleavage is represented in red. 
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The dissection resulted in N- and C-terminal fragments, designated N-UBQ 
(spanning residues 1-46) and C-UBQ (spanning residues 47-76). At the C-terminal 
of the N-UBQ fragment a residue of cysteine was inserted to allow the coupling of 
methylviologen (Fig. 3.3). 
 
 
N-UBQ : 1MQIFVKTLTGKTITLEVEPSDTIENVKAlQDKEGIPPDQQRLIFA46-Cys 
C-UBQ : Trp-Gly-47GKQLEDGRTLSDYNIQKESTLHLVLRLRGG76 
 
Fig. 3.3: Sequence of splitted Ubiquitin fragments 
 
 
 
On the other hand, in the C-UBQ fragment a dipeptide was inserted at the N-
terminal: WG, tryptophan residue was introduced to allow the formation of aromatic 
interaction inside the cavity of CB[8], while glycine was inserted as spacer (Fig. 3.3). 
 
 
 
 
Fig. 3.4: Schematic representation of reassembly of fragments with CB[8] 
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Designed fragments should self-assemble in the presence of CB[8] to refold native 
ubiquitin. Indeed CB[8] is able to bind two aromatic guests in this case, 
methylviologen and tryptophan, and to stabilize the complex in its cavity through 
electronic charge transfer (CT) mechanism, as described in Fig. 3.4. 
 
3.2. Synthesis of C-UBQ fragment 
Aggregation of the peptide chain during peptide synthesis is a major problem in 
both Boc and Fmoc chemistries. It results in incomplete acylation of the growing 
peptide chain and is the major source of deletion peptides. Incomplete acylation is 
usually caused by -sheet formation, which has been studied extensively. By 
exploring the secondary structure of the C-UBQ fragment, it is evident that two 
consistent β-strands are present in this region. Furthermore the presences of many 
hydrophobic residues make the peptide chain very aggregating in the assembly 
phase and presumably insoluble after the cleavage. HPLC purification of poorly 
soluble peptides is a major practical problem resulting in low loading of the peptide 
onto the column, poor resolution and low yields. In addition, hydrophobic and 
aggregated peptides are often hard to characterize by mass spectrometry because 
of poor ionization ability. 
Moreover, exploring the primary sequence of the C-UBQ fragment, the Asp-Gly 
sequence is present: this is particularly prone to ―Aspartimide formation‖, that is one 
of the most frequently encountered side reactions affecting Fmoc SPPS, which 
results from a ring-closure between the β-carboxy side-chain of aspartic acid and 
the nitrogen of the α-carboxamide. 
Such aspartimides are very susceptible to base-catalyzed epimerization (32) and 
readily undergo ring-opening reactions giving mixtures of often inseparable a-, b-
aspartyl peptides and α- and β-piperidides (Fig. 3.5) (33). 
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Fig. 3.5: Mechanism of aspartimide formation 
 
An eﬃcient general strategy to counteract β-sheet formation and aspartimide 
formation during the synthesis of a peptide is reversible modiﬁcation of selected 
peptide bonds. Reversible protection of the peptide backbone using modified N-(2-
hydroxy-4-methoxybenzyl) (Hmb) groups was introduced by Wahlstrom et al. (34). 
In particular the phenolic oxygen in Hmb is protected with a Boc-N-methyl-N-[2-
(methylamino)ethyl] carbamoyl group (Boc-Nmec). Thus it is possible to introduce 
modified Hmb groups into a peptide chain as dipeptides. (Fig. 3.6) 
  
 
 
 
Fig. 3.6: Structure of the dipeptide Fmoc-Asp-(Boc-NmecHmb)Gly-OH 
 
 
During synthesis of the peptide, Hmb-protected peptides attached to a solid phase 
are less prone to β-sheet and aspartimide formation, and moreover coupling of the 
remaining residues usually proceeds with significantly enhanced efficiency. 
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During cleavage of the peptide from the resin with TFA, the Boc group was removed 
but the protonated methyl-(2-methylamino-ethyl) carbamoyl group remained 
attached to the Hmb group 3. In this form, peptide have a greatly increased 
solubility in aqueous solutions as a result of both the β-sheet-disrupting eﬀect of the 
benzylated peptide bond, and the solubilizing eﬀect of the cationic charge. After 
puriﬁcation, the peptide was exposed to slightly alkaline reaction conditions during 
which an intramolecular cyclization reaction produced the Hmb-protected peptide 4 
and N,N’-dimethylimidazoldione (5). The Hmb group can be removed with TFA. In 
the fully deprotected form, the peptide 6 could be isolated either by an additional 
chromatographic step or simply by precipitation (Fig. 3.7). 
 
 
 
 
 
Fig. 3.7: General scheme for the use of Fmoc dipeptides with peptide bonds 
protected with modiﬁed 2-hydroxy-4-methoxybenzyl groups, R=CH(CH3)2. 
(a) Peptide synthesis; (b) TFA, RP-HPLC puriﬁcation; (c) DMF/water, N-methylmorpholine; 
(d) TFA, diisopropylsilane 
 
 
 
We therefore synthesized Fmoc-Asp-(Boc-NmecHmb)Gly-OH as outlined in 
Scheme 3.1. 
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3.2.1. Synthesis of Fmoc-Asp-(Boc-Nmec-Hmb)Gly-OH 
The Hmb derivative of the benzyl ester of glycine 9 was obtained by the reductive 
alkylation of H-Gly-OBzl (7) with hydroxymethoxybenzyl aldehyde (8) in ethanol, 
and the free base was isolated as a crystalline compound. Acylation of 9 with Fmoc-
Asp-OH/N,N’-diisopropylcarbodiimide gave the dipeptide Fmoc-Asp-(Hmb)Gly-OBzl 
(10) as a solid foam after purification by dry flash chromatography. 
The phenolic hydroxyl group was activated with p-nitrophenylchloroformate followed 
by treatment with mono-Boc-N,N’-dimethylethylenamine to give carbamate 11. 
Introduction of the Boc-Nmec group resulted in a large increase in retention time of 
product 11 in TLC systems, and facilitated purification by dry flash chromatography. 
The benzyl ester was removed by catalytic hydrogenation, and the extent of the 
reaction was followed by TLC. The reaction was terminated when traces of 9-
methylfluorene were detected by TLC. 
 
+
7
98
10
11
 
    
Scheme 3.1: Synthesis of Fmoc-Asp-(Boc-Nmec-Hmb)Gly-OH 
 
 
After purification by dry flash chromatography, the protected dipeptide  was 
obtained as a solid foam in an overall yield of 45%. The 1H NMR and 13C NMR 
spectra were in accordance with the expected structure (data not shown). 
Moreover, the compound was characterized with MALDI-TOF (MWth=816.3) (Fig. 
3.8). 
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Fig. 3.8: MALDI spectrum of Fmoc-Asp(Boc-Nmec-Hmb)Gly 
(MWth=816.5/MWexp=817.0) 
 
 
 
3.2.2. Peptide Synthesis of C-UBQ fragment and purification 
Initially the C.terminal fragment 53-76 (23 amino acids) was synthesized, 
before coupling of the dipeptide  of Fmoc-Asp(Boc-Nmec-Hmb)Gly-OH. The 
Fmoc-amino acids were coupled using PyBOP/DIEA in DMF, and a solution of 
20% piperidine/0.1M HOBt was used for the deprotection of Fmoc group. 
The dipeptide  Fmoc-Asp-(Boc-Nmec-Hmb)Gly-OH was coupled to fragment 
C-UBQ 53-76 using DIC a stronger activator in DMF. The reaction was carried 
out for 30 min under microwave followed by 60 min at room temperature. For 
the couplings of the following seven 7 residues DIC was used.    
The product C-UBQ was cleaved with TFA and precipitated five times with cold 
diethyl ether. The resulting Hmb-protected peptide was re-dissolved in 
acetonitrile/water, lyophilized, and analyzed by RP-HPLC and MALDI 
experiment (MWth=3905.6) (Fig. 3.9). 
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Fig. 3.9: Analytical chromatogram at 210 nm of crude C-UBQ (upper) and 
MALDI spectrum of crude C-UBQ (lower) (MWth=3905.5/MWexp=3904.0) 
 
 
Purification was carried out using a preparative Varian Polaris C8 column 
applying a gradient of acetonitrile (10 % to 60 % B in 30 min). The pure 
product (C-UBQ) was analyzed at MALDI-TOF (Fig. 3.10). 
197 
 
3906
In
te
n
si
ty
m/z
 
 
Fig. 3.10: MALDI spectrum of the pure C-UBQ (MWth=3905.5/MWexp=3906.0)  
 
 
 
3.3. Peptide Synthesis of N-UBQ fragment 
By visual inspection of primary sequence also this fragment shows possible 
problems associated with aggregation and aspertimmide formation. 
But alternative ways were done for the synthesis of this fragment. It is well-known 
that the incorporation of HOBt (0.1 M) in the piperidine solution allows a reduced 
level of aspartimide formation. In addition, the use of piperazine in place of 
piperidine has demonstrated significantly lower levels of aspartimide formation (35).  
Piperazine is less odorous and toxic than piperidine, but with a pKa of 9.8 compared 
to 11.1 for piperidine, piperazine is a slower deprotection reagent. For conventional 
synthesis of hydrophobic sequences, the use of piperazine may not be desirable. 
But according to Stacey et al. (35), microwave energy is able to accelerate Fmoc 
deprotection substantially with piperazine and that complete Fmoc removal can be 
accomplished with piperazine in 3 min without the presence of deletion products. 
On these basis the use of piperazine coupled with microwave synthesis was 
employed to reduce aspartimide formation. Furthermore deprotection was 
performed in two stages using a fresh solution  of 5 % (v/v) piperazine in DMF-0.1M 
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HOBt. An initial deprotection of 30 s at 50 W was followed by a 3-min deprotection 
at 50 W, with a maximum temperature of 80 °C. The coupling step was performed 
with 5 equiv. of Fmoc protected amino acid in DMF (0.2 M), 4.5 equiv. of DIC in 
DMF (0.45 M) and 10 equiv. of DIPEA in NMP (2 M). All couplings were performed 
for 10 min at 25 W at a maximum temperature of 75° C. Following completion of the 
sequence the peptide was released from the resin with concomitant removal of side 
chain protecting groups by treatment with TFA//H2O/TIS (95/2.5/2.5, v/v/v) at room 
temperature for 2 h. The crude peptide was precipitated in cold Et2O. 
 
 
3.3.1. Synthesis of MV-(N-UBQ) fragment 
To a suspension of MV-C2-Benz-Mal (10 mg, 0.012 mmol) in 100 mL of 100 
mM phosphate buffer (pH = 7) was added the crude N-terminal fragment (30 
mg, 0.0026 mmol) and the mixture was stirred at room temperature for 24 
hours. The solution was concentrated by lyophilisation and analyzed with ESI 
experiment (MWth=5724). (Fig. 3.11). 
 
 
ESI
[M+4/4]
[M+5/5]
[M+6/6]
[M+7/7]
[M+10/10]
 
Fig. 3.11: ESI spectrum of pure MV-(N-UBQ) fragment 
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4. DISCUSSION 
Methods developed based on protein reassembly have several advantages such as 
rapidity, homogeneous format, and ability to perform in vivo screening (11). In 
addition when the reassembly is assisted by interacting pairs of proteins used such 
as leucine zippers (36) it reduces the possibility of false positives compared to the 
strategy where self-complementation is used for the reassembly of proteins as in 
the case of beta-galactosidase (10). Limitations of this method include, high 
background signal, possible interference in reassembly by the matrix components.  
The biggest challenge of splitting strategy is designing fragments of reporter with 
aﬀecting the 3-D structure of the protein drastically. For overcoming the problems 
linked to the reassembly assisted by the interaction with a host partner, in this study 
the host-guest chemistry for protein reassembly has been exploited , through non 
covalent interaction in CB[8] cavity of splitted fragments. CB [8] shows greater 
affinity to positively charged guest and its cavity is able to bind simultaneously two 
aromatic rings due to the formation of a cooperative bond between rings which 
results in greater interaction in the charge transfer between them.  
Here we focuesd on ubiqutin both for its essential regulatory biological function and 
for its small size. The separated protein regions were obtained by chemical 
synthesis: at the C-terminal fragment (residues 47-76) was inserted a glycine as a 
spacer and then a tryptophan indole group, for the binding to the CB[8]. This 
fragment was synthesized using a microwave procedure, but the synthesis was 
rather complex due to the formation of aspartimmide. In order to avoid this side 
reaction, the dipeptide Fmoc-Asp-Gly-OH was synthesized, in it the amide bond is 
further protected with a derivative of the Hmb (2-hydroxy-4-methoxybenzyl) and 
employed  for the development of the synthesis. At the C-terminus of N-terminal 
fragment (residues 1-46), a cysteine was inserted to allow the connection with 
"methylviologen", which has an aromatic ring strongly depleted of electrons for the 
formation of the ternary complex with CB[8]. The raw product was conjugated to 
methylviologen via preferential binding of the thiolate group with the maleimide 
function and was confirmed by ESI-MS. These preliminary synthetic results are very 
promising for the future development of this project that will be structural studies of 
individual fragments by solution state spectroscopy (NMR, CD, Fluorescence) and 
the structural and functional characterization of the ternary complex through the 
same techniques and with biochemical assays such as SPR, ITC and ELISA. 
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The protein reassembly through host-chemistry strategy can have a wide variety of 
applications: primarily in the study of protein folding determinants and then in the 
design of specific modulators of protein folding and biological function. 
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CONCLUSIONS 
The innovative concept that proteins exert their function by establishing intricate 
contact networks rather than acting as independent entities is of outstanding 
importance both in the comprehension of molecular mechanisms underlying 
biological processes and in modern drug discovery. Protein-protein interactions are 
the ensemble of fine tuned recognition events that take place at protein surfaces. 
These contacts frequently involve large protein surface areas, which comprise 
several contact sites but, alternatively, they can be mediated by ―hot spots‖ 
represented by few crucial amino acids. Many studies have highlighted the role of 
peptide molecules as powerful tools for the characterization and the regulation of 
these interactions. Peptides are particularly suitable as models for proteins that are 
not fully folded in their isolated states but that achieve conformational stability upon 
the formation of complexes with other partners. The characterization of the 
structural determinants of protein-protein recognition represents an important step 
for the development of molecular entities able to modulate these interactions. 
The identification of compounds able to modulate protein-protein interactions 
represents a major goal for modern drug discovery. Both structure-based design 
and screening of combinatorial collections have been successfully applied, in this 
instance often small peptides and peptidomimetics have been selected as inhibitors 
of protein complexes. In many cases, the lack of sufficient structural information on 
protein interacting regions renders the combinatorial approach the most suitable 
method, but the use of completely random peptide libraries often produces 
redundant chemical species that complicate the deconvolution phases of screening 
and puzzles the way to the identification of active compounds. Thus, in order  to 
avoid the synthesis of too large combinatorial libraries  in two case-studies during 
this doctoral thesis a simplified approach was followed in it libraries of short 
peptides, made of a small subset of amino acids were prepared and screened. This 
approach has been applied to the identification of inhibitors of the protein complex 
between PED/PEA15 and PLD1 that is involved in the molecular mechanisms of 
insulin resistance occurring in type 2 diabetes. This study led to the identification of 
several short peptide inhibitors rich in aromatic and H-donor donor features through 
the employment of ELISA and SPR binding assay. These short sequences will be 
converted in small organic molecules following medicinal chemistry rules and 
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actually can be considered as interesting starting scaffold for the design of new 
therapeutic agents in type 2 diabetes.  
On the other hand, the screening of small but focused libraries is increasingly used 
to target specific  systems. This method has been applied to the identification of 
mimicking peptides of KIR region of SOCS1 that is involved in JAK2 recognition. 
This interaction plays a key role in molecular mechanisms of psoriasis. After the 
identification of a shorter SOCS1-KIR domain, through an Ala-scanning 
investigation, focused peptide library in which non essential residues were 
randomized in a simplified approach were built and assayed. This screening led to 
the selection of new peptides more effective than natural sequences; indeed one 
decapeptide resulted binds to JAK2 with a dissociation constant in the nanomolar 
range and was able to block STAT1 phosphorylation. Actually cellular and in vivo 
experiments are ongoing in order to investigate its  therapeutic applicability. 
Rational approaches for the identification of protein interacting regions  provide 
deeper insights into the recognition molecular mechanism This rational approach 
has been applied to other two projects in this thesis. The complex between proteins  
CypA and AIF is involved in apoptotic cell death, but at structural level only a 
docked theoretical model is available. In this model few molecular contacts between 
proteins are detectable, thus a set of sequences were designed in order to map 
crucial residues of AIF domains involved in the interaction with CypA. The selective 
disruption of the CypA-AIF complex with these peptides mimicking the protein 
surfaces was analysed by competition and direct binding SPR experiments. These 
experiments allowed to identify an active sequence that,   once properly modified, 
could be as a potential suppress the pro-apoptotic action of AIF. 
This minimalistic approach was successfully applied to another protein complex 
IB-α/Tat, two proteins involved in the replication of HIV-1. Here IB-α-based 
peptides were designed and tested in SPR assays. Also in this project the 
interacting region of IB-α was restricted to a shorter region  (26 residues) 
representing a promising starting point for the development of molecules able to 
block HIV-1 infection. The characterization of IB-α peptides has provided novel 
insights into the intrinsic properties of IB-α fragments and structural determinants 
of IB-α/Tat recognition.  
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In the investigation of protein folding determinants and then in the design of specific 
modulators of proteic folding and biological function, the protein reassembly through 
host-chemistry strategy could represent a valid approach. During a period of six 
months spent at Cambridge University, a protein splitting approach was applied to 
the small a regulator protein Ubiqutin. Two dissected protein regions were obtained 
by chemical synthesis: at the C-terminal fragment (residues 47-76) was inserted a 
glycine as a spacer and then a tryptophan indole group, for the binding to the 
macrocycle CB[8]; instead at the C-terminus of N-terminal fragment (residues 1-46), 
a cysteine was inserted to allow the connection with "methylviologen", which has an 
aromatic ring strongly depleted of electrons for the formation of the ternary complex 
with CB[8]. The preliminary synthetic results obtained resulted promising for the 
future development of this project that will be structural studies of individual 
fragments and the structural and functional characterization of the ternary complex.  
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ABBREVIATIONS: 
TIS:   Triisopropylsilane 
TFA:   Trifluoroacetic acid 
Fmoc:   Fluorenylmethoxycarbonyl 
HPLC:  High Performance Liquid Chromatography 
LC-MS:  Liquid Chromatography Mass Spectrometry 
SPR:   Surface Plasmon Resonance 
Acm:    acetamidomethyl 
TCEP:  Tris(2-Carboxyethyl) phosphine 
IC50:   Concentration giving 50% of Inhibition 
PED/PEA15:  Phosphoprotein Enriched in Diabetes/Phosphoprotein Enriched in 
Astrocytes15 
PLD:   Phospholipase D 
ELISA:  Enzyme-Linked ImmunoSorbent Assay 
EDC:    1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride 
NHS:    N-hydroxy-succinimide 
DMF:                       Dimethylformamide 
DCM:   Dichloromethane 
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